Document:

EX-10.5

 Exhibit 10.5 

Execution Version 
 GUARANTY AND
SECURITY AGREEMENT 
 dated as of August 9, 2018 

by and among 

Endologix, Inc., 
 as
Borrower Representative, 
 the other Grantors, Borrowers and Guarantors party hereto from time to time 

and 
 DEERFIELD ELGX
REVOLVER, LLC, 
 as agent for itself and the other Secured Parties 

 

 GUARANTY AND SECURITY AGREEMENT 

This GUARANTY AND SECURITY AGREEMENT (this “Agreement”), dated as of August 9, 2018, by and among Endologix, Inc., a
Delaware corporation (“Borrower Representative”), CVD/RMS Acquisition Corp., a Delaware corporation (“CVD”), Nellix, Inc., a Delaware corporation (“Nellix”), TriVascular Technologies, Inc., a
Delaware corporation (“TriVascular Technologies”), TriVascular, Inc., a California corporation (“TriVascular California”), Endologix Canada, LLC, a Delaware limited liability company (“Endologix
Canada”), TriVascular Sales LLC, a Texas limited liability company (“Sales”), RMS/Endologix Sideways Merger Corp., a Delaware corporation (“Sideways”), each other Person who becomes a party hereto pursuant
to Section 8.15 (together with the Borrower Representative, CVD, Nellix, TriVascular Technologies, TriVascular California, Endologix Canada, Sales and Sideways, the “Grantors” or the
“Borrowers” and each, a “Grantor” or a “Borrower”), each other Person signatory hereto as a “Guarantor” (as defined below) and Deerfield ELGX Revolver, LLC, as Agent. 

RECITALS 
 A. The
Lenders have agreed to extend credit to Borrowers pursuant to the Credit Agreement (defined below). Each Borrower is affiliated with each other Grantor and Guarantor. 

B. Borrowers, the other Grantors and the other Guarantors are engaged in interrelated businesses, and each Grantor and each Guarantor will
derive substantial direct and indirect benefit from extensions of credit under the Credit Agreement. 
 C. It is a condition precedent to
Lenders’ obligation to make their respective extensions of credit and provide the Revolver Commitments to the Borrowers under the Credit Agreement that the Grantors and the Guarantors shall have executed and delivered this Agreement to Agent.

 In consideration of the premises and to induce Lenders and Agent to enter into the Credit Agreement and the other Loan Documents to which
they are a party and to induce Lenders to make their respective extensions of credit to the Borrower thereunder, each Grantor and each Guarantor hereby agrees with Agent (for the benefit of the Secured Parties) as follows: 

SECTION 1. DEFINITIONS. 
 1.1 Unless
otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement, and the following terms are used herein as defined in the UCC (such meanings to be equally applicable to
both the singular and plural forms of the terms defined): “accounts”, “certificated security”, “chattel paper”, “commercial tort claims”, “commodity contract”, “deposit accounts”,
“documents”, “electronic chattel paper”, “equipment”, “farm products”, “fixture”, “general intangibles”, “goods”, “health care insurance receivables”,
“instruments”, “inventory”, “leases”, “letter-of-credit rights”, “money”, “payment intangibles”,
“product”, “record”, “securities account”, “security”, “supporting obligations”, and “tangible chattel paper”. It is hereby agreed that the term “instrument” shall not include
checks received in the ordinary course of business. 
 1.2 Whenever used in this Agreement, the Exhibits or the Schedules attached hereto,
unless the context otherwise requires, the following terms have the following meanings: 
 “Agreement” has the meaning set
forth in the preamble of this Agreement. 

 “Collateral” means all of Grantors’ assets, whether now owned or
hereafter created, acquired or arising, including without limitation, all of Grantors’ right, title and interest in and to the following: 

(a) all goods, accounts (including health care insurance receivables), equipment, inventory, contract rights or rights to
payment of money, leases, license agreements and other licenses, franchise agreements, general intangibles, commercial tort claims (including any Identified Claims), documents, instruments (including any promissory notes) (and any distribution of
property made on, in respect of or in exchange for such instruments from time to time), chattel paper (whether tangible chattel paper or electronic), cash, Cash Equivalents, deposit accounts, Intellectual Property, Intellectual Property Licenses,
securities accounts, fixtures, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), securities, all other Pledged Collateral and
Pledged Investment Property (including any distribution of property made on, in respect of or in exchange for such Pledged Collateral and/or Pledged Investment Property from time to time) and all supporting obligations related to any of the
foregoing, and financial assets, wherever located; 
 (b) all books and records relating to any of the foregoing; 

(c) all property of any Grantor held by any Secured Party, including all property of every description, in the custody of or in
transit to such Secured Party for any purpose, including safekeeping, collection or pledge, for the account of such Grantor or as to which such Grantor may have any right or power, including but not limited to cash; and 

(d) any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments,
accessories, accessions and improvements to and replacements, products, Proceeds and insurance Proceeds of any or all of the foregoing. 
 Where the context
requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof. Notwithstanding the foregoing, “Collateral” shall not include
Excluded Property; provided, however, that if and when any assets cease to be Excluded Property, the term “Collateral” shall include such assets and a Lien on and security interest in such assets shall be deemed granted
therein pursuant to Section 3.1 hereof. 
 “Copyrights” means any and all rights in any works of
authorship, including (A) copyrights and moral rights, (B) copyright registrations and recordings thereof and all applications in connection therewith including those listed on Schedule 8, (C) income, license fees, royalties, damages, and
payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to
sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world. 

“Credit Agreement” means the Credit Agreement of even date herewith by and among Borrowers, the other Loan Parties party
thereto from time to time, Agent and Lenders, as amended, supplemented, restated or otherwise modified from time to time. 

“Fraudulent Transfer Laws” has the meaning set forth in Section 2.6 hereof. 

“Grantor” has the meaning set forth in the preamble of this Agreement. 

  
 3 

 “Guaranteed Obligations” means all obligations of each Guarantor under the
Loan Documents and all other Obligations (including the fees and other amounts set forth in Section 2.09 of the Credit Agreement). 

“Guarantors” means each Borrower and any other Person who becomes a party to this Agreement pursuant to
Section 8.15. 
 “Identified Claims” means the commercial tort claims described on Schedule
5, as such schedule shall be supplemented from time to time in accordance with the terms and conditions of this Agreement. 

“Intellectual Property License” means, with respect to any Grantor (the “Specified Party”), (A) any licenses
or other similar rights provided to the Specified Party in or with respect to Intellectual Property owned or controlled by any other Person, and (B) any licenses or other similar rights provided to any other Person in or with respect to
Intellectual Property owned or controlled by the Specified Party, in each case, including (1) any software license agreements, (2) the license agreements listed on Schedule 9, and (3) the right to use any of the licenses or
other similar rights described in this definition in connection with the enforcement of the Lender Group’s rights under the Loan Documents. 

“Issuers” means the collective reference to each issuer of Pledged Collateral and Pledged Investment Property. 

“Paid in Full” and “Payment in Full” each means (a) with respect to Guaranteed Obligations, all
Guaranteed Obligations have been repaid in full in cash (other than any unasserted contingent indemnification obligations) and all Commitments have been terminated and (b) with respect to Secured Obligations, all Secured Obligations have been
repaid in full in cash (other than any unasserted contingent indemnification obligations) and all Commitments have been terminated; provided that the foregoing shall be subject to any reinstatement pursuant to (and the other provisions set
forth in) Section 8.18). 
 “Patents” means patents and patent applications, including
(A) the patents and patent applications listed on Schedule 10, (B) all continuations, divisionals, continuations-in-part,
re-examinations, reissues, and renewals thereof and improvements thereon, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including
payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each
Grantor’s rights corresponding thereto throughout the world. 
 “Pledged Collateral” means, collectively, the Pledged
Equity and the Pledged Debt Instruments. 
 “Pledged Debt Instruments” means all right, title and interest of any Grantor
in instruments evidencing any Indebtedness owed to such Grantor or other obligations owed to such Grantor, including all Indebtedness described on Schedule 1, issued by the obligors named therein. Pledged Debt Instruments excludes any
Excluded Property. 
 “Pledged Equity” means collectively, all Pledged Interests and Pledged Stock. 

“Pledged Interests” shall mean, with respect to each limited liability company, partnership or other organization listed on
Schedule 1, (i) the Stock in such limited liability company, partnership or other organization owned by a Grantor and listed on Schedule 1, and the certificates, if any, representing such interests and any interest of such Grantor, as
applicable, on the books and records of such limited liability company, partnership or other organization or on the books and records of any securities 

  
 4 

 
intermediary pertaining to such interests, (ii) the Stock of any other Person whose Stock is at any time hereafter issued or granted to, or held by any Grantor, and (iii) all dividends,
distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all interests set forth in the preceding
clauses (i) and (ii). Pledged Interests excludes any Excluded Property. 
 “Pledged Investment Property” means the
collective reference to (i) all “investment property” as such term is defined in Section 9-102(a)(49) of the UCC and (ii) all “financial assets” as such term is defined in Section 8-102(a)(9) of the UCC, other than any Pledged Equity or Pledged Debt Instruments. Pledged Investment Property excludes any Excluded Property. 

“Pledged Stock” shall mean, with respect to each corporation listed on Schedule 1, the Stock of such corporation owned
by a Grantor and listed on Schedule 1, and the certificates, if any, representing such shares and any interest of such Grantor, as applicable, in the entries on the books of the issuer of such shares or on the books of any securities
intermediary pertaining to such shares and the Stock of any other Person whose Stock is at any time hereafter issued to or granted to or held by any Grantor, and all dividends, distributions, cash, warrants, rights, options, instruments, securities
and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such shares. Pledged Stock excludes any Excluded Property. 

“Proceeds” means all “proceeds” as such term is defined in
Section 9-102(a)(64) of the UCC and, in any event, shall include all dividends or other income from the Pledged Investment Property, collections thereon or distributions or payments with respect thereto.

 “Receivable” means any right to payment for goods sold or leased or for services rendered, whether or not such right is
evidenced by an instrument or chattel paper and whether or not it has been earned by performance (including any accounts). 

“Secured Obligations” means the Obligations (including the fees and other amounts set forth in Section 2.09 of the
Credit Agreement). 
 “Trademarks” means any and all trademarks, trade names, registered trademarks, trademark
applications, service marks, registered service marks and service mark applications, including (A) the trade names, registered trademarks, trademark applications, registered service marks and service mark applications listed on Schedule 11, (B)
all renewals thereof, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past
or future infringements or dilutions thereof, (D) the right to sue for past, present and future infringements and dilutions thereof, (E) the goodwill of each Grantor’s business symbolized by the foregoing or connected therewith, and
(F) all of each Grantor’s rights corresponding thereto throughout the world. 
 “Transferred Guarantor” has the
meaning set forth in Section 8.16(c). 
 SECTION 2. GUARANTY. 

2.1 Guaranty. 
 (a) To
induce Lenders to make the Loans and each other Secured Party to make credit available to or for the benefit of one or more Grantors and for the applicable Secured Parties to enter into the Loan Documents, each of the Guarantors hereby, jointly and
severally, absolutely, 

  
 5 

 
unconditionally and irrevocably, as a primary obligor and not only a surety, guarantees to Agent and the other Secured Parties and their respective successors and permitted assigns, the prompt
and complete payment and performance by Borrowers and each other Grantor, as applicable, of the Guaranteed Obligations when due (whether at the stated maturity or earlier, by reason of acceleration, any mandatory prepayment required pursuant to the
terms of the Financing Agreement or otherwise). 
 (b) This Guaranty includes all present and future Guaranteed Obligations including any
under transactions continuing, compromising, extending, increasing, modifying, releasing, or renewing the Guaranteed Obligations, changing the interest rate, payment terms, or other terms and conditions thereof, or creating new or additional
Guaranteed Obligations after prior Guaranteed Obligations have been satisfied in whole or in part. To the maximum extent permitted by law, each Guarantor hereby waives any right to revoke this Guaranty as to future Guaranteed Obligations. If such a
revocation is effective notwithstanding the foregoing waiver, each Guarantor acknowledges and agrees that (i) no such revocation shall be effective until written notice thereof has been received by Agent, (ii) no such revocation shall
apply to any Guaranteed Obligations in existence on the date of receipt by Agent of such written notice (including any subsequent continuation, extension, or renewal thereof, or change in the interest rate, payment terms, or other terms and
conditions thereof), (iii) no such revocation shall apply to any Guaranteed Obligations made or created after such date to the extent made or created pursuant to a legally binding commitment of any member of the Lender Group in existence on the date
of such revocation, (iv) no payment by any Guarantor, any Borrower, or from any other source, prior to the date of Agent’s receipt of written notice of such revocation shall reduce the maximum obligation of such Guarantor hereunder, and
(v) any payment by any Borrower or from any source other than such Guarantor subsequent to the date of such revocation shall first be applied to that portion of the Guaranteed Obligations as to which the revocation is effective and which are
not, therefore, Guaranteed hereunder, and to the extent so applied shall not reduce the maximum obligation of such Guarantor hereunder. This Guaranty shall be binding upon each Guarantor, its successors and assigns and inure to the benefit of and be
enforceable by Agent (for the benefit of the Lender Group) and its successors, transferees, or assigns. 
 (c) The guaranty contained in this
Section 2 is a guaranty of payment and not of collection and shall remain in full force and effect until all of the Guaranteed Obligations shall have been Paid in Full. 

(d) No payment made by any Borrower, any of the Guarantors, any other guarantor or any other Person, or received or collected by Agent or the
other Secured Parties from any Borrower, any of the Guarantors, any other guarantor or any other Person, as applicable, by virtue of any action or proceeding or any set-off or appropriation or application at
any time or from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the Liability of any Guarantor hereunder which Guarantor shall, notwithstanding any such payment
(other than any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations until the Guaranteed Obligations are Paid in Full. 

2.2 No Subrogation. Notwithstanding any payment made by any Guarantor hereunder or any set-off
or application of funds of any Guarantor by Agent or any other Secured Party, no Guarantor shall be entitled to be subrogated to any of the rights of Agent or any other Secured Party against any Borrower or any Guarantor or any collateral security
or guaranty or right of offset held by Agent or any other Secured Party for the payment of the Guaranteed Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from any Borrower or any Guarantor in
respect of payments made by such Guarantor hereunder, until all of the Guaranteed Obligations are Paid in Full. If any amount shall be paid to any Guarantor on account of such subrogation rights at any time

  
 6 

 
when all of the Guaranteed Obligations shall not have been Paid in Full, such amount shall be held by such Guarantor in trust for Agent and the other Secured Parties, segregated from other funds
of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to Agent (for the benefit of the Secured Parties) in the exact form received by such Guarantor (duly indorsed by such Guarantor to Agent), to be applied against
the Guaranteed Obligations, whether matured or unmatured, as set forth in Section 6.5 hereof. 
 2.3 Amendments,
etc. with respect to the Guaranteed Obligations. 
 (a) Each Guarantor shall remain obligated hereunder, without any reservation of
rights against any Guarantor and without notice to or further assent by any Guarantor, notwithstanding the fact that: (i) any demand for payment of any of the Guaranteed Obligations made by Agent or the other Secured Parties may be rescinded by
Agent or the other Secured Parties and any of the Guaranteed Obligations continued, (ii) the Guaranteed Obligations, or the Liability of any other Person upon or for any part thereof, or any collateral security or guaranty therefor or right of
offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by Agent or any other Secured Party, or (iii) any of the Credit
Agreement or the other Loan Documents or any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as Agent or any other Secured Party may deem advisable from time
to time. Agent and the other Secured Parties shall have no obligation to protect, secure, perfect or insure any Lien at any time held by them as security for the Guaranteed Obligations or for the guaranty contained in this
Section 2 or any property subject thereto. 
 (b) Agent or any other Secured Party may, from time to time, in their
reasonable discretion and without notice to or demand upon the Guarantors (or any of them), take any or all of the following actions, without discharging or otherwise affecting the Obligations (including the fees and other amounts set forth in
Section 2.09 of the Credit Agreement) of any Guarantor hereunder and without incurring any Liability hereunder: (i) receive, take and hold additional Collateral to secure any of the Guaranteed Obligations or any obligation hereunder,
(ii) retain or obtain the primary or secondary obligation of any obligor or obligors, in addition to the undersigned, with respect to any of the Guaranteed Obligations, (iii) extend or renew any of the Guaranteed Obligations for one or
more periods (whether or not longer than the original period), alter or exchange any of the Guaranteed Obligations or otherwise modify, amend, supplement or otherwise change any Guaranteed Obligation or any Loan Document (including accelerating or
otherwise changing the time of payment), or release or compromise any obligation of any of the undersigned hereunder or any obligation of any nature of any other obligor with respect to any of the Guaranteed Obligations or otherwise in connection
with the Loan Documents, (iv) release any guaranty or right of offset or their security interest in, or surrender, release or permit any substitution or exchange for, all or any part of any personal property securing any of the Guaranteed
Obligations or any obligation hereunder, or extend or renew for one or more periods (whether or not longer than the original period) or release, compromise, alter or exchange any obligations of any nature of any obligor with respect to any such
personal property, (v) resort to the undersigned (or any of them) for payment of any of the Guaranteed Obligations when due, whether or not Agent or any other Secured Party shall have resorted to any personal property securing any of the
Guaranteed Obligations or any obligation hereunder or shall have proceeded against any other of the undersigned or any other obligor primarily or secondarily obligated with respect to any of the Guaranteed Obligations, (vi) apply to the
Guaranteed Obligations any sums by whomever paid or however realized to any Guaranteed Obligation as set forth in Section 6.5 hereof, (vii) refund at any time any payment received by any Secured Party in respect of any
Guaranteed Obligation, (viii) sell, exchange, enforce, waive, substitute, liquidate, terminate, release, abandon, fail to perfect, subordinate, accept, substitute, surrender, exchange, affect, 

  
 7 

 
impair or otherwise alter or release any Collateral for any Guaranteed Obligation or any other guaranty therefor in any manner, (ix) otherwise deal in any manner with any Borrower or any
other Guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and/or (x) settle, release, compromise, collect or otherwise liquidate the Guaranteed Obligations. 

2.4 Waivers. To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives any and all notice
of the creation, renewal, extension or accrual of any of the Guaranteed Obligations and notice of or proof of reliance by Agent or any other Secured Party upon the guaranty contained in this Section 2 or acceptance of the
guaranty contained in this Section 2. The Guaranteed Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the
guaranty contained in this Section 2, and all dealings between any Borrower and any of the Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, likewise shall be conclusively presumed to have
been had or consummated in reliance upon the guaranty contained in this Section 2. To the extent permitted by Applicable Law, each Guarantor hereby unconditionally and irrevocably waives and agrees not to assert any claim,
defense, setoff or counterclaim based on (i) diligence, promptness, presentment, protest, requirements for any demand for payment or performance and protest and notice of protest, requirements for any notice of default, dishonor or nonpayment
and all other notices whatsoever to or upon any Borrower or any of the Guarantors with respect to the Guaranteed Obligations or any part thereof, (ii) notice of the existence or creation or non-payment of
all or any of the Guaranteed Obligations, (iii) all diligence in collection or protection of or realization upon any Guaranteed Obligations or any security for or guaranty of any Guaranteed Obligations, (iv) any presentment, demand,
protest or further notice or other formality or requirements of any kind with respect to any Guaranteed Obligation (including any accrued but unpaid interest thereon) becoming immediately due and payable, and (v) any defense arising by reason
of a disability or other defense of Borrower or any Guarantor. No obligation of any Guarantor hereunder shall be discharged other than by Payment in Full in cash of the Guaranteed Obligations. Each Guarantor further waives any right such Guarantor
may have under any Applicable Law to require any Secured Party to seek recourse first against any Borrower or any other Person, or to realize upon any Collateral for any of the Obligations (including the fees and other amounts set forth in
Section 2.09 of the Credit Agreement), as a condition precedent to enforcing such Guarantor’s Liability and obligations under this Guaranty. 

2.5 Payments. Each Guarantor hereby guaranties that payments hereunder will be paid to Agent and the other Secured Parties without set-off or counterclaim in Dollars in accordance with Section 2.4 of the Credit Agreement. 

2.6 Limitation of Guaranty. Any term or provision of this Agreement or any other Loan Document to the contrary notwithstanding, the
maximum aggregate amount for which any Guarantor shall be liable hereunder shall not exceed the maximum amount for which such Guarantor can be liable without rendering this Agreement or any other Loan Document, as it relates to such Guarantor,
subject to avoidance under Applicable Laws relating to fraudulent conveyance or fraudulent transfer (including the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and Section 548 of title 11 of the United States Code or
any applicable provisions of comparable Applicable Laws) (collectively, “Fraudulent Transfer Laws”). Any analysis of the provisions of this Agreement for purposes of Fraudulent Transfer Laws shall take into account the right of
contribution established in Section 2.7 hereof and, for purposes of such analysis, give effect to any discharge of intercompany debt as a result of any payment made under this Agreement. 

2.7 Contribution. To the extent that any Guarantor shall be required hereunder to pay any portion of any Guaranteed Obligation exceeding
the greater of (i) the amount of the value 

  
 8 

 
actually received by such Guarantor and its Subsidiaries from the Loans and other Obligations and (ii) the amount such Guarantor would otherwise have paid if such Guarantor had paid the
aggregate amount of the Guaranteed Obligations (excluding the amount thereof repaid by any Borrower and any other Guarantor that is a direct or indirect parent entity of any Borrower) in the same proportion as such Guarantor’s net worth on the
date enforcement is sought hereunder bears to the aggregate net worth of all the Guarantors on such date, then such Guarantor shall be reimbursed by such other Guarantors for the amount of such excess, pro rata, based on the respective net worth of
such other Guarantors on such date. 
 2.8 Guaranty Absolute and Unconditional. Each Guarantor hereby waives and agrees not to assert
any defense, whether arising in connection with or in respect of any of the following or otherwise, and hereby agrees that its obligations under this Agreement are irrevocable, absolute and unconditional and shall not be discharged as a result of or
otherwise affected by any of the following (which may not be pleaded and evidence of which may not be introduced in any proceeding with respect to this Agreement) to the fullest extent not prohibited by Applicable Law: 

(a) the invalidity or unenforceability of any obligation of any Borrower or any Guarantor under any Loan Document or any other agreement or
instrument relating thereto (including any amendment, consent or waiver thereto), or any security for, or other guaranty of, any Guaranteed Obligation or any part thereof, or the lack of perfection or continuing perfection or failure of priority of
any security for the Guaranteed Obligations or any part thereof; 
 (b) the absence of (i) any attempt to collect any Guaranteed
Obligation or any part thereof from any Borrower or any Guarantor or other action to enforce the same or (ii) any action to enforce any Loan Document or any Lien thereunder; 

(c) the failure by any Person to take any steps to perfect and maintain any Lien on, or to preserve any rights with respect to, any Collateral;

 (d) any workout, insolvency, bankruptcy proceeding, reorganization, arrangement, liquidation or dissolution by or against any Borrower,
any Guarantor or any of Borrower’s Subsidiaries or any procedure, agreement, order, stipulation, election, action or omission thereunder, including any discharge or disallowance of, or bar or stay against collecting, any Guaranteed Obligation
(or any interest thereon) in or as a result of any such proceeding; 
 (e) any foreclosure, whether or not through judicial sale, and any
other sale or other disposition of any Collateral or any election following the occurrence of an Event of Default by any Secured Party to proceed separately against any Collateral in accordance with such Secured Party’s rights under any
Applicable Law; or 
 (f) any other defense, setoff, counterclaim or any other circumstance that might otherwise constitute a legal or
equitable discharge of any Borrower, any Guarantor or any Subsidiary of any Borrower, in each case other than the Payment in Full in cash of the Guaranteed Obligations. 

2.9 Reliance. Each Guarantor hereby assumes responsibility for keeping itself informed of the financial condition of Borrowers, each
Guarantor and any other guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and of all other circumstances bearing upon the risk of nonpayment of any Guaranteed Obligation or any part thereof that diligent inquiry would
reveal, and each Guarantor hereby agrees that no Secured Party shall have any duty to advise any Guarantor of information known to it regarding such condition or any such circumstances. In the event any Secured Party, in its sole discretion,
undertakes at any time or from time to time to provide any such 

  
 9 

 
information to any Guarantor, such Secured Party shall be under no obligation to (i) undertake any investigation not a part of its regular business routine, (ii) disclose any
information that such Secured Party, pursuant to accepted or reasonable commercial finance or banking practices, wishes to maintain confidential, or (iii) make any future disclosures of such information or any other information to any
Guarantor. 
 SECTION 3. GRANT OF SECURITY INTEREST. 

3.1 Grant. Each Grantor hereby collaterally assigns and grants to Agent, for the benefit of the Secured Parties, a Lien on and security
interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations. Notwithstanding the foregoing, no Lien
or security interest is hereby granted on any Excluded Property. Each Grantor hereby represents and warrants as of (i) the Closing Date, (ii) the date of the making of each Revolving Loan (or other extension of credit) made thereafter,
(iii) the date of each amendment, consent or waiver of this Agreement or the Credit Agreement executed by any Grantor and (iv) solely with respect to any new Grantor that joins this Agreement after the Closing Date, on the date such new
Grantor joins this Agreement, that the Excluded Property, when taken as a whole, is not material to the business operations or financial condition of the Grantors, taken as a whole. 

SECTION 4. REPRESENTATIONS AND WARRANTIES. 

To induce Agent and Lenders to enter into the Credit Agreement and to induce Lenders to make extensions of credit to Borrowers thereunder, each
Grantor jointly and severally hereby represents and warrants to Agent and the other Secured Parties that the following are true, correct and complete, in each case to the extent and in the manner set forth herein, on the Closing Date and as of
(i) the Closing Date, (ii) the date of the making of each Revolving Loan (or other extension of credit) made thereafter, (iii) the date of each amendment, consent or waiver of this Agreement or the Credit Agreement executed by any
Grantor and (iv) solely with respect to any new Grantor that joins this Agreement after the Closing Date, on the date such new Grantor joins this Agreement: 

4.1 Title; No Other Liens. Except for the Lien granted to Agent pursuant to this Agreement and other Permitted Liens, such Grantor owns,
or has rights or the power to transfer rights in, each item of the Collateral free and clear of any and all Liens of others. Such Grantor (i) is the record and beneficial owner of the Collateral pledged by it hereunder constituting instruments
or certificates and (ii) has rights in or the power to transfer each other item of Collateral in which a Lien is granted by it hereunder, free and clear of any other Lien (other than Permitted Liens). No effective financing statement or other
public notice with respect to all or any part of the Collateral is on file or of record in any public office, except filings evidencing Permitted Liens. 

4.2 Perfected Liens. The security interests granted in the Collateral pursuant to this Agreement (i) will constitute valid and
continuing perfected security interests in all of the Grantors’ rights in the Collateral in favor of Agent as collateral security for the Secured Obligations, enforceable in accordance with the terms hereof, except as such enforceability may be
limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally, upon (A) in the case of all Collateral in which a security interest may be perfected by filing a
financing statement under the UCC, completion of the filings and other actions specified on Schedule 2 (which filings and other documents referred to on Schedule 2 have been delivered to Agent in completed form), (B) with respect to
any deposit account or securities account, the execution of Control Agreements, (C) in the case of all Copyrights, Trademarks and Patents for which UCC filings are insufficient, all appropriate 

  
 10 

 
filings having been made with the applicable Intellectual Property registries, including but not limited to the United States Copyright Office or the United States Patent and Trademark Office, as
applicable, (D) in the case of letter-of-credit rights that are not supporting obligations of Collateral, the execution of a contractual obligation granting control
to Agent over such letter-of-credit rights and (E) in the case of electronic chattel paper with payment or amounts owing thereon in excess of $250,000 in the
aggregate, the completion of all steps necessary to grant control to Agent over such electronic chattel paper; and (ii) shall be prior to all other Liens on the Collateral except for Permitted Priority Liens, upon (A) in the case of all
Pledged Collateral and Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such Pledged Collateral and Pledged Investment Property consisting of instruments and certificates, in each case properly
endorsed for transfer to Agent (for the benefit of the Secured Parties) or in blank, (B) in the case of all Pledged Investment Property not in certificated form and deposit accounts, the execution of Control Agreements with respect to such
Pledged Investment Property and deposit accounts and (C) in the case of all other instruments and tangible chattel paper that has aggregate payments or amounts owing thereunder in excess of $250,000 in the aggregate that are not Pledged
Collateral or Pledged Investment Property, the delivery thereof to Agent (for the benefit of the Secured Parties) of such instruments and tangible chattel paper. Except as set forth in this Section 4.2 or as otherwise
provided in the Credit Agreement, all actions by each Grantor necessary or otherwise requested by Agent to perfect the Liens granted hereunder on the Collateral have been duly taken. 

4.3 Grantor Information. On the Closing Date, Schedule 3 sets forth (i) each Grantor’s and each Guarantor’s
jurisdiction of organization, (ii) the location of each Grantor’s and each Guarantor’s chief executive office, (iii) each Grantor’s and each Guarantor’s exact legal name as it appears on its organizational documents and
(iv) each Grantor’s organizational identification number (to the extent a Grantor or Guarantor is organized in a jurisdiction which assigns such numbers) and federal employer identification number. 

4.4 Collateral Locations. On the Closing Date, Schedule 4 sets forth (i) each place of business of each Grantor and each
Guarantor (including its chief executive office), (ii) all locations where any material portion of inventory and equipment owned by each Grantor is kept (other than (A) inventory or equipment that is otherwise in transit or out for repair,
refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Credit Agreement), (iii) all
locations where each Grantor’s books and records concerning the Collateral are kept and (iv) whether each such Collateral location and place of business (including each Grantor’s chief executive office) is owned or leased (and if
leased, specifies the complete name and notice address of each lessor) or otherwise occupied (and if otherwise occupied, describes the nature of such occupation). On the Closing Date, no Collateral (other than (A) inventory or equipment that is
otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction
permitted by the Credit Agreement) is located outside the United States or in the possession of any lessor, bailee, warehouseman or consignee, except as indicated on Schedule 4. 

4.5 Certain Property. None of the Collateral constitutes, or is the Proceeds of, (i) farm products,
(ii) as-extracted collateral, (iii) timber to be cut or (iv) vessels, aircraft or any other personal property subject to any certificate of title or other registration statute of the United
States, any State or other jurisdiction, except for motor vehicles owned by the Grantors and used by employees of the Grantors in the Ordinary Course of Business. 

4.6 Pledged Collateral and Pledged Investment Property. 

  
 11 

 (a) The Pledged Collateral pledged by each Grantor hereunder is listed on
Schedule 1 and, with respect to the Pledged Equity, constitutes all the issued and outstanding equity interests of each Issuer owned by such Grantor as set forth on Schedule 1. None of the Pledged Equity is a
certificated security or otherwise represented or evidenced by any certificate other than the Pledged Equity in Nellix, Inc., CVD/RMS Acquisition Corp., RMS/Endologix Sideways Merger Corp., TriVascular, Inc., and TriVascular Technologies, Inc., and
no foreign Issuer has certificated its Stock nor is any Grantor (or any representative, agent or any other Related Party of any Grantor) holding any certificate of Stock of any foreign Issuer. 

(b) All of the Pledged Equity has been duly authorized and validly issued and, in the case of shares of capital stock and membership interests,
is fully paid and nonassessable. 
 (c) Each of the Pledged Equity, Pledged Debt Instruments and Pledged Investment Property constitutes the
legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws
affecting creditors’ rights generally. 
 (d) Schedule 1A lists all Pledged Investment Property owned by each Grantor. Each
Grantor is the record and beneficial owner of, and has good and valid title to, the Pledged Investment Property pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person, except Permitted Liens. 

(e) All Pledged Collateral (other than uncertificated Pledged Equity) and all Pledged Investment Property consisting of instruments and
certificates has been delivered to Agent (for the benefit of the Secured Parties) in accordance with Section 5.1 hereof to the extent required thereby. 

(f) Upon the occurrence and during the continuance of an Event of Default, Agent shall be entitled to exercise all of the rights of the Grantor
granting the security interest in any Pledged Equity, and a transferee or assignee of such Pledged Equity shall become a holder of such Pledged Equity to the same extent as such Grantor and be entitled to participate in the management of the Issuer
of such Pledged Equity, and, subject to Agent’s exercise of remedies pursuant to Section 6 hereof, upon the transfer of the entire interest of such Grantor, such Grantor shall, by operation of law, cease to be a holder
of such Pledged Equity. 
 4.7 Receivables. 

(a) No amount over $250,000 in the aggregate payable to a Grantor under or in connection with any account is evidenced by any instrument or
chattel paper which, to the extent required hereunder, has not been delivered to Agent (for the benefit of the Secured Parties), properly endorsed for transfer. 

(b) No obligor on any Receivable in excess of $250,000 in the aggregate is a Governmental Authority, unless any assignment of claims act or law
has been complied with for the benefit of Agent. 
 4.8 Credit Agreement. Each Grantor and each Guarantor makes each of the
representations and warranties made by Borrowers in Article IV of the Credit Agreement to the extent applicable to it on the date such Grantor or Guarantor becomes a party hereto (which representations and warranties shall be deemed to be re-made (i) as of the date of each amendment, consent or waiver of this Agreement or the Credit Agreement executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement
after the Closing Date, on the date such new 

  
 12 

 
Grantor joins this Agreement). Such representations and warranties shall be incorporated herein by this reference as if fully set forth herein. 

4.9 Commercial Tort Claims. The only commercial tort claims that any Grantor is asserting or intends to assert in which the potential
recovery exceeds $250,000 in the aggregate are those listed on Schedule 5, as may be supplemented from time to time by delivery thereof to Agent, which sets forth such information separately for each Grantor. 

4.10 Enforcement. No material permit, notice to or filing with any Governmental Authority or any other Person or any material consent
from any Person is required for the exercise by Agent of its rights (including voting rights) provided for in this Agreement or the enforcement of remedies in respect of the Collateral pursuant to this Agreement, including the transfer of any
Collateral, except (i) as may be required in connection with the disposition of any portion of the Pledged Collateral by laws affecting the offering and sale of securities generally, (ii) any approvals that may be required to be obtained
from any bailees or landlords to collect the Collateral, (iii) permits or consents which have been obtained and notices or filings which have been made, and (iv) any requirements set forth in any assignment of claims act and laws. 

4.11 Accounts. Set forth on Schedule 6, as such Schedule may be updated from time to time to reflect changes resulting from
transactions permitted under the Loan Documents) is a listing of all of Grantors’ and their Subsidiaries’ Deposit Accounts and Securities Accounts, including, with respect to each bank or securities intermediary (a) the name and
address of such Person, and (b) the account numbers of the Deposit Accounts or Securities Accounts maintained with such Person. 
 4.12
Real Property. Schedule 7 sets forth all Real Property owned by any of the Grantors as of the Closing Date. 
 4.13
Intellectual Property. As of the Closing Date: (i) Schedule 8 provides a complete and correct list of all registered Copyrights owned by any Grantor and all other Copyrights owned by any Grantor and material to the conduct of the
business of any Grantor; (ii) Schedule 9 provides a complete and correct list of all Intellectual Property Licenses (other than license agreements for commercially available
off-the-shelf software that is generally available to the public which have been licensed to a Grantor pursuant to end-user
licenses) entered into by any Grantor that are material to the business of such Grantor, including any Intellectual Property Licenses that relate to Intellectual Property that is incorporated in any Inventory, software, or other product marketed,
sold, licensed, or distributed by such Grantor; (iii) Schedule 10 provides a complete and correct list of all Patents owned by any Grantor; and (iv) Schedule 11 provides a complete and correct list of all registered
Trademarks owned by any Grantor and all other Trademarks owned by any Grantor and material to the conduct of the business of any Grantor. 
 SECTION 5.
COVENANTS. 
 Each Grantor covenants and agrees with Agent that, from and after the date of this Agreement until the Secured
Obligations and the Guaranteed Obligations, as applicable, shall have been Paid in Full: 
 5.1 Delivery of Instruments, Certificated
Securities and Chattel Paper. 

  
 13 

 (a) Such Grantor shall (i) deliver to Agent (for the benefit of the Secured Parties),
in suitable form for transfer and in form and substance reasonably satisfactory to Agent, (A) all certificated Pledged Equity, together with stock powers or other suitable instruments for transfer, executed in blank, (B) all Pledged Debt
Instruments and (C) all certificates and instruments evidencing Pledged Investment Property and (ii) to the extent required by Section 5.08 of the Credit Agreement, maintain all other Pledged Investment Property
in an account that is subject to a Control Agreement. No foreign Issuer shall issue certificates of its Stock unless the foregoing provisions of this paragraph are complied with. 

(b) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or
become evidenced by an instrument or tangible chattel paper other than such instrument delivered in accordance with this Section 5.1 and in the possession of Agent, such Grantor shall notify Agent, and upon the written
request of Agent, mark all such instruments and tangible chattel paper with the following legend: “This writing and the obligations evidenced or secured hereby are subject to the security interest of Deerfield ELGX Revolver, LLC, as Agent”
and, at the written request of Agent, shall promptly deliver such instrument or tangible chattel paper to Agent (for the benefit of the Secured Parties), duly indorsed in a manner reasonably satisfactory to Agent. 

(c) Such Grantor shall not grant “control” (within the meaning of such term under Article
9-106 of the UCC) over any Pledged Collateral or Pledged Investment Property to any Person other than Agent (for the benefit of the Secured Parties) or, to the extent permitted under (and subject to the terms
of) the Intercreditor Agreement and subject to the terms of Section 8.21, the Term Agent. 
 (d) If such Grantor is
or becomes the beneficiary of a letter of credit that is (i) not a supporting obligation of any Collateral and (ii) in excess of $250,000 in the aggregate, such Grantor shall promptly, and in any event within five (5) Business Days
after becoming a beneficiary, notify Agent thereof and shall use commercially reasonable efforts to enter into a contractual arrangement reasonably requested by the Agent with respect to the letter-of-credit rights under such letter of credit. Such contractual arrangement shall assign such letter-of-credit rights to
Agent and such assignment shall be sufficient to grant control for the purposes of Section 9-107 of the UCC (or any similar section under any equivalent UCC). Such contractual arrangement shall also
direct all payments thereunder to an account subject to a Control Agreement. The provisions of the contractual arrangement shall be in form and substance reasonably satisfactory to Agent. 

(e) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or
become evidenced by electronic chattel paper, such Grantor shall take all commercially reasonable steps necessary to grant Agent control of all such electronic chattel paper for the purposes of
Section 9-105 of the UCC (or any similar section under any equivalent UCC) and all “transferable records” as defined in each of the Uniform Electronic Transactions Act and the Electronic
Signatures in Global and National Commerce Act. 
 (f) In the event that an Event of Default shall have occurred and be continuing, upon the
request of Agent, any instrument, certificated security or chattel paper not theretofore delivered to Agent and at such time being held by such Grantor shall be promptly (and, in any event, within five (5) Business Days) delivered to Agent (for
the benefit of the Secured Parties), duly indorsed in a manner satisfactory to Agent, to be held as Collateral pursuant to this Agreement and in the case of electronic chattel paper, such Grantor shall cause Agent to have control thereof within the
meaning set forth in Section 9-105 of the UCC. In the event that an Event of Default shall have occurred and be continuing, Agent shall have the right, at any time in its discretion and without notice to
any Grantor, to (i) transfer to or to register in its name or in the name of its nominees any Pledged Collateral or any Pledged Investment 

  
 14 

 
Property and (ii) exchange any certificate or instrument representing or evidencing any Pledged Collateral or any Pledged Investment Property for certificates or instruments of smaller or
larger denominations. 
 5.2 Maintenance of Perfected Security Interest; Further Documentation. 

(a) Such Grantor shall maintain the security interests created by this Agreement as perfected security interests (to the extent such security
interests can be perfected by the filing of UCC financing statements (and, with respect to commercial tort claims, to the extent any commercial tort claims are sufficiently identified herein)) having at least the priority described in
Section 4.2 hereof, and shall defend such security interests against the claims and demands of all Persons whomsoever (other than holders of Permitted Liens). 

(b) Subject to (other than, with respect to the Third Party Agent, during any Third Party Agent Retention Period)
Section 5.20 of the Credit Agreement, such Grantor will furnish to Agent from time to time statements and schedules further identifying and describing the assets and property of such Grantor and such other reports in
connection therewith as Agent may reasonably request, all in reasonable detail in form and substance reasonably satisfactory to Agent. 
 (c)
At any time and from time to time, upon the written request of Agent, and at Grantor’s sole expense, such Grantor will, for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted,
promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as Agent may reasonably request, including (i) filing or authorizing the filing of any financing or continuation
statements under the UCC (or other similar laws) in effect in any jurisdiction with respect to the security interests created hereby; (ii) in the case of Pledged Collateral, Pledged Investment Property and any other relevant Collateral, taking
any such reasonably requested actions necessary to enable Agent (on behalf of the Secured Parties) to obtain “control” (within the meaning of the applicable UCC) with respect to such Pledged Collateral, Pledged Investment Property and
other Collateral to the extent required to be pledged hereunder; (iii) if requested by Agent, delivering, to the extent permitted by Applicable Law, any original motor vehicle certificates of title for vehicles in the aggregate with a fair
market value in excess of $250,000 received by such Grantor from the applicable secretary of state or other Governmental Authority after information reflecting Agent’s security interest has been recorded in such motor vehicles to the extent
required to be pledged thereunder; (iv) use of commercially reasonable efforts to secure all approvals necessary or appropriate for the assignment to or the benefit of Agent of any contractual obligation held by such Grantor and to enforce the
security interests hereunder; and (v) subject to Section 5.08) of the Credit Agreement, executing and delivering any Control Agreements with respect to deposit, securities, commodity and similar accounts. 

(d) Such Grantor shall not use or permit any Collateral to be used unlawfully or in violation of any provision of any Loan Document or any
policy of insurance covering the Collateral. 
 5.3 Changes in Locations, Name, etc. Such Grantor shall not, except upon 10 Business
Days’ prior written notice to Agent (or such lesser notice as Agent may agree to in writing in its sole discretion) and delivery to Agent of (i) all additional financing statements and other documents reasonably requested by Agent as to
the validity, perfection and priority of the security interests provided for herein and (ii) if applicable, a written supplement to Schedule 4 showing any additional location at which inventory or equipment shall be
kept (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales personnel and at medical facilities
or (C) otherwise disposed of in a transaction permitted by the Credit Agreement): 

  
 15 

 (a) permit any of the inventory or equipment comprising Collateral to be kept at a location
subject to the possession or control of any warehouse, consignee, bailee, or any of the Grantors’ agents or processors other than those listed on Schedule 4, other than (i) the inventory or equipment that is otherwise in transit or
out for repair, refurbishment or processing in the Ordinary Course of Business, (ii) de minimis amounts of inventory with sales personnel and at medical facilities or (iii) otherwise disposed of in a transaction permitted by the Credit
Agreement; 
 (b) change its jurisdiction of organization or the location of its chief executive office from that specified on Schedule
3 or in any subsequent notice delivered pursuant to this Section 5.3; or 
 (c) change its name, organizational
identification number (if any), identity or corporate structure, except as permitted by Section 6.01 of the Credit Agreement upon prior written notice thereof to the Agent. 

5.4 Notices. Such Grantor will advise Agent in writing promptly, in reasonable detail, of: 

(a) any Lien (other than Permitted Liens) on any of the Collateral; and 

(b) the occurrence of any other event which would reasonably be expected to have a Material Adverse Effect on the Collateral or on the Liens
created hereby. 
 5.5 Pledged Investment Property and Pledged Collateral. 

(a) If such Grantor shall become entitled to receive or shall receive any certificate, option or rights in respect of the Stock of any Issuer,
whether in addition to, in substitution of, as a conversion of, or in exchange for, any of the Pledged Equity, or otherwise in respect thereof, such Stock shall be Pledged Equity (to the extent consistent with the percentage of such Grantor’s
Stock in such Issuer pledged hereunder, as set forth on Schedule 1) and such Grantor shall accept the same as the agent of Agent, hold the same in trust for Agent (for the benefit of the Secured Parties) and deliver the
same forthwith to Agent (for the benefit of the Secured Parties) in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties), if required by Agent, together with an undated instrument of transfer
covering such certificate duly executed in blank by such Grantor and with, if Agent so requests, signature Guaranteed, to be held by Agent (for the benefit of the Secured Parties), subject to the terms hereof, as additional Collateral for the
Secured Obligations. 
 (b) Upon the occurrence and during the continuance of an Event of Default and the request of Agent, (i) any sums
paid upon or in respect of the Pledged Collateral or Pledged Investment Property upon the liquidation or dissolution of any Issuer shall be paid over to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional
Collateral for the Secured Obligations, and (ii) in case any distribution of capital shall be made on or in respect of the Pledged Collateral, or any property shall be distributed upon or with respect to the Pledged Collateral, pursuant to the
recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected Lien in favor of Agent, be delivered to Agent (for the benefit of
the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations. Upon the occurrence and during the continuance of an Event of Default, if any sums of money or property so paid or distributed in respect of the
Pledged Investment Property shall be received by a Grantor, such Grantor shall, at the request of Agent and until such money or property is paid or delivered to the applicable Secured Parties, hold such money or property in trust for Agent (for the

  
 16 

 
benefit of the Secured Parties), segregated from other funds of such Grantor, as additional Collateral for the Secured Obligations. 

(c) Without the prior written consent of Agent, no Grantor will (i) vote to enable, or take any other action, to permit any Issuer to
issue any Stock of any nature or to issue any other securities or interests convertible into or granting the right to purchase or exchange for any Stock of any nature of any Issuer, except, in each case, as permitted by the Credit Agreement,
(ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Pledged Investment Property or Proceeds thereof other than any such action which is permitted by the Credit Agreement, (iii) create,
incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Pledged Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens, or (iv) enter into any
agreement or undertaking restricting the right or ability of such Grantor or Agent to sell, assign or transfer any of the Pledged Investment Property or Proceeds thereof, except with respect to Permitted Liens and any such action which is permitted
by the Credit Agreement. 
 (d) In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the
terms of this Agreement relating to the Pledged Equity issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify Agent promptly in writing of the occurrence of any of the events described in
Sections 5.5(a) and 5.5(b) hereof with respect to the Pledged Equity issued by it and (iii) the terms of Sections 6.3(c) and 6.7 hereof shall apply to such Grantor with respect to all actions that
may be required of it pursuant to Section 6.3(c) hereof regarding the Pledged Equity issued by it. 
 5.6
Receivables. Other than in the Ordinary Course of Business consistent with its past practice, such Grantor will not (i) grant any extension of the time of payment of any Receivable, (ii) compromise or settle any Receivable for less
than the full amount thereof, (iii) release, wholly or partially, any Person liable for the payment of any Receivable, (iv) allow any credit or discount whatsoever on any Receivable or (v) amend, supplement or modify any Receivable in
any manner that would reasonably be expected to adversely affect the value thereof, in each case, unless taking the foregoing actions would not reasonably be expected, individually or in the aggregate, to cause a Material Adverse Effect. 

5.7 Intellectual Property. Except as permitted by the Credit Agreement, or except, in each case, where the failure to do so could not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect (provided that no such Material Adverse Effect qualifier should apply to Section 5.7(h)): 

(a) Upon the request of Agent, in order to facilitate filings with the United States Patent and Trademark Office and the United States
Copyright Office, each Grantor shall execute and deliver to Agent one or more Copyright Security Agreements, Trademark Security Agreements, or Patent Security Agreements to further evidence Agent’s Lien on such Grantor’s Patents,
Trademarks, or Copyrights, and the General Intangibles of such Grantor relating thereto or represented thereby. 
 (b) Such Grantor (either
itself or through licensees) will (i) continue to use each Trademark (owned by such Grantor), in order to maintain such Trademark in full force and effect free from any claim of abandonment for non-use,
(ii) maintain as in the past the quality of products and services offered under such Trademark, (iii) use, and cause its licensees and sublicensees to use, such Trademark with the appropriate notice of registration and all other notices
and legends required by Applicable Law, (iv) not adopt or use any mark which is confusingly similar or a colorable imitation of such Trademark unless Agent shall obtain a perfected security interest in such Trademark pursuant to this

  
 17 

 
Agreement and (v) not (and not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Trademark (or any goodwill associated therewith) may become
destroyed, harmed, invalidated or impaired in any way. 
 (c) Each Grantor (either itself or through licensees) will not do any act, or omit
to do any act, whereby as a result of such act or omission, any Patent owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, will employ, and cause its licensees and sublicensees to employ,
each such Patent with the appropriate notice of registration and all other notices and legends required by Applicable Law, and will take commercially reasonable steps to establish and preserve the Patents in any patentable invention under Applicable
Law. 
 (d) Each Grantor (either itself or through licensees) (i) will employ, and cause its licensees and sublicensees to employ, each
Copyright owned by such Grantor with the appropriate notice of registration and all other notices and legends required by Applicable Law, and (ii) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do
any act whereby such Copyrights may become invalidated or otherwise impaired, and (iii) will not (either itself or through licensees or sublicensees) do any act whereby any such Copyrights may fall into the public domain. 

(e) Each Grantor (either itself or through licensees or sublicensees) will not (and will not permit any licensee or sublicensee thereof to) do
any act or omit to do any act whereby any trade secret may become unenforceable under any Applicable Law and each Grantor shall take reasonable steps to maintain the confidentiality of, and otherwise protect and enforce its rights in, the
Intellectual Property that is necessary in or material to the conduct of such Grantor’s business, including, as applicable (A) protecting the secrecy and confidentiality of its confidential information and trade secrets by having and
enforcing a policy requiring all current employees, consultants, licensees, vendors and contractors with access to such information to execute appropriate confidentiality agreements; (B) taking actions reasonably necessary to ensure that no
trade secret falls into the public domain due to any action of any Grantor; and (C) protecting the secrecy and confidentiality of the source code of all software programs and applications of which it is the owner or licensee by having and
enforcing a policy requiring any licensees (or sublicensees) of such source code to enter into license agreements with commercially reasonable use and non-disclosure restrictions. 

(f) Such Grantor (either itself or through licensees or sublicensees) will not do any act that infringes, misappropriates, dilutes, violates or
otherwise impairs the Intellectual Property or intellectual property rights of any other Person. 
 (g) Such Grantor will notify Agent
promptly if it knows, or has reason to know, that any application or registration relating to any Intellectual Property owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, or of any
determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country)
regarding such Grantor’s ownership of, or the validity of, any such Intellectual Property or such Grantor’s right to register the same or to own and maintain the same. 

(h) At the time of delivery of (A) if Endologix is required to file reports pursuant to Section 13 or 15(d) of the Exchange Act, the 10-Q and 10K filings (or, if earlier, the time delivery thereof is required by the SEC) as required by Section 5.05(a)(ii) or (B) if Endologix is not required to file reports pursuant to Section 13 of
15(d) of the Exchange Act, the quarterly and annual financial statements as required by Section 5.05(c), each Grantor will notify Agent of applications filed for the registration of any Intellectual Property with the United States Patent and
Trademark Office, the United States Copyright 

  
 18 

 
Office or any similar office or agency in any other country or any political subdivision thereof. Upon the request of Agent, within five (5) Business Days, such Grantor shall execute and
deliver, and have recorded, any and all agreements, instruments, documents, and papers as Agent may request to evidence Agent’s security interest in any Intellectual Property owned by such Grantor, including any Copyright, Patent or Trademark
and the goodwill and general intangibles of such Grantor relating thereto or represented thereby. 
 (i) Such Grantor will take all actions
that are necessary or reasonably requested by Agent to maintain and pursue each application (and to obtain the relevant registration or recordation) and to maintain each registration and recordation of all Intellectual Property owned by it. 

(j) In the event that any Intellectual Property owned by a Grantor is, to its knowledge, infringed upon or misappropriated or diluted by a
third party, such Grantor shall, subject to (other than, with respect to the Third Party Agent, during any Third Party Agent Retention Period) Section 5.20 of the Credit Agreement, (i) take such actions as such Grantor
shall reasonably deem appropriate under the circumstances to protect such Intellectual Property and (ii) promptly notify Agent after it learns thereof and sue for infringement, misappropriation or dilution, to seek injunctive relief where
appropriate and to recover any and all damages for such infringement, misappropriation or dilution. 
 (k) Each Grantor shall require all
employees, consultants, and contractors of such Grantor who are involved in the creation or development of any Intellectual Property for such Grantor to sign agreements that presently assigned all Intellectual Property created or developed for the
Grantor to such Grantor, and obligate such employee, consulting or contractor to hold all confidential information of the Grantor (or of any other Person and held by the Grantor) in confidence. 

(l) Grantors acknowledge and agree that the Lender Group shall have no duties with respect to any Intellectual Property or Intellectual
Property Licenses of any Grantor. Without limiting the generality of this Section 5.7(k), Grantors acknowledge and agree that no member of the Lender Group shall be under any obligation to take any steps necessary to
preserve rights in the Collateral consisting of Intellectual Property or Intellectual Property Licenses against any other Person, but any member of the Lender Group may do so at its option from and after the occurrence and during the continuance of
an Event of Default, and all expenses incurred in connection therewith (including reasonable fees and expenses of attorneys and other professionals) shall be for the sole account of Borrowers and the other Grantors and shall be chargeable to the
Loan Account. 
 5.8 Other Matters. 

(a) Each Grantor authorizes Agent and its Affiliates directors, partners, officers, employees, agents, counsel and advisors and any Third Party
Agent to, at any time and from time to time, file or record financing statements, continuation statements, amendments thereto, and other filing or recording documents or instruments with respect to any Collateral in such forms and in such offices as
Agent or such other Person reasonably determines appropriate to perfect, or continue or maintain perfection of, the security interests of Agent under this Agreement, and such statements, amendments, documents, and instruments may describe the
Collateral covered thereby as “all assets of the debtor” of each Grantor, or words of similar effect and may contain any other information required pursuant to the UCC for the sufficiency of

  
 19 

 
filing office acceptance of any financing statement, continuation statement or amendment, and each Grantor agrees to furnish any such information to Agent promptly upon Agent’s reasonable
request. Any such financing statement, continuation statement or amendment may be signed by Agent on behalf of any Grantor and may be filed at any time in any jurisdiction. A copy of this Agreement shall be sufficient as a financing statement or
other filing or recording document or instrument for filing or recording in any jurisdiction. Such Grantor also hereby ratifies its authorization for Agent and any Third Party Agent to have filed any initial financing statement or amendment thereto
under the UCC (or other similar laws) in effect in any jurisdiction if filed prior to the date hereof To the extent permitted by law, each Grantor hereby (i) waives any right under the UCC or any other Applicable Law to receive notice and/or
copies of any filed or recorded financing statements, amendments thereto, continuations thereof or termination statements and (ii) releases and excuses each Secured Party from any obligation under the UCC or any other Applicable Law to provide
notice or a copy of any such filed or recorded documents. 
 (b) Each Grantor shall, at any time and from time and to time, take such steps
as the Agent may reasonably request for Agent to insure the continued perfection and priority of Agent’s security interest in any of the Collateral and of the preservation of its rights therein. 

(c) If any Grantor shall at any time, acquire a commercial tort claim as set forth in Section 4.9 hereof, such
Grantor shall promptly notify Agent thereof in writing and supplement Schedule 5, therein providing a reasonable description and summary thereof, and upon delivery thereof to Agent, such Grantor shall be deemed to thereby grant to Agent (and
such Grantor hereby grants to Agent) a Lien in and to such commercial tort claim and all Proceeds thereof, all upon the terms of and governed by this Agreement, and such Grantor shall execute and deliver to Agent, in each case in form and substance
reasonably satisfactory to Agent, any document, and take all other action, deemed by Agent to be reasonably necessary or appropriate for Agent to obtain, for the benefit of the Secured Parties, a perfected security interest in all such commercial
tort claims. Any supplement to Schedule 5 delivered pursuant to this Section 5.8(c) shall, after the receipt thereof by Agent, become part of Schedule 5 for all purposes hereunder other than in respect of
representations and warranties made prior to the date of such receipt. 
 5.9 Credit Agreement. Each of the Grantors covenants that it
will, and, if necessary, will cause or enable each Borrower to, fully comply with each of the covenants and other agreements set forth in the Credit Agreement. 

5.10 Agent May Purchase Insurance. If a Grantor at any time or times hereafter shall fail to obtain, maintain or provide to Agent
evidence of any of the policies of insurance or other items required under Section 5.03 of the Credit Agreement or to pay any premium relating thereto, then Agent, without waiving or releasing any obligation or default by
such Grantor hereunder, may (but shall be under no obligation to) obtain and maintain such policies of insurance and pay such premiums and take such other actions with respect thereto as Agent deems advisable upon notice to such Grantor. Such
insurance, if obtained by Agent, may, but need not, protect such Grantor’s interests or pay any claim made by or against such Grantor with respect to the Collateral. Such insurance may be more expensive than the cost of insurance such Grantor
may be able to obtain on its own and may be cancelled only upon such Grantor providing evidence that it has obtained the insurance as required above. All sums disbursed by Agent in connection with any such actions shall constitute Secured
Obligations and Guaranteed Obligations payable upon demand. 
 5.11 Further Assurances. 

(a) Each Grantor agrees that from time to time, at its own expense, such Grantor will promptly execute and deliver all further instruments and
documents, and take all further action, that Agent may reasonably request, in order to perfect and protect the security interest and Lien granted hereby, to create, perfect or protect the security interest and Lien purported to be granted hereby or
to enable Agent to exercise and enforce its rights and remedies hereunder with respect to any of the Collateral. 
  

  
 20 

 (b) Grantor acknowledges that it is not authorized to file any financing statement or
amendment or termination statement with respect to any financing statement filed in connection with this Agreement or the other Loan Documents without the prior written consent of Agent, subject to such Grantor’s rights under Section 9-509(d)(2) of the Code. 
 SECTION 6. REMEDIAL PROVISIONS. 

6.1 Certain Matters Relating to Receivables. Subject to, in each case, the terms of the Intercreditor Agreement (to the extent
applicable): 
 (a) At any time and from time to time after the occurrence and during the continuance of an Event of Default, Agent shall
have the right to make test verifications of the Receivables in any manner and through any medium that it reasonably considers advisable, and each Grantor shall furnish all such assistance and information as Agent may reasonably require in
connection with such test verifications. At any time and from time to time after the occurrence and during the continuance of an Event of Default, upon request of the Agent and at the expense of the relevant Grantor, such Grantor shall cause
independent public accountants or others satisfactory to Agent to furnish to Agent reports showing reconciliations, agings and test verifications of, and trial balances for, the Receivables. 

(b) If requested by Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables, when
collected by any Grantor, (i) shall be forthwith (and, in any event, within two (2) Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties) and
upon notice to such Grantor, in a collateral account maintained under the sole dominion and control of Agent, subject to withdrawal by Agent as provided in Section 6.4 hereof, and (ii) until so turned over, shall be
held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor. Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable detail the nature
and source of the payments included in the deposit. 
 (c) At any time and from time to time after the occurrence and during the continuance
of an Event of Default, at the request of Agent, each Grantor shall deliver to Agent all original and other documents evidencing, and relating to, the agreements and transactions which gave rise to the Receivables, including all original orders,
invoices and shipping receipts and notify account debtors that the accounts or general intangibles that are Collateral have been collaterally assigned to Agent and that payments in respect thereof shall be made directly to Agent. 

(d) Each Grantor hereby irrevocably authorizes and empowers Agent, in Agent’s sole discretion, at any time after the occurrence and during
the continuance of an Event of Default, without notice to such Grantor: (i) to limit or terminate the ability of a Grantor to collect its Receivables or any thereof; to assert, either directly or on behalf of such Grantor, any claim such
Grantor may from time to time have against account debtors and to otherwise enforce such Grantor’s rights against such account debtors; (ii) to receive and collect any and all damages, awards and other monies resulting therefrom and to
apply the same to the Secured Obligations as set forth in Section 6.5 hereof; and (iii) in its own name or in the name of others, to communicate with account debtors to verify with them to Agent’s reasonable
satisfaction the existence, amount and terms of any account or amounts due under any general intangible that is Collateral. 
 6.2
Communications with Obligors; Grantors Remain Liable. 
  

  
 21 

 (a) Agent in its own name or in the name of others may at any time after the occurrence and
during the continuance of an Event of Default communicate with obligors under the Receivables to verify with them to Agent’s satisfaction the existence, amount and terms of any Receivables 

(b) Subject to the terms of the Intercreditor Agreement (to the extent applicable), upon the request of Agent at any time after the occurrence
and during the continuance of an Event of Default, each Grantor shall notify obligors on the Receivables that the Receivables have been assigned to Agent and that payments in respect thereof shall be made directly to Agent. 

(c) Anything herein to the contrary notwithstanding, each Grantor shall remain liable in respect of each of the Receivables to observe and
perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise thereto. No Secured Party shall have any obligation or Liability under any Receivable (or any
agreement giving rise thereto) by reason of or arising out of any Loan Document or the receipt by Agent or any other Secured Party of any payment relating thereto, nor shall any Secured Party be obligated in any manner to perform any of the
obligations of any Grantor under or pursuant to any Receivable (or any agreement giving rise thereto), to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any
performance by any party thereunder, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times. 

6.3 Pledged Investment Property and Pledged Collateral. 

(a) Unless an Event of Default shall have occurred and be continuing and until Agent has notified Borrower Representative otherwise, each
Grantor shall be permitted to receive all cash dividends and distributions paid in respect of the Pledged Collateral and all payments made in respect of the Pledged Investment Property, to the extent permitted in the Credit Agreement, and to
exercise all voting and other rights with respect to the Pledged Collateral and Pledged Investment Property; provided, that no vote shall be cast or other right exercised or action taken that could be reasonably likely to materially impair
the Collateral or which would be inconsistent with or result in any violation of any provision of the Credit Agreement, this Agreement or any other Loan Document. 

(b) If an Event of Default shall occur and be continuing: (i) Agent shall have the right to receive any and all cash dividends and
distributions, payments or other Proceeds paid in respect of the Pledged Collateral and Pledged Investment Property and make application thereof to the Secured Obligations as set forth in Section 6.5 hereof, (ii) Agent
shall have the right to cause any or all of the Pledged Collateral and Pledged Investment Property to be registered in the name of Agent or its nominee and (iii) Agent or its nominee may exercise (x) all voting, consent, corporate and
other rights pertaining to such Pledged Collateral and Pledged Investment Property at any meeting of shareholders, partners or members, as the case may be, of the relevant Issuer or Issuers or otherwise (or by written consent) and (y) any and
all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Pledged Collateral and Pledged Investment Property as if it were the absolute owner thereof (including the right to exchange at its
discretion any and all of the Pledged Collateral and Pledged Investment Property upon the merger, amalgamation, consolidation, reorganization, recapitalization or other fundamental change in the corporate or other structure of any Issuer, or upon
the exercise by any Grantor or Agent of any right, privilege or option pertaining to such Pledged Collateral and Pledged Investment Property, and in connection therewith, the right to deposit and deliver any and all of the Pledged Collateral and
Pledged Investment Property with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as Agent may determine), all without 

  
 22 

 
Liability other than to the extent such Liability is a result of its own willful misconduct or gross negligence as determined by a court of competent jurisdiction in a final non-appealable order or to account for property actually received by it, but Agent shall have no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do
so or delay in so doing. 
 (c) Each Grantor hereby expressly and irrevocably authorizes and instructs, without any further instructions from
such Grantor, each Issuer of the Pledged Collateral and Pledged Investment Property pledged by such Grantor hereunder to (i) comply with any instruction received by it from Agent in writing that (x) states that an Event of Default has
occurred and is continuing and (y) is otherwise in accordance with the terms of this Agreement, and each Grantor agrees that each Issuer shall be fully protected in so complying and (ii) unless otherwise permitted under the Loan Documents,
pay any dividends, distributions or other payments with respect to the Pledged Collateral and Pledged Investment Property directly to Agent. 

(d) In order to permit Agent to exercise the voting and other consensual rights that it is entitled to exercise pursuant hereto and to receive
all dividends and other distributions that it is entitled to receive hereunder, (i) during the existence of an Event of Default, each Grantor shall promptly execute and deliver (or cause to be executed and delivered) to Agent all such proxies,
dividend payment orders and other instruments as Agent may from time to time reasonably request and (ii) without limiting the effect of clause (i) above, such Grantor hereby grants to Agent an irrevocable proxy to vote all or any part of
the Pledged Collateral and the Pledged Investment Property and to exercise all other rights, powers, privileges and remedies to which a holder of the Pledged Collateral or the Pledged Investment Property, as applicable, would be entitled (including
giving or withholding written consents of shareholders, partners or members, as the case may be, calling special meetings of shareholders, partners or members, as the case may be, and voting at such meetings), which proxy shall be effective,
automatically and without the necessity of any action (including any transfer of any Pledged Collateral or Pledged Investment Property on the record books of the Issuer thereof) by any other person (including the Issuer of such Pledged Collateral or
Pledged Investment Property, as applicable, or any officer or agent thereof) solely during the continuance of an Event of Default and which proxy shall only terminate upon the Payment in Full in cash of the Secured Obligations or upon an express
waiver in writing by Agent and the Required Lenders of the underlying Event of Default in accordance with the terms of the Credit Agreement. 

6.4 Proceeds to be Turned Over to Agent. In addition to the rights of Agent specified in Section 6.1 hereof
with respect to payments of Receivables, if an Event of Default shall occur and be continuing and Agent has notified Borrower Representative of the Grantors’ obligations under this Section 6.4, all Proceeds received by
any Grantor consisting of cash, checks and other cash equivalent items shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor, and shall, upon written request of Agent,
forthwith upon receipt by such Grantor, be turned over to Agent in the exact form received by such Grantor (duly indorsed by such Grantor to Agent, if required). Subject to the terms of the Intercreditor Agreement (if applicable), all Proceeds
received by Agent under this Section 6.4 shall be held by Agent in a collateral account maintained under its sole dominion and control. All Proceeds, while held by Agent (for the benefit of the Secured Parties) in any
collateral account (or by such Grantor in trust for Agent (for the benefit of the Secured Parties)) established pursuant hereto, shall continue to be held as collateral security for the Secured Obligations and shall not constitute payment thereof
until applied as provided in Section 6.5 hereof. 
 6.5 Application of Proceeds. Agent may apply all or any
part of Proceeds from the sale of, or other realization upon, all or any part of the Collateral (after deducting all reasonable and 

  
 23 

 
documented external attorneys’ and other fees and out-of-pocket costs and expenses of every kind incurred in
connection therewith or incidental to the care or safekeeping of any Collateral or in any way relating to the Collateral or the rights of Agent and any other Secured Party hereunder) in payment of the Secured Obligations in such order as the Agent
shall determine in its discretion, and may pay any other amount required by any Applicable Law. Any balance of such Proceeds remaining after the Secured Obligations and the Guaranteed Obligations (as applicable) shall have been Paid in Full shall be
paid over to the applicable Grantor or to whomsoever may be lawfully entitled to receive the same. The parties hereto understand and agree that the exercise of remedies hereunder with respect to accounts arising under any Third Party Payor program
may be subject to Applicable Law. 
 6.6 Code and Other Remedies. If an Event of Default shall occur and be continuing, Agent may
exercise, in addition to all other rights and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations, all rights and remedies of a secured party under the UCC
or any other Applicable Law. Without limiting the generality of the foregoing, Agent, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to
or upon any Grantor or any other Person (all and each of which demands, defenses (other than defense of payment), advertisements and notices are hereby waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the
Collateral, or any part thereof, and/or may forthwith sell, lease, assign, give options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or
private sale or sales, at any exchange, broker’s board or office of Agent or elsewhere upon such terms and conditions as they may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery with
assumption of any credit risk. Agent shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or
equity of redemption in any Grantor, which right or equity is hereby waived and released. Each Grantor further agrees, at Agent’s request, to assemble the Collateral and make it available to Agent at places which Agent shall reasonably select,
whether at such Grantor’s premises or elsewhere in connection with the exercise of Agent’s remedies hereunder. Agent shall apply the net Proceeds of any action taken by it pursuant to this Section 6.6, after
deducting all reasonable documented out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of
the Collateral or in any way relating to the Collateral or the rights of Agent hereunder, to the payment in whole or in part of the Secured Obligations, as set forth in Section 6.5 hereof. To the extent permitted by
Applicable Law, each Grantor waives all claims, damages and demands it may acquire against Agent arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by
law, such notice shall be deemed reasonable and proper if given at least 10 calendar days before such sale or other disposition. Agent shall not be obligated to make any sale of Collateral regardless of notification of sale having been given. Agent
may adjourn any public sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor agrees that (A) the internet
shall constitute a “place” for purposes of Section 9-610(b) of the Code and (B) to the extent notification of sale shall be required by law, notification by mail of the URL where a sale
will occur and the time when a sale will commence at least ten (10) days prior to the sale shall constitute a reasonable notification for purposes of Section 9-611(b) of the Code. Each Grantor agrees
that any sale of Collateral to a licensor pursuant to the terms of a license agreement between such licensor and a Grantor is sufficient to constitute a commercially reasonable sale (including as to method, terms, manner, and time) within the
meaning of Section 9-610 of the Code. 
 6.7 Private Sale. Each Grantor recognizes that
Agent may be unable to effect a public sale of any or all the Pledged Collateral and Pledged Investment Property, by reason of certain 

  
 24 

 
prohibitions contained in the Securities Act and applicable state or foreign securities laws or otherwise, or may otherwise determine that a public sale is impracticable, not desirable or not
commercially reasonable, and, accordingly, and may resort to one or more private sales thereof to a restricted group of purchasers that will be obliged to agree, among other things, to acquire such securities for their own account for investment and
not with a view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances,
agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner. Agent shall be under no obligation to delay a sale of any of the Pledged Collateral or Pledged Investment Property for the period of time
necessary to permit the Issuer thereof to register such securities or other interests for public sale under the Securities Act, or under applicable state or foreign securities laws, even if such Issuer would agree to do so. 

Each Grantor agrees to use its commercially reasonable efforts to do or cause to be done all such other acts as may be necessary to make such
sale or sales of all or any portion of the Pledged Collateral and Pledged Investment Property pursuant to this Section 6.7 and Section 6.10 hereof valid and binding and in compliance with
Applicable Law. Each Grantor further agrees that a breach of any of the covenants contained herein will cause irreparable injury to Agent and the other Secured Parties, that Agent and the other Secured Parties have no adequate remedy at law in
respect of such breach and, as a consequence, that each and every covenant contained herein shall be specifically enforceable against such Grantor (except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization,
moratorium or other similar laws affecting creditors’ rights generally), and such Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants. Until all of the Secured Obligations and
all of the Guaranteed Obligations are Paid in Full, each Grantor postpones until such date any and all rights of contribution or subrogation upon the sale or disposition of all or any portion of the Pledged Collateral and Pledged Investment Property
by Agent. 
 6.8 Deficiency. Each Grantor shall remain liable for any deficiency if the Proceeds of any sale or other disposition of
any Collateral are insufficient to Pay in Full the Secured Obligations and the fees and disbursements of any attorneys employed by Agent or any other Secured Party to collect such deficiency. 

6.9 Licenses. Solely for the purpose of enabling Agent (for the benefit of the Secured Parties) to exercise rights and remedies
following and during the continuation of an Event of Default (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, convey, transfer or grant options to purchase any
Collateral), each Grantor hereby grants to Agent, for the benefit of the Secured Parties, (i) an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor) including in such license the
right to use, practice, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may
be recorded or stored and to all computer software and programs used for the compilation or printout thereof, and (ii) an irrevocable license (without payment of rent or other compensation to such Grantor) to use, operate and occupy all Real
Estate owned, operated, leased, subleased or otherwise occupied by such Grantor; provided, in each case, that no such licenses shall be granted with respect to any Excluded Property. 

6.10 Disposition of Collateral. Without limiting the generality of the foregoing, to the fullest extent not prohibited by Applicable
Law, Agent may, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands,
defenses, advertisements and notices are hereby waived), upon the occurrence and during the continuance of any 

  
 25 

 
Event of Default (personally or through its agents or attorneys), (i) enter upon the premises where any Collateral is located, without any obligation to pay rent, through self-help, without
judicial process, without first obtaining a final judgment or giving any Grantor or any other Person notice or opportunity for a hearing on Agent’s claim or action, (ii) collect, receive, appropriate and realize upon any Collateral and
(iii) sell, assign, convey, transfer, grant option or options to purchase and deliver any Collateral (and enter into contractual obligations to do any of the foregoing), in one or more parcels at public or private sale or sales, at any
exchange, broker’s board or office of any Secured Party or elsewhere upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption of any credit
risk. Agent shall have the right, upon any such public sale or sales and, to the extent permitted by the UCC and other Applicable Law, upon any such private sale, to purchase the whole or any part of the Collateral so sold, free of any right or
equity of redemption of any Grantor, which right or equity is hereby waived and released. 
 6.11 Management of the Collateral. Each
Grantor further agrees, that, upon the occurrence and during the continuance of any Event of Default and to the fullest extent not prohibited by Applicable Law and, in each case, subject to the terms of the Intercreditor Agreement (if applicable),
(i) at Agent’s written request, it shall assemble the Collateral and make it available to Agent at places that Agent shall reasonably select, whether at such Grantor’s premises or elsewhere, (ii) without limiting the foregoing, Agent
also has the right to require that each Grantor store and keep any Collateral pending further action by Agent and, while any such Collateral is so stored or kept, provide such guards and maintenance services as shall be necessary to protect the same
and to preserve and maintain such Collateral in good condition, (iii) until Agent is able to sell, assign, convey or transfer any Collateral, Agent shall have the right to hold or use such Collateral to the extent that it deems appropriate for
the purpose of preserving the Collateral or its value or for any other purpose deemed appropriate by Agent, and (iv) Agent may, if it so elects, seek the appointment of a receiver or keeper to take possession of any Collateral and to enforce
any of Agent’s remedies (for the benefit of the Secured Parties), with respect to such appointment without prior notice or hearing as to such appointment. Agent shall not have any obligation to any Grantor to maintain or preserve the rights of
any Grantor as against third parties with respect to any Collateral while such Collateral is in the possession of Agent. 
 6.12 Direct
Obligation. Neither Agent nor any other Secured Party shall be required to make any demand upon, or pursue or exhaust any right or remedy against, any Grantor, any other Guarantor, any other Loan Party or any other Person with respect to the
payment of the Secured Obligations or the Guaranteed Obligations or to pursue or exhaust any right or remedy with respect to any Collateral therefor or any direct or indirect guaranty thereof All of the rights and remedies of Agent and any other
Secured Party under any Loan Document shall be cumulative, may be exercised individually or concurrently and not exclusive of any other rights or remedies provided by any Applicable Law. To the extent it may lawfully do so, each Grantor absolutely
and irrevocably waives and relinquishes the benefit and advantage of, and covenants not to assert against Agent or any other Secured Party, any valuation, stay, appraisement, extension, redemption or similar laws and any and all rights or defenses
it may have as a surety, now or hereafter existing, arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of any Collateral shall be required by law, such notice shall be deemed reasonable
and proper if given at least ten (10) calendar days before such sale or other disposition. 
 6.13 Commercially Reasonable. To
the extent that any Applicable Law impose duties on Agent to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable for Agent to do any of the following: 

  
 26 

 (a) fail to incur significant costs, expenses or other Liabilities reasonably deemed as such
by Agent to prepare any Collateral for disposition or otherwise to complete raw material or work in process into finished goods or other finished products for disposition; 

(b) fail to obtain permits, or other consents, for access to any Collateral to sell or for the collection or sale of any Collateral, or, if not
required by other Applicable Law, fail to obtain Permits or other consents for the collection or disposition of any Collateral; 
 (c) fail
to exercise remedies against account debtors or other Persons obligated on any Collateral or to remove Liens on any Collateral or to remove any adverse claims against any Collateral; 

(d) advertise dispositions of any Collateral through publications or media of general circulation, whether or not such Collateral is of a
specialized nature, or to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring any such Collateral; 

(e) exercise collection remedies against account debtors and other Persons obligated on any Collateral, directly or through the use of
collection agencies or other collection specialists, hire one or more professional auctioneers to assist in the disposition of any Collateral, whether or not such Collateral is of a specialized nature, or, to the extent deemed appropriate by Agent,
obtain the services of other brokers, investment bankers, consultants and other professionals to assist Agent in the collection or disposition of any Collateral, or utilize Internet sites that provide for the auction of assets of the types included
in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets to dispose of any Collateral; 

(f) dispose of assets in wholesale rather than retail markets; 

(g) disclaim disposition warranties, such as title, possession or quiet enjoyment; or 

(h) purchase insurance or credit enhancements to insure Agent against risks of loss, collection or disposition of any Collateral or to provide
to Agent a guaranteed return from the collection or disposition of any Collateral. 
 Each Grantor acknowledges that the purpose of this
Section 6.13 is to provide a non-exhaustive list of actions or omissions that are commercially reasonable when exercising remedies against any Collateral and that other actions or
omissions by any Secured Party shall not be deemed commercially unreasonable solely on account of not being indicated in this Section 6.13. Without limitation upon the foregoing, nothing contained in this
Section 6.13 shall be construed to grant any rights to any Grantor or to impose any duties on Agent or any other Secured Party that would not have been granted or imposed by this Agreement or by Applicable Law in the
absence of this Section 6.13. 
 SECTION 7. AGENT. 

7.1 Agent’s Appointment as Attorney-in-Fact. 

(a) Each Grantor hereby irrevocably constitutes and appoints Agent and any Affiliates, directors, partners, officers, employees, agents,
counsel and advisors thereof, with full power of substitution, as its true and lawful attorney-in-fact with full power and authority in the place and stead of such
Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of the Loan Documents, to, upon the occurrence and during the continuance of an Event of Default,

  
 27 

 
take any appropriate action and to execute any document or instrument that may be necessary or desirable to accomplish the purposes of the Loan Documents, and, without limiting the generality of
the foregoing, each Grantor hereby gives Agent and its Affiliates, directors, partners, officers, employees, agents, counsel and advisors the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do any of the
following when an Event of Default has occurred and is continuing (subject, as applicable, to compliance by Agent with Applicable Law with respect to Accounts arising under any Third Party Payor programs): 

(i) in the name of such Grantor, in its own name or otherwise, take possession of and indorse and collect any check, draft,
note, acceptance or other instrument for the payment of moneys due under any account or general intangible that is Collateral or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or
equity or otherwise deemed appropriate by Agent for the purpose of collecting any such moneys due under any account or general intangible that is Collateral or with respect to any other Collateral whenever payable; 

(ii) in the case of any Intellectual Property owned by and, in the case of Copyrights, exclusively licensed to such Grantor (to
the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property), execute, deliver and have recorded any document that Agent may request in accordance with this Agreement to evidence, effect,
publicize or record Agent’s security interest in such Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby; 

(iii) pay or discharge taxes and Liens levied or placed on or threatened against any Collateral, effect any repair or pay any
insurance called for by the terms of the Credit Agreement (including all or any part of the premiums therefor and the costs thereof); 

(iv) execute, in connection with any sale provided for in Section 6.7 or
Section 6.10 hereof, any document to effect or otherwise necessary or appropriate in relation to evidence the sale of any Collateral; or 

(v) (A) direct any party liable for any payment under any Collateral to make payment of any moneys due or to become due
thereunder directly to Agent or as Agent shall direct, (B) ask or demand for, and collect and receive payment of and receipt for, any moneys, claims and other amounts due or to become due at any time in respect of or arising out of any
Collateral, (C) sign and indorse any invoice, freight or express bill, bill of lading, storage or warehouse receipt, draft against debtors, assignment, verification, notice and other document in connection with any Collateral, (D) commence
and prosecute any suit, action or proceeding at law or in equity in any court of competent jurisdiction to collect any Collateral and to enforce any other right in respect of any Collateral, (E) defend any actions, suits, proceedings, audits,
claims, demands, orders or disputes brought against such Grantor with respect to any Collateral, (F) settle, compromise or adjust any such actions, suits, proceedings, audits, claims, demands, orders or disputes that are related to Collateral
and, in connection therewith, give such discharges or releases as Agent may deem appropriate, (G) assign any Intellectual Property owned by any Grantor or any Intellectual Property Licenses of any Grantor where such Grantor is the licensor
thereunder (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property or Intellectual Property License, as applicable) throughout the world on such terms and conditions and in such manner
as Agent shall in its sole discretion determine (except, with respect to Trademarks, subject to reasonable quality control in favor of 

  
 28 

 
such Grantor), including the execution and filing of any document necessary to effectuate or record such assignment, or (H) generally, sell, assign, convey, transfer or grant a Lien on, make
any Contractual Obligation with respect to and otherwise deal with, any Collateral as fully and completely as though Agent were the absolute owner thereof for all purposes and do, at Agent’s option, at any time or from time to time, all acts
and things that Agent deems necessary to protect, preserve or realize upon any Collateral and the Secured Parties’ security interests therein and to effect the intent of the Loan Documents, all as fully and effectively as such Grantor might do;

 (vi) if any Grantor fails to perform or comply with any Contractual Obligation contained herein, then during the existence
of an Event of Default, Agent, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such Contractual Obligation; 

(vii) receive and open all mail addressed to any Grantor and to notify postal authorities to change the address for the
delivery of mail to such Grantor to that of Agent; or 
 (viii) use any Intellectual Property or Intellectual Property
Licenses of such Grantor, including but not limited to any labels, Patents, Trademarks, trade names, URLs, domain names, industrial designs, Copyrights, or advertising matter, in preparing for sale, advertising for sale, or selling Inventory or
other Collateral and to collect any amounts due under Accounts, contracts or negotiable Collateral of such Grantor. 
 (b) The expenses of
Agent incurred in connection with actions undertaken as provided in this Section 7.1, together with, during the existence of an Event of Default as set forth in Section 2.05(c) of the Credit
Agreement, interest thereon at a rate set forth in Section 2.05(c) of the Credit Agreement, from the date of payment by Agent to the date reimbursed by the relevant Grantor, shall be payable by such Grantor to Agent on
written demand by Agent to Borrower Representative. 
 (c) Each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to
be done by virtue of, and in accordance with, this Section 7.1. All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement is terminated and the
security interests created hereby are released. 
 7.2 Authority of Agent. Each Grantor acknowledges that the rights and
responsibilities of Agent under this Agreement with respect to any action taken by Agent or the exercise or non-exercise by Agent of any option, voting right, request, judgment or other right or remedy
provided for herein or resulting or arising out of this Agreement shall, as between Agent and the other Secured Parties, be governed by the Credit Agreement and by such other agreements with respect thereto as may exist from time to time among them,
but, as between Agent and any Grantor, Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation or entitlement to
make any inquiry respecting such authority. 
 7.3 Duty; Obligations and Liabilities. 

(a) Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession shall be to
deal with it in the same manner as Agent deals with similar property for its own account. The powers conferred on Agent hereunder are solely to protect Agent’s interest in the Collateral and shall not impose any duty upon Agent to exercise any
such powers. Agent shall be accountable only for amounts that it receives as a result of the exercise of such powers, and 

  
 29 

 
neither it nor any of its Affiliates, directors, partners, officers, employees, agents, counsel or advisors shall be responsible to any Grantor for any act or failure to act hereunder, except for
their own gross negligence, bad faith or willful misconduct, in each case, as determined by a court of competent jurisdiction in a final non-appealable order. In addition, Agent shall not be liable or
responsible for any loss or damage to any Collateral, or for any diminution in the value thereof, by reason of the act or omission of any warehousemen, carrier, forwarding agency, consignee or other bailee if such Person has been selected by Agent
in good faith. 
 (b) No Secured Party and no Affiliates, directors, partners, officers, employees, agents, counsel or advisors thereof shall
be liable for failure to demand, collect or realize upon any Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any
other action whatsoever with regard to any Collateral. The powers conferred on Agent hereunder shall not impose any duty upon any other Secured Party to exercise any such powers. The other Secured Parties shall be accountable only for amounts that
they actually receive as a result of the exercise of such powers, and neither they nor any of their respective officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder, except for their own
gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final non-appealable order. 

SECTION 8. MISCELLANEOUS. 
 8.1
Amendments in Writing. The provisions of this Agreement may be waived, modified, supplemented or amended only by an instrument in writing signed by Borrowers and Agent; provided, however, that annexes and schedules, as
applicable, to this Agreement may be supplemented or modified (but no existing provisions may be modified and no Collateral may be released, except with respect to the removal of items on the schedules in connection with a sale or other Disposition
of Collateral, a merger or Acquisition, in each case, that is permitted under the Credit Agreement) as set forth in Section 5 and Section 8.15 hereof. Notwithstanding anything to the contrary in
the first sentence of this Section 8.1, any time period for performance under this Agreement may be extended, at any time, by Agent in its sole discretion. 

8.2 Notices. All notices, requests and demands to or upon Agent or any Guarantor or Grantor hereunder shall be addressed to such party
and effected in the manner provided for in Article XI of the Credit Agreement and each Guarantor and Grantor hereby appoints the Borrower Representative as its agent to receive notices hereunder. 

8.3 Indemnification by Grantors. Each Grantor and each Guarantor agrees to jointly and severally indemnify, pay, and hold Agent, the
other Secured Parties and the Secured Parties’ Affiliates, officers, directors, employees, agents, and attorneys (the “Indemnitees”) harmless against losses and Liabilities to the extent set forth in
Section 10.03 of the Credit Agreement, the terms of which are incorporated herein by reference as though set forth fully herein. The provisions in this Section 8.3 shall survive Payment in Full of
all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement. 

8.4 Enforcement Expenses. 

(a) The terms of Section 15.07 of the Credit Agreement with respect to costs and expenses are incorporated herein by
reference, mutatis mutandis, and the parties hereto agree to such terms. 

  
 30 

 (b) The agreements in this Section 8.4 shall survive Payment in
Full of all Secured Obligations and the Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement. 

8.5 Nature of Remedies. All Secured Obligations and Guaranteed Obligations of each Grantor and rights of Agent and the other Secured
Parties expressed herein or in any other Loan Document shall be in addition to and not in limitation of those provided by Applicable Law. No failure to exercise and no delay in exercising, on the part of Agent or the other Secured Parties, any
right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other
right, remedy, power or privilege. 
 8.6 Counterparts; Effectiveness. This Agreement may be executed in several counterparts, and by
each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement. 

8.7 Severability. If any provision of this Agreement or any of the other Loan Documents shall be invalid, illegal or unenforceable in
any respect under any law, the validity, legality and enforceability of the remaining provisions hereof or thereof shall not in any way be affected or impaired thereby. The parties hereto shall endeavor in good faith negotiations to replace the
invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provision. 

8.8 Entire Agreement. This Agreement contains the entire understanding of the parties hereto with respect to the matters covered hereby
and supersedes any and all other written and oral communications, negotiations, commitments and writings with respect thereto. All Exhibits, Schedules and Annexes referred to herein are incorporated in this Agreement by reference and constitute a
part of this Agreement. If any provision contained in this Agreement conflicts with any provision of the Credit Agreement, then with regard to such conflicting provisions, the Credit Agreement shall govern and control. 

8.9 Successors; Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns, except, notwithstanding anything to the contrary in this Agreement or any other Loan Document, that Grantors and Guarantors may not assign their rights or obligations hereunder and any such purported, prohibited or
attempted assignment shall be void ab initio. 
 8.10 Applicable Law. THE VALIDITY OF THIS AGREEMENT AND THE OTHER LOAN
DOCUMENTS (UNLESS EXPRESSLY PROVIDED TO THE CONTRARY IN ANOTHER LOAN DOCUMENT IN RESPECT OF SUCH OTHER LOAN DOCUMENT), THE CONSTRUCTION, INTERPRETATION, AND ENFORCEMENT HEREOF AND THEREOF, THE RIGHTS OF THE PARTIES HERETO AND THERETO WITH RESPECT TO
ALL MATTERS ARISING HEREUNDER OR THEREUNDER OR RELATED HERETO OR THERETO, AND ANY CLAIMS, CONTROVERSIES OR DISPUTES ARISING HEREUNDER OR THEREUNDER OR RELATED HERETO OR THERETO SHALL BE DETERMINED UNDER, GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF NEW YORK. 
 8.11 Consent to Jurisdiction; Venue. 

  
 31 

 (a) GRANTORS AND GUARANTORS HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMIT TO THE EXCLUSIVE
JURISDICTION OF THE COMMERCIAL DIVISION NEW YORK STATE SUPREME COURT AND THE FEDERAL COURTS, IN EACH CASE, SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN (AND, IN EACH CASE, THE APPLICABLE STATE AND FEDERAL APPEALS COURTS SITTING IN THE CITY
OF NEW YORK OR, IF NOT AVAILABLE OR APPLICABLE, THE STATE OF NEW YORK), IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO ANY LOAN DOCUMENTS, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL
JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT
AGENT MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. 

(b) THE PARTIES AGREE THAT ALL ACTIONS OR PROCEEDINGS ARISING IN CONNECTION WITH THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS SHALL BE TRIED AND
LITIGATED ONLY IN THE STATE AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, FEDERAL COURTS LOCATED IN THE COUNTY OF NEW YORK, STATE OF NEW YORK; PROVIDED, THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE
BROUGHT, AT AGENT’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE AGENT ELECTS TO BRING SUCH ACTION OR WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. GRANTORS, GUARANTORS AND EACH MEMBER OF THE LENDER GROUP WAIVE, TO THE EXTENT
PERMITTED UNDER APPLICABLE LAW, ANY RIGHT EACH MAY HAVE TO ASSERT THE DOCTRINE OF FORUM NON CONVENIENS OR TO OBJECT TO VENUE TO THE EXTENT ANY PROCEEDING IS BROUGHT IN ACCORDANCE WITH THIS SECTION 8.11. 

8.12 Waiver of Jury Trial. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, GRANTORS, GUARANTORS AND EACH MEMBER OF THE LENDER GROUP
HEREBY WAIVE THEIR RESPECTIVE RIGHTS, IF ANY, TO A JURY TRIAL OF ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION DIRECTLY OR INDIRECTLY BASED UPON OR ARISING OUT OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN,
INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS (EACH A “CLAIM”). GRANTORS, GUARANTORS AND EACH MEMBER OF THE LENDER GROUP REPRESENT THAT EACH HAS REVIEWED THIS WAIVER AND
EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. IN THE EVENT OF LITIGATION, A COPY OF THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 

8.13 Set-off. Each Grantor agrees that Agent and the other Secured Parties have all rights of set-off and bankers’ lien provided by Applicable Law, and in addition thereto, each Grantor agrees that at any time any Event of Default exists, Agent and the other Secured Parties may apply to the payment of
any Secured Obligations and the Guaranteed Obligations as set forth in Section 6.5 hereof, whether or not then due, any and all balances, credits, deposits, accounts or moneys of such Grantor then or thereafter with the
Secured Parties. 
  

  
 32 

 8.14 Acknowledgements. Each Grantor and each Guarantor hereby acknowledges that: 

(a) it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it is a
party; 
 (b) Neither Agent nor any other Secured Party have any fiduciary relationship with or duty to any Grantor or Guarantor arising out
of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors and Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, in connection herewith or therewith is
solely that of debtor and creditor; and 
 (c) no joint venture is created hereby or by the other Loan Documents or otherwise exists by
virtue of the transactions contemplated hereby among the Grantors, Guarantors and the Secured Parties. 
 8.15 Additional
Grantors/Guarantors. The Grantors shall cause each Person, upon becoming a Subsidiary of a Grantor (other than any Excluded Subsidiary) or upon becoming a Subsidiary, limited liability company, other entity or other Person for which any Grantor
divides or splits itself into (or that receives any assets or property of such Grantor from any such division or split), to guaranty Borrowers’ and the other Grantors’ performance of the Secured Obligations and the Guaranteed Obligations
and grant to Agent, for the benefit of the Secured Parties, a security interest in the personal property of such Person (to the extent such personal property would constitute Collateral) to secure the Secured Obligations, its performance under the
Credit Agreement and the other Loan Documents and Borrowers’, each Guarantor’s and the other Grantors’ performance of the Secured Obligations by becoming a party to this Agreement. Upon execution and delivery by such Person of a
joinder agreement in the form of Annex I hereto, such Person shall become a Grantor and Guarantor for all purposes of this Agreement. 

8.16 Releases. 
 (a) At
such time as the Secured Obligations have been Paid in Full, the Collateral shall be automatically released from the Liens created hereby and this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment
in Full of the Secured Obligations or the Guaranteed Obligations), all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall automatically revert to the Grantors. At such time as the
Guaranteed Obligations have been Paid in Full, subject to Section 8.18, the guarantees provided in Section 2 and the remainder of this Agreement shall automatically terminate (other than those
provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations, including those specific provisions of Section 8 hereof expressly surviving Payment in Full of the Secured
Obligations or the Guaranteed Obligations). At the request and sole expense of any Grantor following any such Payment in Full of the Secured Obligations, Agent shall promptly deliver to the Grantors any Collateral held by Agent hereunder, and
execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination and release of the Liens in the Collateral. At the request and sole expense of any Grantor following any such Payment
in Full of the Guaranteed Obligations, Agent shall execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination of the guarantees provided in Section 2.

 (b) If any of the Collateral shall be sold, transferred or otherwise disposed of by any Grantor in a transaction permitted by the Credit
Agreement or with the written consent of Agent and the 

  
 33 

 
Required Lenders, then Agent, at the reasonable written request and sole expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents reasonably necessary
for the release of the Liens created hereby on such Collateral; provided that Borrowers shall have delivered to Agent, with reasonable notice prior to the date of the proposed release, a written request for release identifying the relevant
Grantor, together with a certification by Borrowers stating that such transaction is in compliance with the Credit Agreement and the other Loan Documents (including the relevant provision of the Loan Documents pursuant to which such transfer or
other disposition is permitted, together with any additional evidence reasonably requested by Agent). 
 (c) If, in compliance with the terms
and provisions of the Loan Documents, (i) all or substantially all of the Stock of any Guarantor is sold or otherwise transferred to a Person or Persons none of which is a Loan Party in a transaction permitted under the Loan Documents or with
the written consent of Agent and the Required Lenders or (ii) any Guarantor becomes an Excluded Subsidiary as a result of a transaction permitted under the Loan Documents (any such Guarantor, and any Guarantor referred to in clause (i), a
“Transferred Guarantor”), such Transferred Guarantor shall, upon the consummation of such sale or transfer or other transaction, be automatically released from its obligations under this Agreement (including under this
Section 8.16) and the other Loan Documents, including its obligations to pledge and grant any Collateral owned by it and, in the case of a sale of all or substantially all of the Stock of the Transferred Guarantor, the
pledge of such Stock to the Agent hereunder shall be automatically released, and, so long as the Borrowers shall have provided the Agent such certifications or documents as the Agent shall reasonably request, the Agent, at the sole expense of the
Grantors, shall take such actions as are reasonably necessary and requested by the Grantors in writing to effect each release described in this Section 8.16. 

8.17 Obligations and Liens Absolute and Unconditional. Each Grantor and each Guarantor understands and agrees that the obligations of
each Grantor under this Agreement shall be construed as continuing, absolute and unconditional without regard to (i) the validity or enforceability of any Loan Document, any of the Secured Obligations or any other collateral security therefor
or guaranty or right of offset with respect thereto at any time or from time to time held by Agent or any other Secured Party, (ii) any defense, set-off or counterclaim (other than a defense of payment or
performance) which may at any time be available to or be asserted by any Grantor, Guarantor or any other Person against Agent or any other Secured Party, or (iii) any other circumstance whatsoever (with or without notice to or knowledge of any
Grantor or Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of any Grantor or Guarantor for the Secured Obligations or the Guaranteed Obligations, in bankruptcy or in any other instance. When making
any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor or Guarantor, Agent and any other Secured Party may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and
remedies as they may have against any other Grantor or Guarantor or any other Person or against any collateral security for the Secured Obligations or guaranty for the Guaranteed Obligations or any right of offset with respect thereto, and any
failure by Agent or any other Secured Party to make any such demand, to pursue such other rights or remedies or to collect any payments from any other Grantor or Guarantor or any other Person or to realize upon any such collateral security or
guaranty or to exercise any such right of offset, or any release of any other Grantor or Guarantor or any other Person or any such collateral security, guaranty or right of offset, shall not relieve any Grantor or Guarantor of any obligation or
Liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of Agent or any other Secured Party against any Grantor or Guarantor. For the purposes hereof “demand”
shall include the commencement and continuance of any legal proceedings. 
  

  
 34 

 8.18 Reinstatement. Each Grantor and Guarantor agrees that, if any payment made by
any Loan Party or other Person and applied to the Secured Obligations or the Guaranteed Obligations is at any time annulled, avoided, set aside, rescinded, invalidated, declared to be fraudulent or preferential or otherwise required to be refunded
or repaid, or the Proceeds of any Collateral are required to be returned by any Secured Party to such Loan Party, its estate, trustee, receiver or any other party, including any Grantor or Guarantor, under any applicable bankruptcy law, state or
federal law, common law or equitable cause, then, to the extent such payment or repayment is annulled, avoided, set aside, rescinded, invalidated, refunded, repaid or returned, any Lien or other Collateral securing such liability with respect to the
Secured Obligations and any guarantee herein securing the Guaranteed Obligations shall be and remain in full force and effect, as fully as if such payment had never been made. If, prior to any of the foregoing, (i) any Lien or other Collateral
securing such Grantor’s Secured Obligations or Guarantor’s Guaranteed Obligations shall have been released or terminated by virtue of the foregoing or (ii) any provision of the guaranty hereunder shall have been terminated, cancelled
or surrendered in connection with the foregoing payment, such Lien, other Collateral, guaranty or other provision shall be reinstated in full force and effect and such prior release, termination, cancellation or surrender shall not diminish,
release, discharge, impair or otherwise affect the obligations of any such Grantor in respect of any Lien or other Collateral securing, or any such Guarantor in respect of any guaranty guaranteeing such obligation or the amount of such payment. This
Section 8.18 shall survive the termination of this Agreement pursuant to Section 8.16 or otherwise. The provisions in this Section 8.18 shall survive Payment in Full of
all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement. 

8.19 Independent Obligations. The obligations of each Grantor and each Guarantor hereunder are independent of and separate from the
Secured Obligations and the Guaranteed Obligations. During the continuance of any Event of Default, Agent may, at its sole election, proceed directly and at once, without notice, against any Grantor, any Guarantor and any Collateral to collect and
recover the full amount of any Secured Obligation or Guaranteed Obligation (as applicable) then due, without first proceeding against any other Grantor, any Guarantor, any other Loan Party or any other Collateral or any guaranty and without first
joining any other Grantor, any other Guarantor or any other Loan Party in any proceeding. 
 8.20 No Waiver by Course of Conduct. No
Secured Party shall by any act (except by a written signed instrument by the required Persons pursuant to Section 8.1 hereof and Section 6.6 of the Credit Agreement), delay, indulgence, omission or
otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any Default or Event of Default. No failure to exercise, nor any delay in exercising, on the part of any Secured Party, any right, power or privilege hereunder
or under any other Loan Document shall operate as a waiver thereof No single or partial exercise of any right, power or privilege hereunder or under any other Loan Document shall preclude any other or further exercise thereof or the exercise of any
other right, power or privilege. A waiver by any Secured Party of any right or remedy hereunder or any other Loan Document on any one occasion shall not be construed as a bar to any right or remedy that such Secured Party would otherwise have on any
future occasion. 
 8.21 Intercreditor Agreement. This Agreement is subject, in the manner and the extent, to the terms set forth in
the Intercreditor Agreement. Any Collateral held by (or in the possession or control of) the Term Agent (or its agents or bailees) shall be held as agent and bailee for security and Lien perfection purposes in favor of Agent (for the benefit of the
Secured Parties) in accordance with the terms of the Intercreditor Agreement and the Loan Documents. 
 8.22 Relation to Other Loan
Documents. The provisions of this Agreement shall be read and construed with the other Loan Documents referred to below in the manner so indicated. 
  

  
 35 

 (a) In the event of any conflict between any provision in this Agreement and a provision in
the Credit Agreement, such provision of the Credit Agreement shall control. 
 (b) The provisions of the Copyright Security Agreements,
Trademark Security Agreements, and Patent Security Agreements are supplemental to the provisions of this Agreement, and nothing contained in the Copyright Security Agreements, Trademark Security Agreements, or the Patent Security Agreements shall
limit any of the rights or remedies of Agent hereunder. In the event of any conflict between any provision in this Agreement and a provision in a Copyright Security Agreement, Trademark Security Agreement or Patent Security Agreement, such provision
of this Agreement shall control. 
 [SIGNATURE PAGES FOLLOW] 

  
 36 

 IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed
and delivered as of the date first above written. 
  

							
	GRANTORS AND GUARANTORS:	 		 	ENDOLOGIX, INC.,
		 		 	a Delaware corporation,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer
			
		 		 	CVD/RMS ACQUISITION CORP.,
		 		 	a Delaware corporation,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary
			
		 		 	NELLIX, INC.,
		 		 	a Delaware corporation,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary
			
		 		 	TRIVASCULAR TECHNOLOGIES, INC.,
		 		 	a Delaware corporation,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary

  
 [Signature Page to Guaranty and Security
Agreement] 

							
	GRANTORS AND GUARANTORS CONTINUED:	 		 	TRIVASCULAR, INC.,
		 		 	a California corporation,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary
			
		 		 	ENDOLOGIX CANADA, LLC,
		 		 	a Delaware limited liability company,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary
			
		 		 	TRIVASCULAR SALES, LLC,
		 		 	a Texas limited liability company,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary
			
		 		 	 RMS/ENDOLOGIX SIDEWAYS MERGER

CORP.,

		 		 	a Delaware corporation,
as Grantor and Guarantor
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary

 [Signature Page to Guaranty and Security Agreement] 

							
			
	AGENT:	 		 	DEERFIELD ELGX REVOLVER, LLC, as Agent
			
		 		 	 By: Deerfield Management Company, L.P. (Series C), Manager

 
 By: Flynn Management LLC, General Partner

				
		 		 	By:	 	 /s/ David J. Clark

		 		 	Name:	 	David J. Clark
		 		 	Title:	 	Authorized Signatory

 [Signature Page to Guaranty and Security Agreement] 

 SCHEDULE 1 

PLEDGED EQUITY AND PLEDGED DEBT INSTRUMENTS 

Pledged Equity: 
  

																	
	 Grantor
(owner of
Record of
such
Pledged
Equity)
	  	 Issuer
	  	Par
Value	 	  	 No. of
Shares,
Units
or
Interests
Owned
	  	 Total
Shares,
Units
or
Interests
Authorized
and
Outstanding
	  	Percentage
of Shares,
Units or
Interests
Owned	 	  	 Certificate
(Indicate
No.)

	 Endologix, Inc.
	  	Nellix, Inc.	  	$	0.001	 	  	100 Shares	  	1,000 Shares Authorized; 100 Shares Outstanding	  	 	100	% 	  	65
	 Endologix, Inc.
	  	CVD/RMS
Acquisition
Corp.	  	$	0.001	 	  	100 Shares	  	100 Shares Authorized and Outstanding	  	 	100	% 	  	4
	 Endologix, Inc.
	  	RMS/Endologix Sideways Merger Corp.	  	$	0.001	 	  	100 Shares	  	100 Shares Authorized and Outstanding	  	 	100	% 	  	Com-1
	 Endologix, Inc.
	  	TriVascular Technologies, Inc.	  	$	0.001	 	  	100 Shares	  	1,000 Shares Authorized; 100 Shares Outstanding	  	 	100	% 	  	60
	 Endologix, Inc.
	  	ELGX International Holdings GP	  	 	N.A.	 	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	 	100	% 	  	N.A.
	 Endologix, Inc.
	  	Endologix Bermuda L.P.	  	 	N.A.	 	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	 	99	% 	  	N.A.

																	
	 Grantor
(owner of
Record of
such
Pledged
Equity)
	  	 Issuer
	  	Par
Value	 	  	 No. of
Shares,
Units
or
Interests
Owned
	  	 Total
Shares,
Units
or
Interests
Authorized
and
Outstanding
	  	Percentage
of Shares,
Units or
Interests
Owned	 	  	 Certificate
(Indicate
No.)

	 ELGX International Holdings GP
	  	Endologix Bermuda L.P.	  	 	N.A.	 	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	 	1	% 	  	N.A.
	 Endologix, Inc.
	  	Endologix Singapore Private Limited	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.
	 Endologix, Inc.
	  	Endologix New Zealand Co.	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.
	 Endologix, Inc.
	  	ELGX South Korea Ltd	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.
	 TriVascular Technologies, Inc.
	  	TriVascular,
Inc.	  	$	0.01	 	  	100 Shares	  	100 Shares Authorized and Outstanding	  	 	100	% 	  	CS-4
	 TriVascular, Inc.
	  	TriVascular Sales LLC	  	 	N.A.	 	  	1,000 Units of Membership Interests	  	1,000 Units of Membership Interests	  	 	100	% 	  	N.A.
	 TriVascular, Inc.
	  	TriVascular
Germany
GmbH	  	 	N.A.	 	  	Unspecified number of Company Interests	  	Unspecified number of Company Interests	  	 	100	% 	  	N.A.
	 TriVascular, Inc.
	  	TriVascular
Switzerland
Sarl	  	 	N.A.	 	  	Unspecified number of Company Interests	  	Unspecified number of Company Interests	  	 	100	% 	  	N.A.

																	
	 Grantor
(owner of
Record of
such
Pledged
Equity)
	  	 Issuer
	  	Par
Value	 	  	 No. of
Shares,
Units
or
Interests
Owned
	  	 Total
Shares,
Units
or
Interests
Authorized
and
Outstanding
	  	Percentage
of Shares,
Units or
Interests
Owned	 	  	 Certificate
(Indicate
No.)

	 TriVascular, Inc.
	  	Endologix Canada, LLC	  	 	N.A.	 	  	1,000 Units of Membership Interests	  	1,000 Units of Membership Interests	  	 	100	% 	  	N.A.
	 TriVascular, Inc.
	  	TriVascular, Inc.
Italia Sarl	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.
	 Endologix Bermuda L.P.
	  	Endologix International Holdings B.V.	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.
	 Endologix International Holdings B.V.
	  	Endologix Poland spolkda z ograniczona odpowiedzialnoscia	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.
	 Endologix International Holdings B.V.
	  	Endologix
Italia Sarl	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.
	 Endologix International Holdings B.V.
	  	Endologix International B.V.	  	 	N.A.	 	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	 	100	% 	  	N.A.

 Pledged Debt Instruments: 
  

											
	 Grantor (owner
of Record of such
Pledged
Debt
Instrument)
	  	 Issuer
	  	 Description of Debt
	  	 Final
Maturity
	  	 Principal
Amount
	  	 Certificate
(Indicate
No.)

	 N.A.
	  		  		  		  		  	

 SCHEDULE 1A 

PLEDGED INVESTMENT PROPERTY 
  

					
	 Name of Issuer
	  	Description and Value of Security	  	Loan Party/Subsidiary
	Cianna Medical, Inc.	  	8,677 Shares of Series
A Preferred Stock	  	Endologix, Inc.

 See Schedule 1. 

 SCHEDULE 2 

FILINGS AND PERFECTION 
 To be
attached. 

 Execution Version 

PATENT SECURITY AGREEMENT 

This PATENT SECURITY AGREEMENT (this “Patent Security Agreement”) is made this
9th day of August, 2018, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “Grantors” and each individually
“Grantor”), and DEERFIELD ELGX REVOLVER, LLC, a Delaware limited liability company, in its capacity as agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity,
“Agent”). 
 W I T N E S S E T H: 

WHEREAS, pursuant to that certain Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified
from time to time, the “Credit Agreement”) by and among ENDOLOGIX, INC., a Delaware corporation (“Endologix”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any
additional borrower that may thereafter be added to the Credit Agreement (individually as a “Borrower”, and collectively with any entities that become party thereto as Borrower and each of their successors and permitted assigns, the
“Borrowers”), the lenders party thereto as “Lenders” (such Lenders, together with their respective successors and assigns in such capacity, each, individually, a “Lender” and, collectively, the
“Lenders”), and Agent, the Lender Group has agreed to make certain financial accommodations available to the Borrowers from time to time pursuant to the terms and conditions thereof; 

WHEREAS, the members of the Lender Group are willing to make the financial accommodations to the Borrowers as provided for in the Credit
Agreement and the other Loan Documents, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group, that certain Guaranty and Security Agreement, dated as of
August 9, 2018 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “Guaranty and Security Agreement”); and 

WHEREAS, pursuant to the Guaranty and Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender
Group, this Patent Security Agreement. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows: 

1. DEFINED TERMS. All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Guaranty
and Security Agreement or, if not defined therein, in the Credit Agreement, and this Patent Security Agreement shall be subject to the rules of construction set forth in Section 1.04 of the Credit Agreement, which rules of construction are
incorporated herein by this reference, mutatis mutandis. 
 2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Each Grantor
hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of each member of the Lender Group, to secure the Secured Obligations, a continuing security interest (referred to in this Patent Security Agreement as the
“Security Interest”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “Patent Collateral”): 

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I; 

  
 1 

 (b) all divisionals, continuations, continuations-in-part, reissues, reexaminations, or extensions of the foregoing; and 
 (c) all
products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future infringement of any Patent or any Patent exclusively licensed under any Intellectual Property License, including the right
to receive damages, or right to receive license fees, royalties, and other compensation under any Patent Intellectual Property License. 
 3.
SECURITY FOR SECURED OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the
generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Agent, the other members of the Lender Group or any of
them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor. 
 4.
PROTECTION OF PATENT SECURITY INTEREST BY GRANTORS. Each Grantor shall, at its sole cost, expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section 6 of the
Guaranty and Security Agreement in respect of the Patent Collateral. 
 5. REPRESENTATIONS AND WARRANTIES. Each Grantor represents and
warrants that: 
 (a) Schedule I hereto is a true, correct and complete list of all Patents and Patent Intellectual Property Licenses in
which each Grantor purports to have an ownership or license interest. 
 (b) Such Grantor has the legal right and authority to enter into
this Patent Security Agreement and perform its terms. 
 (c) If such Grantor amends its name, such Grantor shall provide copies of such
amendment documentation to Agent and shall, if necessary, re-register such Grantor’s Patents and Patent Intellectual Property Licenses with the appropriate Governmental Authority and shall execute and
deliver such agreements or documentation as Agent shall reasonably request in writing to maintain a perfected first priority security interest in the Patent Collateral subject to Permitted Liens. 

6. SECURITY AGREEMENT. The Security Interest in the Collateral granted pursuant to this Patent Security Agreement is granted in
conjunction with the security interests granted to Agent, for the benefit of the Lender Group, pursuant to the Guaranty and Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the
Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent
there is any inconsistency between this Patent Security Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control. 

7. AUTHORIZATION TO SUPPLEMENT. If any Grantor shall obtain rights to any new patent application or issued patent or become entitled to
the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent
application, the provisions of this Patent Security Agreement shall automatically apply thereto. Each Grantor shall notify Agent of applications filed for the registration of any Patents with the United

  
 2 

 
States Patent Office in accordance with Section 5.7(g) of the Guaranty and Security Agreement. Without limiting Grantors’ obligations under this Section, Grantors hereby authorize Agent
unilaterally to modify this Patent Security Agreement by amending Schedule I to include any such new patent rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule
I shall in any way affect, invalidate or detract from Agent’s continuing security interest in all Collateral, whether or not listed on Schedule I. 

8. NO VIOLATION OF LOAN DOCUMENTS. The representations, warranties or covenants contained herein are supplemental to those
representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document. 

9. GRANTOR’S RIGHTS TO ENFORCE PATENTS. Prior to Agent’s giving of notice to Grantor following the occurrence and during the
continuance of an Event of Default, such Grantor shall have the exclusive right to sue for past, present and future infringement of the Patent Collateral, including the right to seek injunctions and/or money damages, in an effort by such Grantor to
protect the Patent Collateral against encroachment by third parties, provided, however, that: 
 (a) Any money damages awarded or received by
such Grantor on account of such suit (or the threat of such suit) shall constitute Patent Collateral. 
 (b) Any damages recovered in any
action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guaranty and Security Agreement. 

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such
Grantor’s rights under this Section 9. 
 10. RIGHTS UPON DEFAULT. Upon the occurrence and during the continuance of any
Event of Default, Agent may exercise all rights and remedies as provided for in the Guaranty and Security Agreement. 
 11. NO LIMITATION;
LOAN DOCUMENTS. This Patent Security Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the Patent Collateral with the United States Patent Office. The
security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of the Lender Group, under the Guaranty and Security Agreement and the other Loan Documents. The
other Loan Documents (and all rights and remedies of Grantor, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms. 

12. TERMINATION; RELEASE OF PATENT COLLATERAL. This Patent Security Agreement and all obligations of each Grantor and Agent hereunder
shall terminate on the date upon which the Obligations have been Paid in Full. Upon termination of this Patent Security Agreement, Agent shall, at the reasonable expense of the Grantor, take such actions required by the Credit Agreement or the
Guaranty and Security Agreement or as otherwise reasonably requested by Grantor to release its security interest in the Patent Collateral. 

13. BINDING EFFECT; BENEFITS. This Patent Security Agreement shall be binding upon each Grantor and its successors and assigns, and
shall inure to the benefit of Agent, Lenders and their respective successors and assigns. 

  
 3 

 14. COUNTERPARTS. This Patent Security Agreement is a Loan Document. This Patent
Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall
constitute but one and the same Patent Security Agreement. Delivery of an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original
executed counterpart of this Patent Security Agreement. Any party delivering an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of
this Patent Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Patent Security Agreement. 

15. CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE PROVISION. THIS PATENT SECURITY AGREEMENT SHALL BE SUBJECT TO THE
PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTIONS 8.11 AND 8.12 OF THE GUARANTY AND SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS
MUTANDIS. 
 [signature page follows] 

  
 4 

 Execution Version 

IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be executed and delivered as of the day and year first
above written. 
  

							
	GRANTORS:	 		 	ENDOLOGIX, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer
			
		 		 	NELLIX, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary
			
		 		 	TRIVASCULAR, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary

  
 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be
executed and delivered as of the day and year first above written. 
  

							
		 		 	ACCEPTED AND ACKNOWLEDGED BY:
			
	AGENT:	 		 	DEERFIELD ELGX REVOLVER, LLC
		 		 	by: Deerfield Management Company, L.P. (Series C), Manager
		 		 	By: Flynn Management LLC, General Partner
				
		 		 	By:	 	 /s/ David J. Clark

		 		 	Name:	 	David J. Clark
		 		 	Title:	 	Authorized Signatory

  
 6 

 SCHEDULE I 

to 
 PATENT SECURITY AGREEMENT 

Patents 
  

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Stent graft	 	US9757262B2	 	US13943246A	 	2013-07-16
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US9700701B2	 	US13544426A	 	2012-07-09
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US9687374B2	 	US15379268A	 	2016-12-14
						
	ENDOLOGIX INC.	 	US	 	Percutaneous method and device to treat dissections	 	US9579103B2	 	US12771711A	 	2010-04-30

  
 7 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US9549835B2	 	US14462485A	 	2014-08-18
						
	ENDOLOGIX INC.	 	US	 	Method and system for treating aneurysms	 	US9415195B2	 	US13441762A	 	2012-04-06
						
	ENDOLOGIX INC.	 	US	 	Devices and methods to treat vascular dissections	 	US9393100B2	 	US13988175A	 	2013-05-17
						
	ENDOLOGIX INC.	 	US	 	Method for forming materials in situ within a medical device	 	US9289536B2	 	US14201332A	 	2014-03-07
						
	ENDOLOGIX INC.	 	US	 	Apparatus and method of placement of a graft or graft system	 	US9149381B2	 	US14172126A	 	2014-02-04

  
 8 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Stent graft	 	US8821564B2	 	US13397952A	 	2012-02-16
						
	ENDOLOGIX INC.	 	US	 	Apparatus and methods for repairing aneurysms	 	US8814928B2	 	US12616928A	 	2009-11-12
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US8808350B2	 	US13408952A	 	2012-02-29
						
	ENDOLOGIX INC.	 	US	 	Graft systems having semi-permeable filling structures and methods for their use	 	US8801768B2	 	US13355705A	 	2012-01-23
						
	ENDOLOGIX INC	 	US	 	Bifurcated graft deployment systems and methods	 	US8764812B2	 	US13745682A	 	2013-01-18

  
 9 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Apparatus and method of placement of a graft or graft system	 	US8672989B2	 	US13546950A	 	2012-07-11
						
	ENDOLOGIX INC.	 	US	 	Graft deployment system	 	US8568466B2	 	US13269332A	 	2011-10-07
						
	ENDOLOGIX INC.	 	US	 	Dual concentric guidewire and methods of bifurcated graft deployment	 	US8523931B2	 	US11623022A	 	2007-01-12
						
	ENDOLOGIX INC.	 	US	 	Stent graft	 	US8491646B2	 	US12837398A	 	2010-07-15
						
	ENDOLOGIX INC.	 	US	 	Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve	 	US8377110B2	 	US10820455A	 	2004-04-08

  
 10 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Bifurcated graft deployment systems and methods	 	US8357192B2	 	US13046541A	 	2011-03-11
						
	ENDOLOGIX INC.	 	US	 	Bifurcated graft deployment systems and methods	 	US8236040B2	 	US12101863A	 	2008-04-11
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US8216295B2	 	US12496446A	 	2009-07-01
						
	ENDOLOGIX INC.	 	US	 	Apparatus and method of placement of a graft or graft system	 	US8221494B2	 	US12390346A	 	2009-02-20
						
	ENDOLOGIX INC.	 	US	 	Methods and systems for endovascular aneurysm treatment	 	US8182525B2	 	US12421297A	 	2009-04-09

  
 11 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Single puncture bifurcation graft deployment system	 	US8167925B2	 	US12732095A	 	2010-03-25
						
	ENDOLOGIX INC.	 	US	 	Bifurcation graft deployment catheter	 	US8147535B2	 	US11189101A	 	2005-07-25
						
	ENDOLOGIX INC.	 	US	 	Material for creating multi-layered films and methods for making the same	 	US8133559B2	 	US13100483A	 	2011-05-04
						
	ENDOLOGIX INC.	 	US	 	Stent graft	 	US8118856B2	 	US12844266A	 	2010-07-27
						
	ENDOLOGIX INC.	 	US	 	Graft systems having filling structures supported by scaffolds and methods for their use	 	US8048145B2	 	US11413460A	 	2006-04-28

  
 12 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Graft deployment system	 	US8034100B2	 	US10722367A	 	2003-11-25
						
	ENDOLOGIX INC.	 	US	 	Material for creating multi-layered films and methods for making the same	 	US7951448B2	 	US12858274A	 	2010-08-17
						
	ENDOLOGIX INC	 	US	 	Self expanding bifurcated endovascular prosthesis	 	US7892277B2	 	US11417883A	 	2006-05-03
						
	ENDOLOGIX INC.	 	US	 	Material for creating multi-layered films and methods for making the same	 	US7790273B2	 	US11752750A	 	2007-05-23
						
	ENDOLOGIX INC.	 	US	 	Devices for repairing aneurysms	 	US7682383B2	 	US10481386A	 	2004-06-14

  
 13 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	System and methods for endovascular aneurysm treatment	 	US7666220B2	 	US11482503A	 	2006-07-07
						
	ENDOLOGIX INC.	 	US	 	Methods and systems for endovascular aneurysm treatment	 	US7530988B2	 	US11187471A	 	2005-07-22
						
	ENDOLOGIX INC	 	US	 	Self expanding bifurcated endovascular prosthesis	 	US7520895B2	 	US10119525A	 	2002-04-08
						
	ENDOLOGIX INC	 	US	 	Bifurcation graft deployment catheter	 	US6953475B2	 	US10675060A	 	2003-09-30
						
	ENDOLOGIX INC.	 	US	 	Implantable vascular graft	 	US6733523B2	 	US09891620A	 	2001-06-26

  
 14 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	Single puncture bifurcation graft deployment system	 	US6663665B2	 	US09795993A	 	2001-02-28
						
	ENDOLOGIX INC.	 	US	 	Bifurcation graft deployment catheter	 	US6660030B2	 	US09747094A	 	2000-12-22
						
	ENDOLOGIX INC	 	US	 	Endoluminal vascular prosthesis	 	US6508835B1	 	US09723979A	 	2000-11-28
						
	ENDOLOGIX INC.	 	US	 	Bifurcation graft deployment catheter	 	US6500202B1	 	US09525778A	 	2000-03-15
						
	ENDOLOGIX INC.	 	US	 	Dual wire placement catheter	 	US6440161B1	 	US09348356A	 	1999-07-07

  
 15 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Single puncture bifurcation graft deployment system	 	US6261316B1	 	US09266661A	 	1999-03-11
						
	ENDOLOGIX INC.	 	US	 	Articulating bifurcation graft	 	US6197049B1	 	US09251363A	 	1999-02-17
						
	ENDOLOGIX INC.	 	US	 	Endoluminal vascular prosthesis	 	US6187036B1	 	US09210280A	 	1998-12-11
						
	ENDOLOGIX INC.	 	US	 	Segmented stent for flexible stent delivery system	 	US6187034B1	 	US09229856A	 	1999-01-13
						
	ENDOLOGIX INC.	 	US	 	Endoluminal vascular prosthesis	 	US6077296A	 	US0934689A	 	1998-03-04

  
 16 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Stent delivery system featuring a flexible balloon	 	US6022359A	 	US09229519A	 	1999-01-13
						
	ENDOLOGIX INC.	 	US	 	Radially expandable stent featuring accordion stops	 	US5931866A	 	US09028305A	 	1998-02-24
						
	ENDOLOGIX INC.	 	US	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 	US20180021045A1	 	US15540246A	 	2017-06-27
						
	ENDOLOGIX INC.	 	US	 	CATHETER SYSTEM AND METHODS OF USING SAME	 	US20170304098A1	 	US15632064A	 	2017-06-23
						
	ENDOLOGIX INC.	 	US	 	CATHETER SYSTEM AND METHODS OF USING SAME	 	US20170296791A1	 	US15639028A	 	2017-06-30

  
 17 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20170266025A1	 	US15610242A	 	2017-05-31
						
	ENDOLOGIX INC.	 	US	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 	US20170239035A1	 	US15310198A	 	2016-11-10
						
	ENDOLOGIX INC.	 	US	 	METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES	 	US20170238937A1	 	US15438682A	 	2017-02-21
						
	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20170128246A1	 	US15414499A	 	2017-01-24
						
	ENDOLOGIX INC	 	US	 	METHOD AND SYSTEM FOR TREATING ANEURYSMS	 	US20170007263A1	 	US15205365A	 	2016-07-08

  
 18 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR	 	US20160367731A1	 	US15256462A	 	2016-09-02
						
	ENDOLOGIX INC.	 	US	 	DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS	 	US20160302798A1	 	US15194159A	 	2016-06-27
						
	ENDOLOGIX INC.	 	US	 	SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE	 	US20160030051A1	 	US14776385A	 	2015-09-14
						
	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20150366688A1	 	US14840428A	 	2015-08-31
						
	ENDOLOGIX INC.	 	US	 	METHOD AND SYSTEM FOR TREATING ANEURYSMS	 	US20150250989A1	 	US14717938A	 	2015-05-20

  
 19 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	FENESTRATED PROSTHESIS	 	US20150173923A1	 	US14581675A	 	2014-12-23
						
	ENDOLOGIX INC.	 	US	 	Apparatus and Methods for Repairing Aneurysms	 	US20150012081A1	 	US14330812A	 	2014-07-14
						
	ENDOLOGIX INC.	 	US	 	STENT GRAFT	 	US9907642	 	US14461308A	 	2014-08-15
						
	ENDOLOGIX INC	 	US	 	ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE	 	US20130253638A1	 	US13731908A	 	2012-12-31
						
	ENDOLOGIX INC.	 	US	 	Methods and Systems for Treating Aneurysms	 	US20120184982A1	 	US13354094A	 	2012-01-19

  
 20 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20120109279A1	 	US13287907A	 	2011-11-02
						
	ENDOLOGIX INC.	 	US	 	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE	 	US20110276078A1	 	US12966852A	 	2010-12-13
						
	ENDOLOGIX INC	 	US	 	SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS	 	US20110224782A1	 	US13027077A	 	2011-02-14
						
	ENDOLOGIX INC.	 	US	 	ENDOLUMINAL VASCULAR PROSTHESIS	 	US20110218617A1	 	US13039157A	 	2011-03-02
						
	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20110054587A1	 	US12769546A	 	2010-04-28

  
 21 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	IMPLANTABLE VASCULAR GRAFT	 	US20100318174A1	 	US12860280A	 	2010-08-20
						
	ENDOLOGIX INC	 	US	 	IMPLANTABLE VASCULAR GRAFT	 	US20100318181A1	 	US12860310A	 	2010-08-20
						
	ENDOLOGIX INC.	 	US	 	UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE	 	US20100261662A1	 	US12757900A	 	2010-04-09
						
	ENDOLOGIX INC	 	US	 	GRAFT DEPLOYMENT SYSTEM	 	US20100179636A1	 	US12726257A	 	2010-03-17
						
	ENDOLOGIX INC.	 	US	 	STENT GRAFT DELIVERY SYSTEM	 	US20100036360A1	 	US12429474A	 	2009-04-24

  
 22 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	DOCKING APPARATUS AND METHODS OF USE	 	US20090319029A1	 	US12478208A	 	2009-06-04
						
	ENDOLOGIX INC.	 	US	 	GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS	 	US20100004728A1	 	US12371087A	 	2009-02-13
						
	ENDOLOGIX INC.	 	US	 	METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE	 	US20090155337A1	 	US12269677A	 	2008-11-12
						
	ENDOLOGIX INC.	 	US	 	STENT	 	US20090105806A1	 	US12257149A	 	2008-10-23
						
	ENDOLOGIX INC.	 	US	 	Multi-segmented graft deployment system	 	US20080071343A1	 	US11522292A	 	2006-09-15

  
 23 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	IMPLANTABLE VASCULAR GRAFT	 	US20070299497A1	 	US11764715A	 	2007-06-18
						
	ENDOLOGIX INC.	 	US	 	Methods and systems for aneurysm treatment using filling structures	 	US20070150041A1	 	US11444603A	 	2006-05-31
						
	ENDOLOGIX INC	 	US	 	ENDOLUMINAL VASCULAR PROSTHESIS	 	US20070112412A1	 	US11623679A	 	2007-01-16
						
	ENDOLOGIX INC.	 	US	 	Method and apparatus for decompressing aneurysms	 	US20070078506A1	 	US11580201A	 	2006-10-12
						
	ENDOLOGIX INC.	 	US	 	Method and apparatus for decompressing aneurysms	 	US20050245891A1	 	US11104303A	 	2005-04-12

  
 24 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Vascular stent-graft apparatus	 	US20040167607A1	 	US10787404A	 	2004-02-24
						
	ENDOLOGIX INC.	 	US	 	Stent-graft with positioning anchor	 	US20040116997A1	 	US10668901A	 	2003-09-22
						
	ENDOLOGIX INC.	 	US	 	Flexible vascular graft	 	US20010025195A1	 	US09728582A	 	2000-12-01
						
	ENDOLOGIX INC	 	US	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 	US20170239035A1	 	US15310198A	 	2016-11-10
						
	ENDOLOGIX INC	 	US	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 	US20180021045A1	 	US15540246A	 	2017-06-27

  
 25 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS	 		 	US15737223	 	2017-12-15
						
	ENDOLOGIX INC	 	US	 	Systems and Methods with Stents and Filling Structure	 		 	62/382207	 	2016-08-31
						
	ENDOLOGIX INC	 	US	 	STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS	 		 	62/481560	 	2017-04-04
						
	ENDOLOGIX INC	 	US	 	ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT	 		 	62/489213	 	2017-04-24
						
	ENDOLOGIX INC	 	US	 	ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES	 		 	62/529669	 	2017-07-07

  
 26 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING	 		 	62/532737	 	2017-07-14
						
	ENDOLOGIX INC	 	US	 	STENT GRAFT	 		 	15/911629	 	2018-03-05
						
	ENDOLOGIX INC	 	US	 	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	 		 	15/965649	 	2018-04-
						
	ENDOLOGIX INC	 	US	 	MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT	 		 	62/661569	 	2018-4-23
						
	ENDOLOGIX INC	 	US	 	ADVANCED KINK RESISTANT STENT GRAFT	 		 	16/005269	 	2018-6-11

  
 27 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	 		 	15/985572	 	2018-5-21
						
	ENDOLOGIX INC	 	US	 	SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE	 		 	15/774511	 	2017-8-30
						
	ENDOLOGIX INC	 	US	 	LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS	 		 	15/774548	 	2018-1-23
						
	ENDOLOGIX INC	 	US	 	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE	 		 	16/035497	 	2018-7-13
						
	ENDOLOGIX INC	 	US	 	PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES	 		 	62/678956	 	2018-5-31

  
 28 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	 		 	16/066595	 	
						
	ENDOLOGIX INC	 	US	 	MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT	 		 	62/661569	 	2018-4-23
						
	ENDOLOGIX INC.	 	US	 	FENESTRATED PROSTHESIS	 	US8945202	 	12/769581	 	2015-2-3
						
	ENDOLOGIX INC.	 	US	 	Fenestrated prosthesis	 	US8945202	 	12/769581	 	4/28/10
						
	ENDOLOGIX, INC.	 	US	 	Bifurcated vascular graft deployment device	 	US6210422	 	09/505038	 	2/16/00

  
 29 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX, INC.	 	US	 	Method of deploying bifurcated vascular graft	 	US6156063	 	09/086247	 	5/28/98
						
	ENDOLOGIX, INC.	 	US	 	Bifurcated vascular graft deployment device	 	US6090128	 	08/802478	 	2/20/97
						
	ENDOLOGIX, INC.	 	US	 	Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use	 	US5665117	 	08/620072	 	3/21/96
						
	ENDOLOGIX, INC.	 	US	 	Locking assembly for coupling guidewire to delivery system	 		 	15/317905	 	12/9/16
						
	Endologix, Inc. and The Cleveland Clinic Foundation	 	US	 	Fenestrated prosthesis	 	US8945202	 	US12769581	 	4/28/10

  
 30 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Endologix, Inc.	 	US	 	Single puncture bifurcation graft deployment system	 	US7691135	 	US10690227	 	10/21/03
						
	Endologix, Inc.	 	US	 	Bifurcated vascular graft and method and apparatus for deploying same	 	US6951572	 	US10639255	 	8/12/03
						
	Endologix, Inc.	 	US	 	Radiation delivery balloon catheter	 	US6699170	 	US09688396	 	10/16/00
						
	Endologix, Inc.	 	US	 	Dual wire placement catheter	 	US6689157	 	US10035729	 	12/21/01
						
	Endologix, Inc.	 	US	 	Method for delivering radiation to an intraluminal site in the body	 	US6685618	 	US09944649	 	8/31/01

  
 31 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Endologix, Inc.	 	US	 	Radiation delivery catheters and dosimetry methods	 	US6491619	 	US09648563	 	8/25/00
						
	Endologix, Inc.	 	US	 	Endoluminal vascular prosthesis	 	US6331190	 	US09483411	 	1/14/00
						
	Endologix, Inc.	 	US	 	Bifurcated vascular graft deployment device	 	US6210422	 	US09505038	 	2/16/00
						
	Endologix, Inc.	 	US	 	Method of deploying bifurcated vascular graft	 	US6156063	 	US09086247	 	5/28/98
						
	Endologix, Inc.	 	US	 	Bifurcated vascular graft deployment device	 	US6090128	 	US08802478	 	2/20/97

  
 32 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Endologix, Inc.	 	US	 	Axially non-contracting flexible radially expandable stent	 	US6083259	 	US09192803	 	11/16/98
						
	Endologix, Inc.	 	US	 	Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use	 	US5665117	 	US08620072	 	3/21/96
						
	Endologix, Inc.	 	US	 	Apparatus and method of placement of a graft or graft system	 		 	US14172126	 	2/4/14
						
	Endologix, Inc. and The Cleveland Clinic Foundation	 	US	 	Apparatus and method of placement of a graft or graft system	 		 	US12769506	 	4/28/10
						
	Endologix, Inc.	 	US	 	Stent graft delivery system	 		 	US12429474	 	4/24/09

  
 33 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	ENDOLUMINAL DEVICE AND POLYMER	 		 	62/575827	 	2017-10-23
						
	TRIVASCULAR INC	 	US	 	Advanced Endovascular Graft	 	US9788934B2	 	US14799656A	 	2015-07-15
						
	NELLIX INC.	 	US	 	Stent-graft with positioning anchor	 	US9814612B2	 	US14697433A	 	2015-10-21
						
	NELLIX INC.	 	US	 	System and methods for endovascular aneurysm treatment	 	US9737425B2	 	US14537749A	 	2014-11-10
						
	NELLIX INC.	 	US	 	Stent graft delivery system	 	US9730700B2	 	US14586110A	 	2015-04-23

  
 34 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	NELLIX INC.	 	US	 	Methods for deploying a positioning anchor with a stent-graft	 	US9113999B2	 	US11876458A	 	2007-10-22
						
	NELLIX INC.	 	US	 	Sealing apparatus and methods of use	 	US8945199B2	 	US12478225A	 	2009-06-04
						
	NELLIX INC.	 	US	 	Stent graft delivery system	 	US8926682B2	 	US13243941A	 	2011-09-23
						
	NELLIX INC.	 	US	 	System and methods for endovascular aneurysm treatment	 	US8906084B2	 	US12684074A	 	2010-01-07
						
	NELLIX INC.	 	US	 	Graft systems having filling structures supported by scaffolds and methods for their use	 	US8870941B2	 	US13285897A	 	2011-10-31

  
 35 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	NELLIX INC.	 	US	 	STENT GRAFT DELIVERY SYSTEM	 	US20180028192A1	 	US15676869A	 	2017-08-14
						
	NELLIX INC.	 	US	 	SEALING APPRATUS AND METHODS OF USE	 	US20150148892A1	 	US14612048A	 	2015-02-02
						
	NELLIX INC.	 	US	 	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE	 	US10022249	 	US14525019A	 	2014-10-27
						
	NELLIX, INC.	 	US	 	System and methods of Endovascular Aneurysm Treatment	 		 	14/682414	 	8/21/17
						
	Nellix, Inc.	 	US	 	Vascular stent-graft apparatus and forming method	 	US6695833	 	US09671550	 	9/27/00

  
 36 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US9867727B2	 	US14320773A	 	2014-07-01
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US9788934B2	 	US14799656A	 	2015-07-15
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft for aneurysms involving major branch vessels	 	US9724186B2	 	US14050835A	 	2013-10-10
						
	TRIVASCULAR INC.	 	US	 	System and method of pivoted stent deployment	 	US9713523B2	 	US14452343A	 	2014-08-05
						
	TRIVASCULAR INC.	 	US	 	Systems and methods for guidewire crossover for bifurcated prostheses	 	US9655754B2	 	US14323059A	 	2014-07-03

  
 37 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 	US9585774B2	 	US14823076A	 	2015-08-11
						
	TRIVASCULAR INC.	 	US	 	PTFE layers and methods of manufacturing	 	US9549829B2	 	US14458349A	 	2014-08-13
						
	TRIVASCULAR INC.	 	US	 	Delivery catheter for endovascular device	 	US9498363B2	 	US13835491A	 	2013-03-15
						
	TRIVASCULAR INC	 	US	 	Low profile stent and delivery system	 	US9463101B2	 	US14923477A	 	2015-10-27
						
	TRIVASCULAR INC.	 	US	 	PTFE layers and methods of manufacturing	 	US9446553B2	 	US14230318A	 	2014-03-31

  
 38 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US9351858B2	 	US14704013A	 	2015-05-05
						
	TRIVASCULAR INC.	 	US	 	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	 	US9308301B2	 	US13089960A	 	2011-04-19
						
	TRIVASCULAR INC.	 	US	 	Endovascular delivery system with an improved radiopaque marker scheme	 	US9233015B2	 	US13803050A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	Low profile stent graft and delivery system	 	US9192462B2	 	US13803037A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	Fenestrated inflatable graft	 	US9144486B2	 	US13652471A	 	2012-10-15

  
 39 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 	US9132025B2	 	US13803067A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	Endovascular delivery system with flexible and torqueable hypotube	 	US9066828B2	 	US13803062A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US9050754B2	 	US12729182A	 	2010-03-22
						
	TRIVASCULAR INC.	 	US	 	Durable stent graft with tapered struts and stable delivery methods and devices	 	US8992595B2	 	US13799207A	 	2013-03-13
						
	TRIVASCULAR INC.	 	US	 	In vitro testing of endovascular device	 	US8978448B2	 	US13649066A	 	2012-10-10

  
 40 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft delivery system and method of treatment	 	US8900288B2	 	US12566104A	 	2009-09-24
						
	TRIVASCULAR INC.	 	US	 	Method of delivering advanced endovascular graft and system	 	US8864814B2	 	US13246651A	 	2011-09-27
						
	TRIVASCULAR INC.	 	US	 	PTFE layers and methods of manufacturing	 	US8840824B2	 	US12910281A	 	2010-10-22
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US8801769B2	 	US13737351A	 	2013-01-09
						
	TRIVASCULAR INC.	 	US	 	Apparatus for manufacturing an endovascular graft section	 	US8783316B2	 	US12697504A	 	2010-02-01

  
 41 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	PTFE layers and methods of manufacturing	 	US8728372B2	 	US12915636A	 	2010-10-29
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US8709065B2	 	US12491336A	 	2009-06-25
						
	TRIVASCULAR INC.	 	US	 	Virtual prototyping and testing for medical device development	 	US8666714B2	 	US13523765A	 	2012-06-14
						
	TRIVASCULAR INC.	 	US	 	Asymmetric stent apparatus and method	 	US8663309B2	 	US11861828A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US8361136B2	 	US12566793A	 	2009-09-25

  
 42 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US8348989B2	 	US11429735A	 	2006-05-08
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US8328861B2	 	US11941434A	 	2007-11-16
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft and method of delivery	 	US8241346B2	 	US13246643A	 	2011-09-27
						
	TRIVASCULAR INC.	 	US	 	Inflatable porous implants and methods for drug delivery	 	US8267989B2	 	US12860364A	 	2010-08-20
						
	TRIVASCULAR INC.	 	US	 	Inflatable intraluminal graft	 	US8226708B1	 	US10168053A	 	2002-06-14

  
 43 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Stent and delivery system for deployment thereof	 	US8226701B2	 	US11861756A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	Virtual prototyping and testing for medical device development	 	US8224632B2	 	US12904994A	 	2010-10-14
						
	TRIVASCULAR INC.	 	US	 	Dual chamber cuff structure	 	US8216297B2	 	US11504434A	 	2006-08-14
						
	TRIVASCULAR INC.	 	US	 	Barbed radially expandable stent	 	US8167927B2	 	US13245661A	 	2011-09-26
						
	TRIVASCULAR INC.	 	US	 	Securement assembly and method for expandable endovascular device	 	US8083789B2	 	US11941450A	 	2007-11-16

  
 44 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	System and method of pivoted stent deployment	 	US8066755B2	 	US11861716A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	Constant force material delivery system and method	 	US7971751B2	 	US12724068A	 	2010-03-15
						
	TRIVASCULAR INC.	 	US	 	Passive hemostatic sheath valve	 	US7901379B2	 	US11298285A	 	2005-12-09
						
	TRIVASCULAR INC.	 	US	 	Virtual prototyping and testing for medical device development	 	US7840393B1	 	US09679725A	 	2000-10-04
						
	TRIVASCULAR INC.	 	US	 	Inflatable porous implants and methods for drug delivery	 	US7803178B2	 	US10769532A	 	2004-01-30

  
 45 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US7766954B2	 	US11333595A	 	2006-01-17
						
	TRIVASCULAR INC.	 	US	 	Constant force material delivery system and method	 	US7708163B2	 	US11360077A	 	2006-02-23
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US7682475B2	 	US11870748A	 	2007-10-11
						
	TRIVASCULAR INC.	 	US	 	Method for manufacturing an endovascular graft section	 	US7678217B2	 	US11522490A	 	2006-09-15
						
	TRIVASCULAR INC.	 	US	 	Inflatable implant	 	US7632291B2	 	US10461853A	 	2003-06-13

  
 46 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US7615071B2	 	US11390732A	 	2006-03-28
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for expandable intracorporeal device	 	US7338518B2	 	US11201028A	 	2005-08-10
						
	TRIVASCULAR INC.	 	US	 	Passive hemostatic sheath valve	 	US7241276B2	 	US10636871A	 	2003-08-06
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US7147660B2	 	US10327711A	 	2002-12-20
						
	TRIVASCULAR INC.	 	US	 	Kink resistant endovascular graft	 	US7150758B2	 	US10384103A	 	2003-03-06

  
 47 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Radially expandable stent	 	US7147661B2	 	US10029559A	 	2001-12-20
						
	TRIVASCULAR INC.	 	US	 	Method and apparatus for shape forming endovascular graft material	 	US7147455B2	 	US10868292A	 	2004-06-14
						
	TRIVASCULAR INC.	 	US	 	Method for manufacturing an endovascular graft section	 	US7125464B2	 	US10029557A	 	2001-12-20
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US7081129B2	 	US10132754A	 	2002-04-24
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US7090693B1	 	US10029584A	 	2001-12-20

  
 48 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Delivery system and method for expandable intracorporeal device	 	US7066951B2	 	US10419312A	 	2003-04-17
						
	TRIVASCULAR INC.	 	US	 	Method and apparatus for shape forming endovascular graft material	 	US6776604B1	 	US10029570A	 	2001-12-20
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated endovascular graft	 	US6761733B2	 	US09917371A	 	2001-07-27
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for endovascular graft	 	US6733521B2	 	US09834278A	 	2001-04-11
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for expandable intracorporeal device	 	US6602280B2	 	US09774733A	 	2001-01-31

  
 49 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US6395019B2	 	US09133978A	 	1998-08-14
						
	TRIVASCULAR INC	 	US	 	ENDOVASCULAR GRAFT	 	US20170348125A1	 	US15686214A	 	2017-08-25
						
	TRIVASCULAR INC	 	US	 	ADVANCED ENDOVASCULAR GRAFT	 	US20170348087A1	 	US15686218A	 	2017-08-25
						
	TRIVASCULAR INC	 	US	 	ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS	 	US20170296327A1	 	US15638559A	 	2017-06-30
						
	TRIVASCULAR INC	 	US	 	SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES	 	US20170216064A1	 	US15491074A	 	2017-04-19

  
 50 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	US	 	Low Profile Stent Graft and Delivery System	 	US9987123	 	US15263469A	 	2016-09-13
						
	TRIVASCULAR INC	 	US	 	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG	 	US20170035549A1	 	US15299542A	 	2016-10-21
						
	TRIVASCULAR INC.	 	US	 	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE	 	US20170035590A1	 	US15298166A	 	2016-10-19
						
	TRIVASCULAR INC	 	US	 	PTFE LAYERS AND METHODS OF MANUFACTURING	 	US20160367354A1	 	US15251011A	 	2016-08-30
						
	TRIVASCULAR INC	 	US	 	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME	 	US10034787	 	US14970621A	 	2015-12-16

  
 51 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	US	 	NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER	 	US20160193392A1	 	US15068415A	 	2016-03-11
						
	TRIVASCULAR INC.	 	US	 	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	 	US9956101	 	US14958085A	 	2015-12-03
						
	TRIVASCULAR INC.	 	US	 	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT	 	US20160113796A1	 	US14920828A	 	2015-10-22
						
	TRIVASCULAR INC.	 	US	 	ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE	 	US20150265446A1	 	US14717080A	 	2015-05-20
						
	TRIVASCULAR INC.	 	US	 	INFLATABLE OCCLUSION WIRE-BALLOON FOR AORTIC APPLICATIONS	 	US20150250481A1	 	US14643217A	 	2015-03-10

  
 52 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	 	US20150164667A1	 	US14631818A	 	2015-02-25
						
	TRIVASCULAR INC.	 	US	 	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES	 	US20150157479A1	 	US14615337A	 	2015-02-05
						
	TRIVASCULAR INC.	 	US	 	TANDEM MODULAR ENDOGRAFT	 	US20150088244A1	 	US14492674A	 	2014-09-22
						
	TRIVASCULAR INC.	 	US	 	ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE	 	US20150073523A1	 	US14481834A	 	2014-09-09
						
	TRIVASCULAR INC.	 	US	 	GATE WIRE FOR CONTRALATERAL LEG ACCESS	 	US20140194970A1	 	US14151373A	 	2014-01-09

  
 53 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	SAC LINER FOR ANEURYSM REPAIR	 	US20140194973A1	 	US14151195A	 	2014-01-09
						
	TRIVASCULAR INC.	 	US	 	ASYMMETRIC STENT APPARATUS AND METHOD	 	US20140135899A1	 	US14157350A	 	2014-01-16
						
	TRIVASCULAR INC.	 	US	 	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	 	US20130268056A1	 	US13803033A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	ADVANCED KINK RESISTANT STENT GRAFT	 	US9993328	 	US13803046A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	VASCULAR GRAFT HAVING LIMITED END STRUCTURE	 	US20130096665A1	 	US13650705A	 	2012-10-12

  
 54 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	INFLATABLE INTRALUMINAL GRAFT	 	US20120265290A1	 	US13532887A	 	2012-06-26
						
	TRIVASCULAR INC.	 	US	 	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	 	US20120191174A1	 	US13297219A	 	2011-11-15
						
	TRIVASCULAR INC.	 	US	 	SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT	 	US20120083870A1	 	US13277117A	 	2011-10-19
						
	TRIVASCULAR INC.	 	US	 	BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS	 	US20120016457A1	 	US13245652A	 	2011-09-26
						
	TRIVASCULAR INC.	 	US	 	FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT	 	US20110218609A1	 	US13024255A	 	2011-02-09

  
 55 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	HINGED ENDOVASCULAR DEVICE	 	US20100331958A1	 	US12747499A	 	2010-09-07
						
	TRIVASCULAR INC.	 	US	 	Inflatable Implant	 	US20100076481A1	 	US12628623A	 	2009-12-01
						
	TRIVASCULAR INC.	 	US	 	METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT	 	US20100016943A1	 	US12566808A	 	2009-09-25
						
	TRIVASCULAR INC.	 	US	 	MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY	 	US20090099649A1	 	US12245620A	 	2008-10-03
						
	TRIVASCULAR INC.	 	US	 	ALIGNMENT STENT APPARATUS AND METHOD	 	US20090082845A1	 	US11861746A	 	2007-09-26

  
 56 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	SYSTEM AND METHOD OF SECURING STENT BARBS	 	US20090082847A1	 	US11861731A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	APPARATUS FOR SECURING STENT BARBS	 	US20090082841A1	 	US11861739A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	PTFE LAYERS AND METHODS OF MANUFACTURING	 	US20090036971A1	 	US12250915A	 	2008-10-14
						
	TRIVASCULAR INC.	 	US	 	PTFE LAYERS AND METHODS OF MANUFACTURING	 	US20090036973A1	 	US12250946A	 	2008-10-14
						
	TRIVASCULAR INC.	 	US	 	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	 	US20060222596A1	 	US11097467A	 	2005-04-01

  
 57 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Hybrid modular endovascular graft	 	US20060224232A1	 	US11097718A	 	2005-04-01
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US20060009833A1	 	US11205793A	 	2005-08-15
						
	TRIVASCULAR INC.	 	US	 	Methods, compositions and devices for embolizing body lumens	 	US20050158272A1	 	US11031311A	 	2005-01-07
						
	TRIVASCULAR INC.	 	US	 	Endoluminal prosthesis endoleak management	 	US20050090804A1	 	US10691849A	 	2003-10-22
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US20050027347A1	 	US10640368A	 	2003-08-13

  
 58 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Layered endovascular graft	 	US20040220664A1	 	US10803153A	 	2004-03-17
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US20040138734A1	 	US10686863A	 	2003-10-16
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US20030216802A1	 	US10289136A	 	2002-11-05
						
	TRIVASCULAR INC.	 	US	 	Inflatable intraluminal graft	 	US20030225453A1	 	US10289137A	 	2002-11-05
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US20030120338A1	 	US10091641A	 	2002-03-05

  
 59 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US20030004560A1	 	US10122474A	 	2002-04-11
						
	TRIVASCULAR INC.	 	US	 	Layered endovascular graft	 	US20020010508A1	 	US09970576A	 	2001-10-04
						
	TRIVASCULAR, INC.	 	US	 	Stent-graft with improved flexibility	 		 	15/568834	 	10/24/17
						
	Trivascular, Inc.	 	US	 	Passive hemostatic sheath valve	 	US7901379	 	US11298285	 	12/9/05
						
	Trivascular, Inc.	 	US	 	Fluid mixing apparatus and method	 	US7178978	 	US10658074	 	9/8/03

  
 60 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Delivery system and method for expandable intracorporeal device	 	US6602280	 	US09774733	 	1/31/01
						
	Trivascular, Inc.	 	US	 	Endovascular graft	 	US6395019	 	US09133978	 	8/14/98
						
	Trivascular, Inc.	 	US	 	Layered endovascular graft	 	US6331191	 	US09200317	 	11/25/98
						
	Trivascular, Inc.	 	US	 	Endovascular graft having longitudinally displaceable sections	 	US6132457	 	US09177295	 	10/22/98
						
	Trivascular, Inc.	 	US	 	Low profile stent graft and delivery system	 		 	US15263469	 	9/13/16

  
 61 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Delivery catheter for endovascular device	 		 	US15298166	 	10/19/16
						
	Trivascular, Inc.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 		 	US15299542	 	10/21/16
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US15251011	 	8/30/16
						
	Trivascular, Inc.	 	US	 	Endovascular delivery system with an improved radiopaque marker scheme	 		 	US14970621	 	12/16/15
						
	Trivascular, Inc.	 	US	 	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	 		 	US15068415	 	3/11/16

  
 62 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Internal iliac preservation devices and methods	 		 	US14958085	 	12/3/15
						
	Trivascular, Inc.	 	US	 	Stent graft delivery system with access conduit	 		 	US14920828	 	10/22/15
						
	Trivascular, Inc.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 		 	US14823076	 	8/11/15
						
	Trivascular, Inc.	 	US	 	Low profile stent and delivery system	 		 	US14923477	 	10/27/15
						
	Trivascular, Inc.	 	US	 	Endovascular delivery system with flexible and torqueable hypotube	 		 	US14717080	 	5/20/15

  
 63 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Inflatable occlusion wire-balloon for aortic applications	 		 	US14643217	 	3/10/15
						
	Trivascular, Inc.	 	US	 	Advanced endovascular graft and delivery system	 		 	US14631818	 	2/25/15
						
	Trivascular, Inc.	 	US	 	Durable stent graft with tapered struts and stable delivery methods and devices	 		 	US14615337	 	2/5/15
						
	Trivascular, Inc.	 	US	 	Tandem modular endograft	 		 	US14492674	 	9/22/14
						
	Trivascular, Inc.	 	US	 	Endoleak isolation sleeves and methods of use	 		 	US14481834	 	9/9/14

  
 64 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Sac liner for aneurysm repair	 		 	US14151195	 	1/9/14
						
	Trivascular, Inc.	 	US	 	Gate wire for contralateral leg access	 		 	US14151373	 	1/9/14
						
	Trivascular, Inc.	 	US	 	Asymmetric stent apparatus and method	 		 	US14157350	 	1/16/14
						
	Trivascular, Inc.	 	US	 	Low profile stent graft and delivery system	 		 	US13803033	 	3/14/13
						
	Trivascular, Inc.	 	US	 	Advanced kink resistant stent graft	 		 	US13803046	 	3/14/13

  
 65 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Vascular graft having limited end structure	 		 	US13650705	 	10/12/12
						
	Trivascular, Inc.	 	US	 	Inflatable intraluminal graft	 		 	US13532887	 	6/26/12
						
	Trivascular, Inc.	 	US	 	Advanced endovascular graft and delivery system	 		 	US13297219	 	11/15/01
						
	Trivascular, Inc.	 	US	 	System and method of pivoted stent deployment	 		 	US13277117	 	10/19/11
						
	Trivascular, Inc.	 	US	 	Barbed radially expandable stent with slotted struts	 		 	US13245652	 	9/26/11

  
 66 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Fill tube manifold and delivery methods for endovascular graft	 		 	US13024255	 	2/9/11
						
	Trivascular, Inc.	 	US	 	Hinged endovascular device	 		 	US12747499	 	9/7/10
						
	Trivascular, Inc.	 	US	 	Inflatable implant	 		 	US12628623	 	12/1/09
						
	Trivascular, Inc.	 	US	 	Method of delivering advanced endovascular graft	 		 	US12566808	 	9/25/09
						
	Trivascular, Inc.	 	US	 	Modular vascular graft for low profile percutaneous delivery	 		 	US12245620	 	10/3/08

  
 67 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	System and method of securing stent barbs	 		 	US11861731	 	9/26/07
						
	Trivascular, Inc.	 	US	 	Alignment stent apparatus and method	 		 	US11861746	 	9/26/07
						
	Trivascular, Inc.	 	US	 	Apparatus for securing stent barbs	 		 	US11861739	 	9/26/07
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US12250946	 	10/14/08
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US12250915	 	10/14/08

  
 68 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US11106150	 	4/13/05
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US11106131	 	4/13/05
						
	Trivascular, Inc.	 	US	 	Hybrid modular endovascular graft	 		 	US11097718	 	4/1/05
						
	Trivascular, Inc.	 	US	 	Non-degradable low swelling, water soluble radiopaque hydrogel polymer	 		 	US11097467	 	4/1/05
						
	Trivascular, Inc.	 	US	 	Delivery system and method for bifurcated graft	 		 	US11205793	 	8/15/05

  
 69 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Modular endovascular graft	 		 	US11077938	 	3/11/05
						
	Trivascular, Inc.	 	US	 	Methods, compositions and devices for embolizing body lumens	 		 	US11031311	 	1/7/05
						
	Trivascular, Inc.	 	US	 	Endoluminal prosthesis endoleak management	 		 	US10691849	 	10/22/03
						
	Trivascular, Inc.	 	US	 	Endovascular graft joint and method for manufacture	 		 	US10640368	 	8/13/03
						
	Trivascular, Inc.	 	US	 	Layered endovascular graft	 		 	US10803153	 	3/17/04

  
 70 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Delivery system and method for bifurcated graft	 		 	US10686863	 	10/16/03
						
	Trivascular, Inc.	 	US	 	Inflatable intraluminal graft	 		 	US10289137	 	11/5/02
						
	Trivascular, Inc.	 	US	 	Endovascular graft	 		 	US10289136	 	11/5/02
						
	Trivascular, Inc.	 	US	 	Advanced endovascular graft	 		 	US10091641	 	3/5/02
						
	Trivascular, Inc.	 	US	 	Delivery system and method for bifurcated graft	 		 	US10122474	 	4/11/02

  
 71 

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Layered endovascular graft	 		 	US09970576	 	10/3/01
						
	ENDOLOGIX INC.	 	US	 	STENT GRAFT SYSTEMS WITH RESTRAINTS IN CIRCUMFERENTIAL CHANNELS AND METHODS THEREOF	 		 	62/678961	 	5/31/2018
						
	ENDOLOGIX INC.	 	US	 	PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS	 		 	15/429090	 	2/9/2017
						
	NELLIX, INC.	 	US	 	SYSTEM AND METHODS FOR ENDOVASCULAR ANEURYSM TREATMENT	 	2018-0064566	 	15/682414	 	8/21/2017
						
	TRIVASCULAR INC.	 	US	 	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME	 		 	16/049560	 	7/30/2018

  
 72 

 Execution Version 

TRADEMARK SECURITY AGREEMENT 

This TRADEMARK SECURITY AGREEMENT (this “Trademark Security Agreement”) is made this 9th day of August, 2018, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “Grantors” and each individually
“Grantor”), and DEERFIELD ELGX REVOLVER, LLC, a Delaware limited liability company, in its capacity as agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity,
“Agent”). 
 W I T N E S S E T H: 

WHEREAS, pursuant to that certain Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified
from time to time, the “Credit Agreement”) by and among ENDOLOGIX, INC., a Delaware corporation (“Endologix”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any
additional borrower that may thereafter be added to the Credit Agreement (individually as a “Borrower”, and collectively with any entities that become party thereto as Borrower and each of their successors and permitted assigns, the
“Borrowers”), the lenders party thereto as “Lenders” (such Lenders, together with their respective successors and assigns in such capacity, each, individually, a “Lender” and, collectively, the
“Lenders”), and Agent, the Lender Group has agreed to make certain financial accommodations available to the Borrowers from time to time pursuant to the terms and conditions thereof; 

WHEREAS, the members of the Lender Group are willing to make the financial accommodations to the Borrowers as provided for in the Credit
Agreement and the other Loan Documents, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group, that certain Guaranty and Security Agreement, dated as of
August 9, 2018 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “Guaranty and Security Agreement”); and 

WHEREAS, pursuant to the Guaranty and Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender
Group, this Trademark Security Agreement. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows: 

1. DEFINED TERMS. All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Guaranty
and Security Agreement or, if not defined therein, in the Credit Agreement, and this Trademark Security Agreement shall be subject to the rules of construction set forth in Section 1.04 of the Credit Agreement, which rules of construction are
incorporated herein by this reference, mutatis mutandis. 
 2. GRANT OF SECURITY INTEREST IN TRADEMARK COLLATERAL. Each Grantor
hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of each member of the Lender Group, to secure the Secured Obligations, a continuing security interest (referred to in this Trademark Security Agreement as the
“Security Interest”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired or arising (collectively, the “Trademark Collateral”): 

(a) all of its Trademarks and Trademark Intellectual Property Licenses to which it is a party including those referred to on Schedule I;

  
 1 

 (b) all goodwill of the business connected with the use of, and symbolized by, each
Trademark and each Trademark Intellectual Property License; and 
 (c) all products and proceeds (as that term is defined in the Code) of the
foregoing, including any claim by such Grantor against third parties for past, present or future (i) infringement or dilution of any Trademark or any Trademarks exclusively licensed under any Intellectual Property License, including right to
receive any damages, (ii) injury to the goodwill associated with any Trademark, or (iii) right to receive license fees, royalties, and other compensation under any Trademark Intellectual Property License. 

3. SECURITY FOR SECURED OBLIGATIONS. This Trademark Security Agreement and the Security Interest created hereby secures the payment and
performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Trademark Security Agreement secures the payment of all amounts which constitute part of the Secured
Obligations and would be owed by Grantors, or any of them, to Agent, the other members of the Lender Group or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

 4. PROTECTION OF TRADEMARK SECURITY INTEREST BY GRANTORS. Each Grantor shall, at its sole cost, reasonable expense and risk, in
connection with the operation of its business, comply with the requirements set forth in Section 6 of the Guaranty and Security Agreement in respect of the Trademark Collateral. 

5. REPRESENTATIONS AND WARRANTIES. Each Grantor represents and warrants that: 

(a) Schedule I hereto is a true, correct and complete list of all Trademarks and Trademark Intellectual Property Licenses in which each Grantor
purports to have an ownership or license interest. 
 (b) Such Grantor has the legal right and authority to enter into this Trademark
Security Agreement and perform its terms. 
 (c) If such Grantor amends its name, such Grantor shall provide copies of such amendment
documentation to Agent and shall, if necessary, re-register such Grantor’s Trademarks and Trademark Intellectual Property Licenses with the appropriate Governmental Authority and shall execute and deliver
such agreements or documentation as Agent shall reasonably request in writing to maintain a perfected first priority security interest in the Trademark Collateral subject to Permitted Liens. 

6. SECURITY AGREEMENT. The Security Interest in the Collateral granted pursuant to this Trademark Security Agreement is granted in
conjunction with the security interests granted to Agent, for the benefit of the Lender Group, pursuant to the Guaranty and Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with respect to the
Security Interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent
there is any inconsistency between this Trademark Security Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control. 

7. AUTHORIZATION TO SUPPLEMENT. If any Grantor shall obtain rights to any new trademarks, the provisions of this Trademark Security
Agreement shall automatically apply thereto. Each 

  
 2 

 
Grantor shall notify Agent of applications filed for the registration of any Trademarks with the United States Trademark Office in accordance with Section 5.7(g) of the Guaranty and Security
Agreement. Without limiting Grantors’ obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Trademark Security Agreement by amending Schedule I to include any such new trademark rights of each
Grantor. Notwithstanding the foregoing, no failure to so modify this Trademark Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent’s continuing security interest in all Collateral, whether or
not listed on Schedule I. 
 8. NO VIOLATION OF LOAN DOCUMENTS. The representations, warranties or covenants contained herein
are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document. 

9. GRANTOR’S RIGHTS TO ENFORCE TRADEMARKS. Prior to Agent’s giving of notice to Grantor following the occurrence and during
the continuance of an Event of Default, such Grantor shall have the exclusive right to sue for past, present and future infringement of the Trademark Collateral, including the right to seek injunctions and/or money damages, in an effort by such
Grantor to protect the Trademark Collateral against encroachment by third parties, provided, however, that: 
 (a) Any money damages awarded
or received by such Grantor on account of such suit (or the threat of such suit) shall constitute Trademark Collateral. 
 (b) Any damages
recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guaranty and Security Agreement. 

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such
Grantor’s rights under this Section 9. 
 10. RIGHTS UPON DEFAULT. Upon the occurrence and during the continuance of any
Event of Default, Agent may exercise all rights and remedies as provided for in the Guaranty and Security Agreement. 
 11. NO LIMITATION;
LOAN DOCUMENTS. This Trademark Security Agreement has been executed and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the Trademark Collateral with the United States Trademark
Office. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of the Lender Group, under the Guaranty and Security Agreement and the other Loan
Documents. The other Loan Documents (and all rights and remedies of Grantor, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms. 

12. TERMINATION; RELEASE OF TRADEMARK COLLATERAL. This Trademark Security Agreement and all obligations of each Grantor and Agent
hereunder shall terminate on the date upon which the Obligations have been Paid in Full. Upon termination of this Trademark Security Agreement, Agent shall, at the reasonable expense of the Grantor, take such actions required by the Credit Agreement
or the Guaranty and Security Agreement or as otherwise reasonably requested by Grantor to release its security interest in the Trademark Collateral. 
  

  
 3 

 13. BINDING EFFECT; BENEFITS. This Trademark Security Agreement shall be binding upon
each Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns. 

14. COUNTERPARTS. This Trademark Security Agreement is a Loan Document. This Trademark Security Agreement may be executed in any number
of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Trademark Security
Agreement. Delivery of an executed counterpart of this Trademark Security Agreement by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Trademark Security
Agreement. Any party delivering an executed counterpart of this Trademark Security Agreement by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Trademark Security Agreement but the
failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Trademark Security Agreement. 

15. CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE PROVISION. THIS TRADEMARK SECURITY AGREEMENT SHALL BE SUBJECT TO
THE PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTIONS 8.11 AND 8.12 OF THE GUARANTY AND SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS
MUTANDIS. 
 [signature page follows] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Trademark Security Agreement to be
executed and delivered as of the day and year first above written. 
  

							
	GRANTORS:	 		 	ENDOLOGIX, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer
			
		 		 	TRIVASCULAR, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name:	 	Vaseem Mahboob
		 		 	Title:	 	Chief Financial Officer and Secretary

  
 [SIGNATURE PAGE TO
TRADEMARK SECURITY AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have caused this Trademark Security Agreement to be
executed and delivered as of the day and year first above written. 
  

							
		 		 	 ACCEPTED AND ACKNOWLEDGED BY:
  

	AGENT:	 		 	 DEERFIELD ELGX REVOLVER, LLC

by: Deerfield Management Company, L.P. (Series C), Manager
 By:
Flynn Management LLC, General Partner

				
		 		 	By:	 	 /s/ David J. Clark

		 		 	 Name:
 Title:
	 	 David J. Clark
 Authorized
Signatory

  
 6 

 SCHEDULE I 

to 
 TRADEMARK SECURITY AGREEMENT

 Trademark Registrations/Applications 
  

									
	 Grantor
	  	 Country
	  	 Mark
	  	Registration No.	  	Registration Date
	Endologix, Inc.	  	USA	  	DURAPLY	  	5433696	  	3/27/18
					
	Endologix, Inc.	  	USA	  	INTELIX	  	5059968	  	10/11/16
					
	Endologix, Inc.	  	USA	  	EVAS FORWARD	  	5306786	  	10/10/17
					
	Endologix, Inc.	  	USA	  	VELA	  	5296578	  	9/26/17
					
	Endologix, Inc.	  	USA	  	ANGIOTIP	  	5205176	  	5/16/17
					
	Endologix, Inc.	  	USA	  	ACTIVESEAL	  	5396605	  	2/6/18
					
	Endologix, Inc.	  	USA	  	INNOVATION THAT EMPOWERS	  	4841631	  	10/27/15
					
	Endologix, Inc.	  	USA	  	INNOVATION TAKING SHAPE	  	4220343	  	10/9/12
					
	Endologix, Inc.	  	USA	  	XPAND	  	4168563	  	7/3/12
					
	Endologix, Inc.	  	USA	  	AFX	  	4214460	  	9/25/12
					
	Endologix, Inc.	  	USA	  	INTUITRAK DELIVERY SYSTEM	  	3649866	  	7/7/09
					
	Endologix, Inc.	  	USA	  	INTUITRAK	  	3649757	  	7/7/09
					
	Endologix, Inc.	  	USA	  	NELLIX	  	3880178	  	11/23/10
					
	Endologix, Inc.	  	USA	  	SUREPASS	  	3593259	  	3/17/09
					
	Endologix, Inc.	  	USA	  	POWERLINK XL	  	3573999	  	2/10/09
					
	Endologix, Inc.	  	USA	  	POWERLINK	  	2456038	  	5/29/01
					
	Endologix, Inc.	  	USA	  	ENDOLOGIX	  	2257799	  	6/29/99
					
	TriVascular, Inc.	  	USA	  	OVATION ALTO	  	5195890	  	5/2/17
					
	TriVascular, Inc.	  	USA	  	CUSTOMSEAL	  	4732342	  	5/5/15
					
	TriVascular, Inc.	  	USA	  	OVATION PRIME	  	4452625	  	12/17/13
					
	TriVascular, Inc.	  	USA	  	OVATION PRIME ABDOMINAL STENT GRAFT SYSTEM	  	4449077	  	12/10/13
					
	TriVascular, Inc.	  	USA	  	TRIVASCULAR	  	4395789	  	9/3/13
					
	TriVascular, Inc.	  	USA	  	OVATION	  	4440468	  	11/26/13
					
	TriVascular, Inc.	  	USA	  	TRIVASCULAR	  	2867015	  	7/27/04

 SCHEDULE 3 

GRANTOR INFORMATION 
  

									
	 GRANTOR
(exact legal name)
	  	 STATE/COUNTRY
OF
ORGANIZATION
	  	 FEDERAL
EMPLOYER
IDENTIFICATION
NUMBER
	  	 CHIEF EXECUTIVE
OFFICE
	  	 ORGANIZATIONAL
IDENTIFICATION
NUMBER

	Endologix, Inc.	  	Delaware	  	68-0328265	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	2338745
					
	CVD/RMS Acquisition Corp.	  	Delaware	  	33-0928438	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	2955166
					
	RMS/Endologix Sideways Merger Corp	  	Delaware	  	03-0512974	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	3530477
					
	Nellix, Inc.	  	Delaware	  	94-3398416	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	3359980
					
	TriVascular Technologies, Inc.	  	Delaware	  	87-0807313	  	3910 Brickway Blvd.,
County of Santa Rosa,
Sonoma, CA 95403 U.S.A.	  	4387054
					
	TriVascular, Inc.	  	California	  	68-0402620	  	3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.	  	C2065374
					
	Endologix
Canada, LLC	  	Delaware	  	47-2442872	  	3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.	  	5647226
					
	TriVascular Sales LLC	  	Texas	  	46-0859179	  	3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.	  	801644988

 SCHEDULE 4 

PLACES OF BUSINESS / LOCATION OF COLLATERAL 
  

									
	 Grantor
	  	 Location
	  	 Specify Whether
Location Has
(i) Inventory
and/or
Equipment,
(ii) Books and
Records, or (iii) Both
	  	 Interest
	  	 Lessor/Property

Owner/Lessee

	Endologix, Inc.	  	2 Musick, Irvine, County of Orange, CA 92618 U.S.A.	  	Both	  	Lease	  	The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	Endologix, Inc.	  	33 & 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A	  	Inventory and/or Equipment	  	Lease	  	The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	Endologix, Inc.	  	 378 Commercial Street, Malden, MA 02148
  

165 Chubb Avenue, Lyndhurst, NJ 07071
  

1130 Commerce Blvd, Swedesboro, NJ 08085
  

2250 Outerloop Drive, Louisville, KY 40219
	  	Inventory and/or Equipment	  	Third Party Warehouse	  	UPS
					
	Endologix, Inc.	  	54 Yangcheon-ro, Gangseo-gu, Seoul 07522	  	Inventory and/or Equipment (no other Collateral is located at this location)	  	Third Party Warehouse	  	TNT Express Korea

									
	 Grantor
	  	 Location
	  	 Specify Whether
Location Has
(i) Inventory
and/or
Equipment,
(ii) Books and
Records, or (iii) Both
	  	 Interest
	  	 Lessor/Property

Owner/Lessee

	Endologix, Inc.	  	10 Anson Road #21-04 & #21-04A International Plaza Singapore 079903	  	Inventory and/or
Equipment (no other Collateral is located at this location)	  	Occupied	  	Endologix Singapore Private Limited
					
	Endologix, Inc.	  	A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea	  	Inventory and/or
Equipment (no other Collateral is located at this location)	  	Occupied	  	N.A.
					
	Endologix, Inc.	  	Grantor and each Guarantor’s sales representatives hold Trunk Inventory in their possession for sales calls and procedures, which Trunk Inventory is not held at a specific location or locations.	  	 Inventory and/or
Equipment (no other Collateral is located at this location)

 
	  	 N.A.
  
	  	 N.A.
  

					
		  	 Certain Inventory of the Grantor and each Guarantor is held by numerous third parties on a consignment basis at various locations.
	  	 Inventory and/or
Equipment (no other Collateral is located at this location)
	  	 N.A.
	  	 N.A.

									
	 Grantor
	  	 Location
	  	 Specify Whether
Location Has
(i) Inventory
and/or
Equipment,
(ii) Books and
Records, or (iii) Both
	  	 Interest
	  	 Lessor/Property

Owner/Lessee

	CVD/RMS Acquisition Corp.	  	2 Musick, Irvine, County of Orange, CA 92618 U.S.A.	  	Books and Records	  	Occupied	  	The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	Nellix, Inc.	  	2 Musick, Irvine, County of Orange, CA 92618 U.S.A.	  	Books and Records	  	Occupied	  	The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	RMS/Endologix Sideways Merger Corp.	  	2 Musick, Irvine, County of Orange, CA 92618 U.S.A.	  	Books and Records	  	Occupied	  	The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	TriVascular Technologies,
Inc.	  	3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.	  	Books and Records	  	Occupied	  	Sonoma Airport Properties LLC
					
	TriVascular, Inc.	  	3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.	  	Both	  	Lease	  	Sonoma Airport Properties LLC
					
	TriVascular Sales LLC	  	3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.	  	Books and Records	  	Occupied	  	Sonoma Airport Properties LLC
					
	Endologix Canada, LLC	  	3910 Brickway Blvd., Santa Rosa, County of Sonoma, CA 95403 U.S.A.	  	Books and Records	  	Occupied	  	Sonoma Airport Properties LLC

 SCHEDULE 5 

COMMERCIAL TORT CLAIMS 
 None. 

 SCHEDULE 6 

ACCOUNTS 
  

													
	ENTITY	  	COUNTRY	  	ACCT	  	 	  	CURR	  	BANK	  	USE
	Endologix Inc	  	US	  	XXXXX1702	  	USD	  		  	Bank of America	  	Operating account
	Endologix Inc	  	US	  	XXXXX1689	  	USD	  		  	Bank of America	  	Payroll account
	Endologix Inc	  	US	  	XXXXX5279	  	USD	  		  	Wells Fargo	  	Old Operating account
	Endologix Inc	  	US	  	XXXXX5311	  	USD	  		  	Wells Fargo	  	Old payroll account
	Endologix Inc	  	US	  	XXXXX3910	  	USD	  		  	Bank of America	  	Lockbox account
	Endologix Inc	  	US	  	XXXXX4066	  	USD	  		  	Bank of America	  	Credit Card Cash Collateral account
	Trivascular Inc	  	US	  	XXXXX5539	  	USD	  		  	Silicon Valley Bank	  	Operating account
	Trivascular Inc	  	The Netherlands	  	XXXXX8640	  	EUR	  		  	KBC Bank NV Nederland	  	Currency account
	Trivascular Inc	  	UK London	  	XXXXX8709	  	GBP	  		  	National Westminster Bank	  	Currency account
	Trivascular Sales LLC	  	US	  	XXXXX7400	  	USD	  		  	Silicon Valley Bank	  	Payroll account
	Endologix Canada LLC	  	Canada	  	XXXXX7912	  	CAD	  		  	Bank of Montreal	  	Operating account

 SCHEDULE 7 

REAL PROPERTY 
 None. 

 SCHEDULE 8 

COPYRIGHTS 
 None. 

 SCHEDULE 9 

INTELLECTUAL PROPERTY LICENSES 
  

	 	1.	 Inbound License Agreement, dated as of February 22, 2006, by and between Incept LLC and Nellix, Inc.

  

	 	2.	 Inbound Amendment No. 1. to License Agreement, dated as of April 30, 2012, by and between Incept LLC
and Nellix, Inc. 

  

	 	3.	 Inbound Amendment No. 2 to License Agreement, dated as of December 3, 2014, by and between Incept LLC
and Nellix, Inc. 

  

	 	4.	 Inbound Master License Agreement, dated as of May 5, 2008, by and between SurModics, Inc. and Endologix,
Inc. 

  

	 	5.	 Inbound Development and OEM Device Supply Agreement, dated as of August 5, 2015, by and between Bard
Peripheral Vascular, Inc. and Endologix, Inc. 

  

	 	6.	 Inbound License Agreement, dated as of June 22, 2011, by and between NorMedix, LLC and Endologix, Inc.

  

	 	7.	 Inbound Settlement and Patent License Agreement, dated as of March 17, 2016, by and between LifePort
Sciences, LLC and Endologix, Inc. 

  

	 	8.	 Inbound License Agreement, dated as of July 23, 2013, by and between Thomas L. Fogarty and Endologix, Inc.

  

	 	9.	 Inbound License Agreement, dated as of March 28, 2008, by and between Trivascular, Inc. (formerly
Trivascular 2, Inc.) and Boston Scientific Scimed, Inc. and Endovascular Technologies, Inc. 

 SCHEDULE 10 

PATENTS 
 See attached. 

 PATENT SCHEDULE 
  

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Stent graft	 	US9757262B2	 	US13943246A	 	2013-07-16
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US9700701B2	 	US13544426A	 	2012-07-09
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US9687374B2	 	US15379268A	 	2016-12-14
						
	ENDOLOGIX INC.	 	US	 	Percutaneous method and device to treat dissections	 	US9579103B2	 	US12771711A	 	2010-04-30
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US9549835B2	 	US14462485A	 	2014-08-18

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Method and system for treating aneurysms	 	US9415195B2	 	US13441762A	 	2012-04-06
						
	ENDOLOGIX INC.	 	US	 	Devices and methods to treat vascular dissections	 	US9393100B2	 	US13988175A	 	2013-05-17
						
	ENDOLOGIX INC.	 	US	 	Method for forming materials in situ within a medical device	 	US9289536B2	 	US14201332A	 	2014-03-07
						
	ENDOLOGIX INC.	 	US	 	Apparatus and method of placement of a graft or graft system	 	US9149381B2	 	US14172126A	 	2014-02-04
						
	ENDOLOGIX INC.	 	US	 	Stent graft	 	US8821564B2	 	US13397952A	 	2012-02-16
						
	ENDOLOGIX INC.	 	US	 	Apparatus and methods for repairing aneurysms	 	US8814928B2	 	US12616928A	 	2009-11-12

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US8808350B2	 	US13408952A	 	2012-02-29
						
	ENDOLOGIX INC.	 	US	 	Graft systems having semi-permeable filling structures and methods for their use	 	US8801768B2	 	US13355705A	 	2012-01-23
						
	ENDOLOGIX INC	 	US	 	Bifurcated graft deployment systems and methods	 	US8764812B2	 	US13745682A	 	2013-01-18
						
	ENDOLOGIX INC.	 	US	 	Apparatus and method of placement of a graft or graft system	 	US8672989B2	 	US13546950A	 	2012-07-11
						
	ENDOLOGIX INC.	 	US	 	Graft deployment system	 	US8568466B2	 	US13269332A	 	2011-10-07
						
	ENDOLOGIX INC.	 	US	 	Dual concentric guidewire and methods of bifurcated graft deployment	 	US8523931B2	 	US11623022A	 	2007-01-12

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Stent graft	 	US8491646B2	 	US12837398A	 	2010-07-15
						
	ENDOLOGIX INC.	 	US	 	Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve	 	US8377110B2	 	US10820455A	 	2004-04-08
						
	ENDOLOGIX INC.	 	US	 	Bifurcated graft deployment systems and methods	 	US8357192B2	 	US13046541A	 	2011-03-11
						
	ENDOLOGIX INC.	 	US	 	Bifurcated graft deployment systems and methods	 	US8236040B2	 	US12101863A	 	2008-04-11
						
	ENDOLOGIX INC.	 	US	 	Catheter system and methods of using same	 	US8216295B2	 	US12496446A	 	2009-07-01
						
	ENDOLOGIX INC.	 	US	 	Apparatus and method of placement of a graft or graft system	 	US8221494B2	 	US12390346A	 	2009-02-20

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Methods and systems for endovascular aneurysm treatment	 	US8182525B2	 	US12421297A	 	2009-04-09
						
	ENDOLOGIX INC.	 	US	 	 Single puncture bifurcation graft
 deployment
system
	 	US8167925B2	 	US12732095A	 	2010-03-25
						
	ENDOLOGIX INC.	 	US	 	Bifurcation graft deployment catheter	 	US8147535B2	 	US11189101A	 	2005-07-25
						
	ENDOLOGIX INC.	 	US	 	Material for creating multi-layered films and methods for making the same	 	US8133559B2	 	US13100483A	 	2011-05-04
						
	ENDOLOGIX INC.	 	US	 	Stent graft	 	US8118856B2	 	US12844266A	 	2010-07-27
						
	ENDOLOGIX INC.	 	US	 	Graft systems having filling structures supported by scaffolds and methods for their use	 	US8048145B2	 	US11413460A	 	2006-04-28

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Graft deployment system	 	US8034100B2	 	US10722367A	 	2003-11-25
						
	ENDOLOGIX INC.	 	US	 	Material for creating multi-layered films and methods for making the same	 	US7951448B2	 	US12858274A	 	2010-08-17
						
	ENDOLOGIX INC	 	US	 	Self expanding bifurcated endovascular prosthesis	 	US7892277B2	 	US11417883A	 	2006-05-03
						
	ENDOLOGIX INC.	 	US	 	Material for creating multi-layered films and methods for making the same	 	US7790273B2	 	US11752750A	 	2007-05-23
						
	ENDOLOGIX INC.	 	US	 	Devices for repairing aneurysms	 	US7682383B2	 	US10481386A	 	2004-06-14
						
	ENDOLOGIX INC.	 	US	 	System and methods for endovascular aneurysm treatment	 	US7666220B2	 	US11482503A	 	2006-07-07

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Methods and systems for endovascular aneurysm treatment	 	US7530988B2	 	US11187471A	 	2005-07-22
						
	ENDOLOGIX INC	 	US	 	Self expanding bifurcated endovascular prosthesis	 	US7520895B2	 	US10119525A	 	2002-04-08
						
	ENDOLOGIX INC	 	US	 	Bifurcation graft deployment catheter	 	US6953475B2	 	US10675060A	 	2003-09-30
						
	ENDOLOGIX INC.	 	US	 	Implantable vascular graft	 	US6733523B2	 	US09891620A	 	2001-06-26
						
	ENDOLOGIX INC	 	US	 	 Single puncture bifurcation graft
 deployment
system
	 	US6663665B2	 	US09795993A	 	2001-02-28
						
	ENDOLOGIX INC.	 	US	 	Bifurcation graft deployment catheter	 	US6660030B2	 	US09747094A	 	2000-12-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	Endoluminal vascular prosthesis	 	US6508835B1	 	US09723979A	 	2000-11-28
						
	ENDOLOGIX INC.	 	US	 	Bifurcation graft deployment catheter	 	US6500202B1	 	US09525778A	 	2000-03-15
						
	ENDOLOGIX INC.	 	US	 	Dual wire placement catheter	 	US6440161B1	 	US09348356A	 	1999-07-07
						
	ENDOLOGIX INC.	 	US	 	 Single puncture bifurcation graft
 deployment
system
	 	US6261316B1	 	US09266661A	 	1999-03-11
						
	ENDOLOGIX INC.	 	US	 	Articulating bifurcation graft	 	US6197049B1	 	US09251363A	 	1999-02-17
						
	ENDOLOGIX INC.	 	US	 	Endoluminal vascular prosthesis	 	US6187036B1	 	US09210280A	 	1998-12-11

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Segmented stent for flexible stent delivery system	 	US6187034B1	 	US09229856A	 	1999-01-13
						
	ENDOLOGIX INC.	 	US	 	Endoluminal vascular prosthesis	 	US6077296A	 	US0934689A	 	1998-03-04
						
	ENDOLOGIX INC.	 	US	 	Stent delivery system featuring a flexible balloon	 	US6022359A	 	US09229519A	 	1999-01-13
						
	ENDOLOGIX INC.	 	US	 	Radially expandable stent featuring accordion stops	 	US5931866A	 	US09028305A	 	1998-02-24
						
	ENDOLOGIX INC.	 	US	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 	US20180021045A1	 	US15540246A	 	2017-06-27
						
	ENDOLOGIX INC.	 	US	 	CATHETER SYSTEM AND METHODS OF USING SAME	 	US20170304098A1	 	US15632064A	 	2017-06-23

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	CATHETER SYSTEM AND METHODS OF USING SAME	 	US20170296791A1	 	US15639028A	 	2017-06-30
						
	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20170266025A1	 	US15610242A	 	2017-05-31
						
	ENDOLOGIX INC.	 	US	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 	US20170239035A1	 	US15310198A	 	2016-11-10
						
	ENDOLOGIX INC.	 	US	 	METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES	 	US20170238937A1	 	US15438682A	 	2017-02-21
						
	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20170128246A1	 	US15414499A	 	2017-01-24
						
	ENDOLOGIX INC	 	US	 	METHOD AND SYSTEM FOR TREATING ANEURYSMS	 	US20170007263A1	 	US15205365A	 	2016-07-08

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR	 	US20160367731A1	 	US15256462A	 	2016-09-02
						
	ENDOLOGIX INC.	 	US	 	DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS	 	US20160302798A1	 	US15194159A	 	2016-06-27
						
	ENDOLOGIX INC.	 	US	 	SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE	 	US20160030051A1	 	US14776385A	 	2015-09-14
						
	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20150366688A1	 	US14840428A	 	2015-08-31
						
	ENDOLOGIX INC.	 	US	 	METHOD AND SYSTEM FOR TREATING ANEURYSMS	 	US20150250989A1	 	US14717938A	 	2015-05-20
						
	ENDOLOGIX INC.	 	US	 	FENESTRATED PROSTHESIS	 	US20150173923A1	 	US14581675A	 	2014-12-23

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Apparatus and Methods for Repairing Aneurysms	 	US20150012081A1	 	US14330812A	 	2014-07-14
						
	ENDOLOGIX INC.	 	US	 	STENT GRAFT	 	US9907642	 	US14461308A	 	2014-08-15
						
	ENDOLOGIX INC	 	US	 	ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE	 	US20130253638A1	 	US13731908A	 	2012-12-31
						
	ENDOLOGIX INC.	 	US	 	Methods and Systems for Treating Aneurysms	 	US20120184982A1	 	US13354094A	 	2012-01-19
						
	ENDOLOGIX INC.	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20120109279A1	 	US13287907A	 	2011-11-02
						
	ENDOLOGIX INC.	 	US	 	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE	 	US20110276078A1	 	US12966852A	 	2010-12-13

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS	 	US20110224782A1	 	US13027077A	 	2011-02-14
						
	ENDOLOGIX INC.	 	US	 	ENDOLUMINAL VASCULAR PROSTHESIS	 	US20110218617A1	 	US13039157A	 	2011-03-02
						
	ENDOLOGIX INC	 	US	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	 	US20110054587A1	 	US12769546A	 	2010-04-28
						
	ENDOLOGIX INC	 	US	 	IMPLANTABLE VASCULAR GRAFT	 	US20100318174A1	 	US12860280A	 	2010-08-20
						
	ENDOLOGIX INC	 	US	 	IMPLANTABLE VASCULAR GRAFT	 	US20100318181A1	 	US12860310A	 	2010-08-20
						
	ENDOLOGIX INC.	 	US	 	UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE	 	US20100261662A1	 	US12757900A	 	2010-04-09

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	GRAFT DEPLOYMENT SYSTEM	 	US20100179636A1	 	US12726257A	 	2010-03-17
						
	ENDOLOGIX INC.	 	US	 	STENT GRAFT DELIVERY SYSTEM	 	US20100036360A1	 	US12429474A	 	2009-04-24
						
	ENDOLOGIX INC.	 	US	 	DOCKING APPARATUS AND METHODS OF USE	 	US20090319029A1	 	US12478208A	 	2009-06-04
						
	ENDOLOGIX INC.	 	US	 	GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS	 	US20100004728A1	 	US12371087A	 	2009-02-13
						
	ENDOLOGIX INC.	 	US	 	METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE	 	US20090155337A1	 	US12269677A	 	2008-11-12
						
	ENDOLOGIX INC.	 	US	 	STENT	 	US20090105806A1	 	US12257149A	 	2008-10-23

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Multi-segmented graft deployment system	 	US20080071343A1	 	US11522292A	 	2006-09-15
						
	ENDOLOGIX INC	 	US	 	IMPLANTABLE VASCULAR GRAFT	 	US20070299497A1	 	US11764715A	 	2007-06-18
						
	ENDOLOGIX INC.	 	US	 	Methods and systems for aneurysm treatment using filling structures	 	US20070150041A1	 	US11444603A	 	2006-05-31
						
	ENDOLOGIX INC	 	US	 	ENDOLUMINAL VASCULAR PROSTHESIS	 	US20070112412A1	 	US11623679A	 	2007-01-16
						
	ENDOLOGIX INC.	 	US	 	Method and apparatus for decompressing aneurysms	 	US20070078506A1	 	US11580201A	 	2006-10-12
						
	ENDOLOGIX INC.	 	US	 	Method and apparatus for decompressing aneurysms	 	US20050245891A1	 	US11104303A	 	2005-04-12

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC.	 	US	 	Vascular stent-graft apparatus	 	US20040167607A1	 	US10787404A	 	2004-02-24
						
	ENDOLOGIX INC.	 	US	 	Stent-graft with positioning anchor	 	US20040116997A1	 	US10668901A	 	2003-09-22
						
	ENDOLOGIX INC.	 	US	 	Flexible vascular graft	 	US20010025195A1	 	US09728582A	 	2000-12-01
						
	ENDOLOGIX INC	 	US	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 	US20170239035A1	 	US15310198A	 	2016-11-10
						
	ENDOLOGIX INC	 	US	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 	US20180021045A1	 	US15540246A	 	2017-06-27
						
	ENDOLOGIX INC	 	US	 	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS	 		 	US15737223	 	2017-12-15

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	Systems and Methods with Stents and Filling Structure	 		 	62/382207	 	2016-08-31
						
	ENDOLOGIX INC	 	US	 	STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS	 		 	62/481560	 	2017-04-04
						
	ENDOLOGIX INC	 	US	 	ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT	 		 	62/489213	 	2017-04-24
						
	ENDOLOGIX INC	 	US	 	ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES	 		 	62/529669	 	2017-07-07
						
	ENDOLOGIX INC	 	US	 	STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING	 		 	62/532737	 	2017-07-14
						
	ENDOLOGIX INC	 	US	 	STENT GRAFT	 		 	15/911629	 	2018-03-05

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	 		 	15/965649	 	2018-04-
						
	ENDOLOGIX INC	 	US	 	 MODULATION OF INFLAMMATORY
 RESPONSE
FOLLOWING
 ENDOVASCULAR TREATMENT
	 		 	62/661569	 	2018-4-23
						
	ENDOLOGIX INC	 	US	 	ADVANCED KINK RESISTANT STENT GRAFT	 		 	16/005269	 	2018-6-11
						
	ENDOLOGIX INC	 	US	 	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	 		 	15/985572	 	2018-5-21
						
	ENDOLOGIX INC	 	US	 	SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE	 		 	15/774511	 	2017-8-30
						
	ENDOLOGIX INC	 	US	 	 LONGITUDINALLY EXTENDABLE
 STENT GRAFT SYSTEMS
AND
 METHODS
	 		 	15/774548	 	2018-1-23

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	US	 	 GRAFT SYSTEMS HAVING FILLING
 STRUCTURES
SUPPORTED BY
 SCAFFOLDS AND METHODS FOR THEIR USE
	 		 	16/035497	 	2018-7-13
						
	ENDOLOGIX INC	 	US	 	PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES	 		 	62/678956	 	2018-5-31
						
	ENDOLOGIX INC	 	US	 	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	 		 	16/066595	 	
						
	ENDOLOGIX INC	 	US	 	 MODULATION OF INFLAMMATORY
 RESPONSE
FOLLOWING
 ENDOVASCULAR TREATMENT
	 		 	62/661569	 	2018-4-23
						
	ENDOLOGIX INC.	 	US	 	FENESTRATED PROSTHESIS	 	US8945202	 	12/769581	 	2015-2-3
						
	ENDOLOGIX INC.	 	US	 	Fenestrated prosthesis	 	US8945202	 	12/769581	 	4/28/10

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX, INC.	 	US	 	 Bifurcated vascular graft deployment

device
	 	US6210422	 	09/505038	 	2/16/00
						
	ENDOLOGIX, INC.	 	US	 	Method of deploying bifurcated vascular graft	 	US6156063	 	09/086247	 	5/28/98
						
	ENDOLOGIX, INC.	 	US	 	 Bifurcated vascular graft deployment

device
	 	US6090128	 	08/802478	 	2/20/97
						
	ENDOLOGIX, INC.	 	US	 	 Endovascular prosthesis with improved
 sealing
means for aneurysmal arterial
 disease and method of use
	 	US5665117	 	08/620072	 	3/21/96
						
	ENDOLOGIX, INC.	 	US	 	Locking assembly for coupling guidewire to delivery system	 		 	15/317905	 	12/9/16
						
	Endologix, Inc. and The Cleveland Clinic Foundation	 	US	 	Fenestrated prosthesis	 	US8945202	 	US12769581	 	4/28/10

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Endologix, Inc.	 	US	 	 Single puncture bifurcation graft
 deployment
system
	 	US7691135	 	US10690227	 	10/21/03
						
	Endologix, Inc.	 	US	 	Bifurcated vascular graft and method and apparatus for deploying same	 	US6951572	 	US10639255	 	8/12/03
						
	Endologix, Inc.	 	US	 	Radiation delivery balloon catheter	 	US6699170	 	US09688396	 	10/16/00
						
	Endologix, Inc.	 	US	 	Dual wire placement catheter	 	US6689157	 	US10035729	 	12/21/01
						
	Endologix, Inc.	 	US	 	Method for delivering radiation to an intraluminal site in the body	 	US6685618	 	US09944649	 	8/31/01
						
	Endologix, Inc.	 	US	 	Radiation delivery catheters and dosimetry methods	 	US6491619	 	US09648563	 	8/25/00

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Endologix, Inc.	 	US	 	Endoluminal vascular prosthesis	 	US6331190	 	US09483411	 	1/14/00
						
	Endologix, Inc.	 	US	 	 Bifurcated vascular graft deployment

device
	 	US6210422	 	US09505038	 	2/16/00
						
	Endologix, Inc.	 	US	 	Method of deploying bifurcated vascular graft	 	US6156063	 	US09086247	 	5/28/98
						
	Endologix, Inc.	 	US	 	 Bifurcated vascular graft deployment

device
	 	US6090128	 	US08802478	 	2/20/97
						
	Endologix, Inc.	 	US	 	Axially non-contracting flexible radially expandable stent	 	US6083259	 	US09192803	 	11/16/98
						
	Endologix, Inc.	 	US	 	 Endovascular prosthesis with improved
 sealing
means for aneurysmal arterial
 disease and method of use
	 	US5665117	 	US08620072	 	3/21/96

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Endologix, Inc.	 	US	 	Apparatus and method of placement of a graft or graft system	 		 	US14172126	 	2/4/14
						
	Endologix, Inc. and The Cleveland Clinic Foundation	 	US	 	Apparatus and method of placement of a graft or graft system	 		 	US12769506	 	4/28/10
						
	Endologix, Inc.	 	US	 	Stent graft delivery system	 		 	US12429474	 	4/24/09
						
	ENDOLOGIX INC	 	WO	 	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS	 	WO2016210363A1	 	PCT/US2016/039414	 	2016-06-24
						
	ENDOLOGIX INC	 	JP	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 	JP2017517321A	 	JP2016569901	 	2015-05-05
						
	ENDOLOGIX INC	 	CN	 	Endoluminal Prosthesis Systems and Methods	 		 	201680037099.X	 	2017-12-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	JP	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 		 	2017-534803	 	2017-06-28
						
	ENDOLOGIX INC	 	US	 	ENDOLUMINAL DEVICE AND POLYMER	 		 	62/575827	 	2017-10-23
						
	TRIVASCULAR INC	 	US	 	Advanced Endovascular Graft	 	US9788934B2	 	US14799656A	 	2015-07-15
						
	ENDOLOGIX INC	 	WO	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 	WO2016109757A1	 	PCT/US2015/068204	 	2015-12-30
						
	ENDOLOGIX INC	 	WO	 	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	 	WO2017117068A1	 	PCT/US2016/068575	 	2016-12-23
						
	ENDOLOGIX INC	 	WO	 	SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE	 	WO2017197313A1	 	PCT/US2017/032490	 	2017-05-12

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	PCT	 	SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE	 		 	PCT/US2017/049482	 	2017-08-30
						
	ENDOLOGIX INC	 	PCT	 	LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS	 		 	PCT/US2018/014920	 	2018-01-23
						
	ENDOLOGIX INC	 	PCT	 	STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING	 		 	PCT/US2018/042158	 	2018-7-13
						
	ENDOLOGIX INC	 	PCT	 	 ENDOVASCULAR SYSTEMS,
 DEVICES, AND METHODS

ALLOWING FOR BRANCH DEVICE PLACEMENT IN CHANNEL OF MAIN GRAFT
	 		 	PCT/US2018/028959	 	2018-4-23
						
	ENDOLOGIX INC	 	PCT	 	ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES	 		 	PCT/US2018/041152	 	7/6/2018
						
	ENDOLOGIX INC	 	EP	 	DUAL CONCENTRIC GUIDEWIRE AND METHODS OF BIFURCATED GRAFT DEPLOYMENT | DOPPELTER KONZENTRISCHER FÜHRUNGSDRAHT UND VERFAHREN ZUM EINSATZ EINES VERZWEIGTEN IMPLANTATS | FIL DE GUIDAGE CONCENTRIQUE	 	EP2117631B1	 	EP2008727613A	 	2008-01-11

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

		 		 	 MIXTE ET PROCÉDÉS DE

DÉPLOIEMENT DE GREFFON À DEUX BRANCHES
	 		 		 	
						
	ENDOLOGIX INC	 	EP	 	 DEVICES FOR REPAIRING
 ANEURYSMS | VORRICHTUNG
ZUM AUSBESSERN EINES ANEURYSMAS | DISPOSITIFS DE REPARATION D’ANEVRISMES
	 	EP1397089B1	 	EP2002730505A	 	2002-06-17
						
	ENDOLOGIX INC	 	EP	 	CATHETER SYSTEM | Kathetersystem | Systèmes de cathéter	 	EP2520320B1	 	EP2012178965A	 	2009-06-30
						
	ENDOLOGIX INC	 	EP	 	 DEVICES FOR REPAIRING
 ANEURYSMS | VORRICHTUNG
ZUM AUSBESSERN EINES ANEURYSMAS | PROTHÈSE POUR LE TRAITEMENT DES ANÉVRISMES
	 	EP2260795B1	 	EP201011024A	 	2002-06-17
						
	ENDOLOGIX INC	 	EP	 	SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE	 	EP1962722B1	 	EP2006850439A	 	2006-12-18

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES
ECHAFAUDAGES	 	EP1874231B1	 	EP2006751879A	 	2006-04-28
						
	ENDOLOGIX INC	 	EP	 	GRAFT DEPLOYMENT SYSTEM | IMPLANTAT-ABLAGESYSTEM | SYSTEME DE DEPLOIEMENT DE TUBE PROTHETIQUE	 	EP1572034B1	 	EP2003790040A	 	2003-11-25
						
	ENDOLOGIX INC	 	EP	 	STENT GRAFT | STENT-IMPLANTAT | GREFFON DE STENT	 	EP2459127B1	 	EP2010806904A	 	2010-07-27
						
	ENDOLOGIX INC	 	EP	 	STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT	 	EP1542616B1	 	EP2003754880A	 	2003-09-22
						
	ENDOLOGIX INC	 	EP	 	Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires	 	EP2422745B1	 	EP2011180827A	 	2005-07-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	Catheter system | Kathetersystem | Système de cathéter	 	EP2293838B1	 	EP2009774381A	 	2009-06-30
						
	ENDOLOGIX INC	 	EP	 	Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire	 	EP1778131B1	 	EP2005773726A	 	2005-07-22
						
	ENDOLOGIX INC	 	EP	 	IMPLANTABLE VASCULAR GRAFT | IMPLANTIERBARE GEFÄSSPROTHESE | GREFFE VASCULAIRE IMPLANTABLE	 	EP1333787B1	 	EP2001990900A	 	2001-11-08
						
	ENDOLOGIX INC	 	EP	 	Bifurcated vascular graft and method and apparatus for deploying same | Abzweigendes Gefässtransplantat sowie Verfahren und Gerät zu dessen Entfaltung | Implant vasculaire à deux branches, procédé et
appareil pour sa mise en place	 	EP1009325B1	 	EP1998906274A	 	1998-02-06
						
	ENDOLOGIX INC	 	EP	 	SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM | EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG | SYSTEME DE DEPLOIEMENT D’UNE GREFFE AU NIVEAU D’UNE BIFURCATION,
A L’AIDE D’UN SEUL ORIFICE	 	EP1159024B1	 	EP2000916167A	 	2000-03-07

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS | SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE | PROTHESE ENDOVASCULAIRE BIFURQUEE A DILATATION AUTOMATIQUE	 	EP1087729B1	 	EP1999957012A	 	1999-05-28
						
	ENDOLOGIX INC	 	EP	 	 ENDOLUMINAL VASCULAR
 PROSTHESIS | PROTHESE
IM
 INNEREN EINES GEFÄSSES |
 PROTHESE VASCULAIRE

ENDOLUMINALE
	 	EP1059893B1	 	EP1998930137A	 	1998-06-15
						
	ENDOLOGIX INC	 	EP	 	ENDOLUMINAL VASCULAR PROSTHESIS | ENDOLUMINALE VASKULÄRE PROTHESE | PROTHESE VASCULAIRE ENDOLUMINALE	 	EP1146833B1	 	EP1999973254A	 	1999-11-10
						
	ENDOLOGIX INC	 	EP	 	DUAL INFLATABLE ARTERIAL PROSTHESIS | DOPPELTE AUFBLASBARE ARTERIENPROTHESE | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE	 	EP3240508A1	 	EP2015876323A	 	2015-12-30
						
	ENDOLOGIX INC	 	EP	 	FORMING HYDROGELS AND MATERIALS THEREFOR | HERSTELLUNG VON HYDROGELEN UND MATERIALIEN DAFÜR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI	 	EP3113722A4	 	EP2015758921A	 	2015-03-06
						
	ENDOLOGIX INC	 	EP	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | MODULARE STENTPROTHESENSYSTEME UND VERFAHREN MIT AUFBLASBAREN	 	EP3148483A4	 	EP2015800658A	 	2015-05-05

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

		 		 	FÜLLSTRUKTUREN | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES	 		 		 	
						
	ENDOLOGIX INC	 	EP	 	LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | VERRIEGELUNGSANORDNUNG ZUR KOPPLUNG EINES FÜHRUNGSDRAHTS AN EIN AUSGABESYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN
FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION	 	EP3139860A1	 	EP2016790254A	 	2016-06-29
						
	ENDOLOGIX INC	 	EP	 	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | FÜLLSTRUKTUR FÜR EIN PROTHESENSYSTEM UND VERWENDUNGSVERFAHREN | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ
D’UTILISATION	 	EP2519191A4	 	EP2010841580A	 	2010-12-21
						
	ENDOLOGIX INC	 	EP	 	METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | VERFAHREN ZUR HERSTELLUNG VON MATERIALIEN IN SITU IN EINER MEDIZINISCHEN VORRICHTUNG | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF
MÉDICAL	 	EP2968692A1	 	EP2014712991A	 	2014-03-07

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION	 	EP2299933A4	 	EP2009770704A	 	2009-06-04
						
	ENDOLOGIX INC	 	EP	 	SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS	 	EP2299931A4	 	EP2009759453A	 	2009-06-04
						
	ENDOLOGIX INC	 	EP	 	BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTEME UND VERFAHREN ZUR FREISETZUNG EINER BIFURKATIONSPROTHESE | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS	 	EP2268227A4	 	EP2009730087A	 	2009-04-10
						
	ENDOLOGIX INC	 	EP	 	METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | VERFAHREN UND SYSTEM ZUR ENDOVASKULÄREN BEHANDLUNG VON ANEURYSMEN | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE	 	EP2693980A1	 	EP2012716880A	 	2012-04-06
						
	ENDOLOGIX INC	 	EP	 	STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE	 	EP2278939A4	 	EP2009733719A	 	2009-04-24

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	CATHETER SYSTEM AND METHODS OF USING SAME | KATHETERSYSTEM UND VERFAHREN ZU SEINER VERWENDUNG | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION	 	EP2680915A1	 	EP2012709432A	 	2012-02-29
						
	ENDOLOGIX INC	 	EP	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE DISPOSITION DE
GREFFE OU DE SYSTÈME DE GREFFE	 	EP2635241A2	 	EP2011781956A	 	2011-11-02
						
	ENDOLOGIX INC	 	EP	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE
GREFFE OU D’UN SYSTÈME DE GREFFE	 	EP2429452A1	 	EP2010717383A	 	2010-04-28
						
	ENDOLOGIX INC	 	WO	 	SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS À CORPS DE GREFFE, CANAL DE REMPLISSAGE GONFLABLE ET STRUCTURE DE REMPLISSAGE	 	WO2017197313A1	 	PCT/US2017/32490A	 	2017-05-12

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	WO	 	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS AVEC GREFFON FENESTRÉ ET STRUCTURE DE REMPLISSAGE	 	WO2017117068A1	 	PCT/US2016/68575A	 	2016-12-23
						
	ENDOLOGIX INC	 	WO	 	LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION	 	WO2017004265A1	 	PCT/US2016/40197A	 	2016-06-29
						
	ENDOLOGIX INC	 	WO	 	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS | SYSTÈMES ET PROCÉDÉS DE PROTHÈSE ENDOLUMINALE	 	WO2016210363A1	 	PCT/US2016/39414A	 	2016-06-24
						
	ENDOLOGIX INC	 	WO	 	DUAL INFLATABLE ARTERIAL PROSTHESIS | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE	 	WO2016109757A1	 	PCT/US2015/68204A	 	2015-12-30
						
	ENDOLOGIX INC	 	WO	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES	 	WO2015183489A1	 	PCT/US2015/29292A	 	2015-05-05
						
	ENDOLOGIX INC	 	WO	 	FORMING HYDROGELS AND MATERIALS THEREFOR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI	 	WO2015134906A1	 	PCT/US2015/19251A	 	2015-03-06

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	WO	 	METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL	 	WO2014159093A1	 	PCT/US2014/21928A	 	2014-03-07
						
	ENDOLOGIX INC	 	WO	 	METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE	 	WO2012139054A1	 	PCT/US2012/32612A	 	2012-04-06
						
	ENDOLOGIX INC	 	WO	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE	 	WO2012061526A3	 	PCT/US2011/59012A	 	2011-11-02
						
	ENDOLOGIX INC	 	WO	 	CATHETER SYSTEM AND METHODS OF USING SAME | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION	 	WO2012118901A1	 	PCT/US2012/27151A	 	2012-02-29
						
	ENDOLOGIX INC	 	WO	 	METHODS AND SYSTEMS FOR TREATING ANEURYSMS | PROCÉDÉS ET SYSTÈMES DE TRAITEMENT D’ANÉVRISMES	 	WO2012100059A1	 	PCT/US2012/21878A	 	2012-01-19
						
	ENDOLOGIX INC	 	WO	 	DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS | DISPOSITIFS ET PROCÉDÉS DE TRAITEMENT DE DISSECTIONS VASCULAIRES	 	WO2012068298A1	 	PCT/US2011/61061A	 	2011-11-16

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	WO	 	STENT GRAFT | ENDOPROTHÈSE COUVERTE	 	WO2011017123A3	 	PCT/US2010/43432A	 	2010-07-27
						
	ENDOLOGIX INC	 	WO	 	STENT GRAFT | ENDOPROTHÈSE COUVERTE	 	WO2011008989A3	 	PCT/US2010/42181A	 	2010-07-15
						
	ENDOLOGIX INC	 	WO	 	PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS | PROCÉDÉ ET DISPOSITIF PERCUTANÉS POUR TRAITER DES DISSECTIONS	 	WO2010127305A3	 	PCT/US2010/33274A	 	2010-04-30
						
	ENDOLOGIX INC	 	WO	 	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE	 	WO2010127040A1	 	PCT/US2010/32843A	 	2010-04-28
						
	ENDOLOGIX INC	 	WO	 	BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS	 	WO2009126906A8	 	PCT/US2009/40239A	 	2009-04-10
						
	ENDOLOGIX INC	 	WO	 	CATHETER SYSTEM | SYSTÈME DE CATHÉTER	 	WO2010002931A1	 	PCT/US2009/49316A	 	2009-06-30

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	WO	 	 DESIGN AND METHOD OF
 PLACEMENT OF A GRAFT OR
GRAFT SYSTEM | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS
	 	WO2009105699A1	 	PCT/US2009/34755A	 	2009-02-20
						
	ENDOLOGIX INC	 	WO	 	METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE | PROCÉDÉ ET AGENT DE STABILISATION <I>IN SITU</I> DU TISSU VASCULAIRE	 	WO2009064806A1	 	PCT/US2008/83267A	 	2008-11-12
						
	ENDOLOGIX INC	 	WO	 	STENT | ENDOPROTHÈSE VASCULAIRE	 	WO2009055615A1	 	PCT/US2008/81022A	 	2008-10-23
						
	ENDOLOGIX INC	 	DE	 	EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG	 	DE60031381T2	 	DE60031381A	 	2000-03-07
						
	ENDOLOGIX INC	 	DE	 	SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE	 	DE69933560T2	 	DE69933560A	 	1999-05-28
						
	ENDOLOGIX INC	 	DE	 	ENDOLUMINALE VASKULÄRE PROTHESE	 	DE69927055T2	 	DE69927055A	 	1999-11-10

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	AU	 	Bifurcated vascular graft and method and apparatus for deploying same | Bifurcated vascular graft deployment device	 	AU725117B2	 	AU199861540A	 	1998-02-06
						
	ENDOLOGIX INC	 	AU	 	Implantable vascular graft	 	AU200230661A	 	AU200230661A	 	2001-11-08
						
	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP1397089	 	EP02730505.1	 	2017-04-19
						
	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP1397089	 	EP02730505.1	 	2017-04-19
						
	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP1397089	 	EP02730505.1	 	2017-04-19
						
	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP2260795	 	EP10011024.6	 	2016-05-25

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP2260795	 	EP10011024.6	 	2016-05-25
						
	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP2260795	 	EP10011024.6	 	2016-05-25
						
	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP2260795	 	EP10011024.6	 	2016-05-25
						
	ENDOLOGIX INC	 	EP	 	DEVICES FOR REPAIRING ANEURYSMS	 	EP2260795	 	EP10011024.6	 	2016-05-25
						
	ENDOLOGIX INC	 	EP	 	ADVANCED KINK-RESISTANT STENT GRAFT	 	EP2833827	 	13714471.3	 	2018-01-31
						
	ENDOLOGIX INC	 	EP	 	ADVANCED KINK-RESISTANT STENT GRAFT	 	EP2833827	 	13714471.3	 	2018-01-31

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	 		 	EP13717893.5	 	2014-11-06
						
	ENDOLOGIX INC	 	EP	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 		 	EP15800658.5	 	2016-11-21
						
	ENDOLOGIX INC	 	EP	 	ANEURYSM SAC ACCESS CONDUIT	 		 	15852460.3	 	2017-04-12
						
	ENDOLOGIX INC	 	EP	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 		 	15876323.5	 	2017-07-13
						
	ENDOLOGIX INC	 	EP	 	Endoluminal Prosthesis Systems and Methods	 		 	16815450.8	 	2017-12-19
						
	ENDOLOGIX INC	 	CN	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 		 	2015800393484	 	2017-01-19

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	CN	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 		 	2015800763903	 	2017-08-17
						
	ENDOLOGIX INC	 	JP	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 		 	2016-569901	 	2016-11-28
						
	ENDOLOGIX INC	 	CN	 	Endoluminal Prosthesis Systems and Methods	 		 	201680037099.X	 	2017-12-22
						
	ENDOLOGIX INC	 	JP	 	DUAL INFLATABLE ARTERIAL PROSTHESIS	 		 	2017-534803	 	2017-06-28
						
	ENDOLOGIX INC	 	JP	 	Endoluminal Prosthesis Systems and Methods	 		 	PCT/US2016/039414	 	2017-12-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	NELLIX INC.	 	US	 	Stent-graft with positioning anchor	 	US9814612B2	 	US14697433A	 	2015-10-21
						
	NELLIX INC.	 	US	 	System and methods for endovascular aneurysm treatment	 	US9737425B2	 	US14537749A	 	2014-11-10
						
	NELLIX INC.	 	US	 	Stent graft delivery system	 	US9730700B2	 	US14586110A	 	2015-04-23
						
	NELLIX INC.	 	US	 	Methods for deploying a positioning anchor with a stent-graft	 	US9113999B2	 	US11876458A	 	2007-10-22
						
	NELLIX INC.	 	US	 	Sealing apparatus and methods of use	 	US8945199B2	 	US12478225A	 	2009-06-04
						
	NELLIX INC.	 	US	 	Stent graft delivery system	 	US8926682B2	 	US13243941A	 	2011-09-23

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	NELLIX INC.	 	US	 	System and methods for endovascular aneurysm treatment	 	US8906084B2	 	US12684074A	 	2010-01-07
						
	NELLIX INC.	 	US	 	Graft systems having filling structures supported by scaffolds and methods for their use	 	US8870941B2	 	US13285897A	 	2011-10-31
						
	NELLIX INC.	 	US	 	STENT GRAFT DELIVERY SYSTEM	 	US20180028192A1	 	US15676869A	 	2017-08-14
						
	NELLIX INC.	 	US	 	SEALING APPRATUS AND METHODS OF USE	 	US20150148892A1	 	US14612048A	 	2015-02-02
						
	NELLIX INC.	 	US	 	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE	 	US10022249	 	US14525019A	 	2014-10-27
						
	NELLIX, INC.	 	US	 	System and methods of Endovascular Aneurysm Treatment	 		 	14/682414	 	8/21/17

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Nellix, Inc.	 	US	 	Vascular stent-graft apparatus and forming method	 	US6695833	 	US09671550	 	9/27/00
						
	ENDOLOGIX INC	 	EP	 	Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire	 	EP1778131B1	 	EP2005773726A	 	2005-07-22
						
	NELLIX INC.	 	EP	 	Method for forming a vascular stent-graft | Verfahren zur Herstellung eines vaskulären Stent-Grafts | Procédé de formation d’un stent-greffe vasculaire.	 	EP1355587B1	 	EP2001973590A	 	2001-09-26
						
	NELLIX INC	 	EP	 	METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | VERFAHREN UND SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | PROCEDES ET SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME
UTILISANT DES STRUCTURES DE REMPLISSAGE	 	EP1962722A4	 	EP2006850439A	 	2006-12-18
						
	ENDOLOGIX INC	 	EP	 	Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires	 	EP2422745A1	 	EP2011180827A	 	2005-07-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX INC	 	EP	 	DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION	 	EP2299933A1	 	EP2009770704A	 	2009-06-04
						
	ENDOLOGIX INC	 	EP	 	SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS	 	EP2299931A1	 	EP2009759453A	 	2009-06-04
						
	ENDOLOGIX INC	 	EP	 	STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE	 	EP2278939A1	 	EP2009733719A	 	2009-04-24
						
	ENDOLOGIX INC	 	EP	 	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES
ECHAFAUDAGES	 	EP1874231A2	 	EP2006751879A	 	2006-04-28
						
	ENDOLOGIX INC	 	EP	 	STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT	 	EP1542616A2	 	EP2003754880A	 	2003-09-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	NELLIX INC.	 	WO	 	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION	 	WO2011082040A1	 	PCT/US2010/061621	 	2010-12-21
						
	NELLIX INC.	 	WO	 	DOCKING APPARATUS AND METHODS OF USE | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION	 	WO2009158170A1	 	PCT/US2009/046308	 	2009-06-04
						
	NELLIX INC.	 	WO	 	SEALING APPARATUS AND METHODS OF USE | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS	 	WO2009149294A1	 	PCT/US2009/046310	 	2009-06-04
						
	NELLIX INC.	 	WO	 	STENT GRAFT DELIVERY SYSTEM | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE	 	WO2009132309A1	 	PCT/US2009/041718	 	2009-04-24
						
	NELLIX INC.	 	WO	 	GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS | ENDOCADRE DE GREFFE AYANT DES CARACTÉRISTIQUES VARIABLES AXIALEMENT	 	WO2009103011A1	 	PCT/US2009/034136	 	2009-02-13
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US9867727B2	 	US14320773A	 	2014-07-01

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US9788934B2	 	US14799656A	 	2015-07-15
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft for aneurysms involving major branch vessels	 	US9724186B2	 	US14050835A	 	2013-10-10
						
	TRIVASCULAR INC.	 	US	 	System and method of pivoted stent deployment	 	US9713523B2	 	US14452343A	 	2014-08-05
						
	TRIVASCULAR INC.	 	US	 	Systems and methods for guidewire crossover for bifurcated prostheses	 	US9655754B2	 	US14323059A	 	2014-07-03
						
	TRIVASCULAR INC.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 	US9585774B2	 	US14823076A	 	2015-08-11
						
	TRIVASCULAR INC.	 	US	 	 PTFE layers and methods of

manufacturing
	 	US9549829B2	 	US14458349A	 	2014-08-13

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Delivery catheter for endovascular device	 	US9498363B2	 	US13835491A	 	2013-03-15
						
	TRIVASCULAR INC	 	US	 	Low profile stent and delivery system	 	US9463101B2	 	US14923477A	 	2015-10-27
						
	TRIVASCULAR INC.	 	US	 	 PTFE layers and methods of

manufacturing
	 	US9446553B2	 	US14230318A	 	2014-03-31
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US9351858B2	 	US14704013A	 	2015-05-05
						
	TRIVASCULAR INC.	 	US	 	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	 	US9308301B2	 	US13089960A	 	2011-04-19
						
	TRIVASCULAR INC.	 	US	 	Endovascular delivery system with an improved radiopaque marker scheme	 	US9233015B2	 	US13803050A	 	2013-03-14

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Low profile stent graft and delivery system	 	US9192462B2	 	US13803037A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	Fenestrated inflatable graft	 	US9144486B2	 	US13652471A	 	2012-10-15
						
	TRIVASCULAR INC.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 	US9132025B2	 	US13803067A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	Endovascular delivery system with flexible and torqueable hypotube	 	US9066828B2	 	US13803062A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US9050754B2	 	US12729182A	 	2010-03-22
						
	TRIVASCULAR INC.	 	US	 	Durable stent graft with tapered struts and stable delivery methods and devices	 	US8992595B2	 	US13799207A	 	2013-03-13

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	In vitro testing of endovascular device	 	US8978448B2	 	US13649066A	 	2012-10-10
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft delivery system and method of treatment	 	US8900288B2	 	US12566104A	 	2009-09-24
						
	TRIVASCULAR INC.	 	US	 	Method of delivering advanced endovascular graft and system	 	US8864814B2	 	US13246651A	 	2011-09-27
						
	TRIVASCULAR INC.	 	US	 	 PTFE layers and methods of

manufacturing
	 	US8840824B2	 	US12910281A	 	2010-10-22
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US8801769B2	 	US13737351A	 	2013-01-09
						
	TRIVASCULAR INC.	 	US	 	Apparatus for manufacturing an endovascular graft section	 	US8783316B2	 	US12697504A	 	2010-02-01

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	 PTFE layers and methods of

manufacturing
	 	US8728372B2	 	US12915636A	 	2010-10-29
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US8709065B2	 	US12491336A	 	2009-06-25
						
	TRIVASCULAR INC.	 	US	 	Virtual prototyping and testing for medical device development	 	US8666714B2	 	US13523765A	 	2012-06-14
						
	TRIVASCULAR INC.	 	US	 	Asymmetric stent apparatus and method	 	US8663309B2	 	US11861828A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US8361136B2	 	US12566793A	 	2009-09-25
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US8348989B2	 	US11429735A	 	2006-05-08

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US8328861B2	 	US11941434A	 	2007-11-16
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft and method of delivery	 	US8241346B2	 	US13246643A	 	2011-09-27
						
	TRIVASCULAR INC.	 	US	 	Inflatable porous implants and methods for drug delivery	 	US8267989B2	 	US12860364A	 	2010-08-20
						
	TRIVASCULAR INC.	 	US	 	Inflatable intraluminal graft	 	US8226708B1	 	US10168053A	 	2002-06-14
						
	TRIVASCULAR INC.	 	US	 	Stent and delivery system for deployment thereof	 	US8226701B2	 	US11861756A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	Virtual prototyping and testing for medical device development	 	US8224632B2	 	US12904994A	 	2010-10-14

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Dual chamber cuff structure	 	US8216297B2	 	US11504434A	 	2006-08-14
						
	TRIVASCULAR INC.	 	US	 	Barbed radially expandable stent	 	US8167927B2	 	US13245661A	 	2011-09-26
						
	TRIVASCULAR INC.	 	US	 	Securement assembly and method for expandable endovascular device	 	US8083789B2	 	US11941450A	 	2007-11-16
						
	TRIVASCULAR INC.	 	US	 	System and method of pivoted stent deployment	 	US8066755B2	 	US11861716A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	Constant force material delivery system and method	 	US7971751B2	 	US12724068A	 	2010-03-15
						
	TRIVASCULAR INC.	 	US	 	Passive hemostatic sheath valve	 	US7901379B2	 	US11298285A	 	2005-12-09

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Virtual prototyping and testing for medical device development	 	US7840393B1	 	US09679725A	 	2000-10-04
						
	TRIVASCULAR INC.	 	US	 	Inflatable porous implants and methods for drug delivery	 	US7803178B2	 	US10769532A	 	2004-01-30
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US7766954B2	 	US11333595A	 	2006-01-17
						
	TRIVASCULAR INC.	 	US	 	Constant force material delivery system and method	 	US7708163B2	 	US11360077A	 	2006-02-23
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US7682475B2	 	US11870748A	 	2007-10-11
						
	TRIVASCULAR INC.	 	US	 	Method for manufacturing an endovascular graft section	 	US7678217B2	 	US11522490A	 	2006-09-15

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Inflatable implant	 	US7632291B2	 	US10461853A	 	2003-06-13
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US7615071B2	 	US11390732A	 	2006-03-28
						
	TRIVASCULAR INC.	 	US	 	 Delivery system and method for
 expandable
intracorporeal device
	 	US7338518B2	 	US11201028A	 	2005-08-10
						
	TRIVASCULAR INC.	 	US	 	Passive hemostatic sheath valve	 	US7241276B2	 	US10636871A	 	2003-08-06
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US7147660B2	 	US10327711A	 	2002-12-20
						
	TRIVASCULAR INC.	 	US	 	Kink resistant endovascular graft	 	US7150758B2	 	US10384103A	 	2003-03-06

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Radially expandable stent	 	US7147661B2	 	US10029559A	 	2001-12-20
						
	TRIVASCULAR INC.	 	US	 	Method and apparatus for shape forming endovascular graft material	 	US7147455B2	 	US10868292A	 	2004-06-14
						
	TRIVASCULAR INC.	 	US	 	Method for manufacturing an endovascular graft section	 	US7125464B2	 	US10029557A	 	2001-12-20
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US7081129B2	 	US10132754A	 	2002-04-24
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US7090693B1	 	US10029584A	 	2001-12-20
						
	TRIVASCULAR INC.	 	US	 	 Delivery system and method for
 expandable
intracorporeal device
	 	US7066951B2	 	US10419312A	 	2003-04-17

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Method and apparatus for shape forming endovascular graft material	 	US6776604B1	 	US10029570A	 	2001-12-20
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated endovascular graft	 	US6761733B2	 	US09917371A	 	2001-07-27
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for endovascular graft	 	US6733521B2	 	US09834278A	 	2001-04-11
						
	TRIVASCULAR INC.	 	US	 	 Delivery system and method for
 expandable
intracorporeal device
	 	US6602280B2	 	US09774733A	 	2001-01-31
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US6395019B2	 	US09133978A	 	1998-08-14
						
	TRIVASCULAR INC	 	US	 	ENDOVASCULAR GRAFT	 	US20170348125A1	 	US15686214A	 	2017-08-25

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	US	 	ADVANCED ENDOVASCULAR GRAFT	 	US20170348087A1	 	US15686218A	 	2017-08-25
						
	TRIVASCULAR INC	 	US	 	ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS	 	US20170296327A1	 	US15638559A	 	2017-06-30
						
	TRIVASCULAR INC	 	US	 	SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES	 	US20170216064A1	 	US15491074A	 	2017-04-19
						
	TRIVASCULAR INC	 	US	 	Low Profile Stent Graft and Delivery System	 	US9987123	 	US15263469A	 	2016-09-13
						
	TRIVASCULAR INC	 	US	 	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG	 	US20170035549A1	 	US15299542A	 	2016-10-21
						
	TRIVASCULAR INC.	 	US	 	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE	 	US20170035590A1	 	US15298166A	 	2016-10-19

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	US	 	PTFE LAYERS AND METHODS OF MANUFACTURING	 	US20160367354A1	 	US15251011A	 	2016-08-30
						
	TRIVASCULAR INC	 	US	 	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME	 	US10034787	 	US14970621A	 	2015-12-16
						
	TRIVASCULAR INC	 	US	 	NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER	 	US20160193392A1	 	US15068415A	 	2016-03-11
						
	TRIVASCULAR INC.	 	US	 	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	 	US9956101	 	US14958085A	 	2015-12-03
						
	TRIVASCULAR INC.	 	US	 	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT	 	US20160113796A1	 	US14920828A	 	2015-10-22
						
	TRIVASCULAR INC.	 	US	 	ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE	 	US20150265446A1	 	US14717080A	 	2015-05-20

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS	 	US20150250481A1	 	US14643217A	 	2015-03-10
						
	TRIVASCULAR INC.	 	US	 	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	 	US20150164667A1	 	US14631818A	 	2015-02-25
						
	TRIVASCULAR INC.	 	US	 	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES	 	US20150157479A1	 	US14615337A	 	2015-02-05
						
	TRIVASCULAR INC.	 	US	 	TANDEM MODULAR ENDOGRAFT	 	US20150088244A1	 	US14492674A	 	2014-09-22
						
	TRIVASCULAR INC.	 	US	 	ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE	 	US20150073523A1	 	US14481834A	 	2014-09-09
						
	TRIVASCULAR INC.	 	US	 	GATE WIRE FOR CONTRALATERAL LEG ACCESS	 	US20140194970A1	 	US14151373A	 	2014-01-09

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	SAC LINER FOR ANEURYSM REPAIR	 	US20140194973A1	 	US14151195A	 	2014-01-09
						
	TRIVASCULAR INC.	 	US	 	ASYMMETRIC STENT APPARATUS AND METHOD	 	US20140135899A1	 	US14157350A	 	2014-01-16
						
	TRIVASCULAR INC.	 	US	 	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	 	US20130268056A1	 	US13803033A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	ADVANCED KINK RESISTANT STENT GRAFT	 	US9993328	 	US13803046A	 	2013-03-14
						
	TRIVASCULAR INC.	 	US	 	 VASCULAR GRAFT HAVING
 LIMITED END
STRUCTURE
	 	US20130096665A1	 	US13650705A	 	2012-10-12
						
	TRIVASCULAR INC.	 	US	 	INFLATABLE INTRALUMINAL GRAFT	 	US20120265290A1	 	US13532887A	 	2012-06-26

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	 	US20120191174A1	 	US13297219A	 	2011-11-15
						
	TRIVASCULAR INC.	 	US	 	SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT	 	US20120083870A1	 	US13277117A	 	2011-10-19
						
	TRIVASCULAR INC.	 	US	 	BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS	 	US20120016457A1	 	US13245652A	 	2011-09-26
						
	TRIVASCULAR INC.	 	US	 	FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT	 	US20110218609A1	 	US13024255A	 	2011-02-09
						
	TRIVASCULAR INC.	 	US	 	HINGED ENDOVASCULAR DEVICE	 	US20100331958A1	 	US12747499A	 	2010-09-07
						
	TRIVASCULAR INC.	 	US	 	Inflatable Implant	 	US20100076481A1	 	US12628623A	 	2009-12-01

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT	 	US20100016943A1	 	US12566808A	 	2009-09-25
						
	TRIVASCULAR INC.	 	US	 	MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY	 	US20090099649A1	 	US12245620A	 	2008-10-03
						
	TRIVASCULAR INC.	 	US	 	ALIGNMENT STENT APPARATUS AND METHOD	 	US20090082845A1	 	US11861746A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	 SYSTEM AND METHOD OF
 SECURING STENT
BARBS
	 	US20090082847A1	 	US11861731A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	APPARATUS FOR SECURING STENT BARBS	 	US20090082841A1	 	US11861739A	 	2007-09-26
						
	TRIVASCULAR INC.	 	US	 	PTFE LAYERS AND METHODS OF MANUFACTURING	 	US20090036971A1	 	US12250915A	 	2008-10-14

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	PTFE LAYERS AND METHODS OF MANUFACTURING	 	US20090036973A1	 	US12250946A	 	2008-10-14
						
	TRIVASCULAR INC.	 	US	 	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	 	US20060222596A1	 	US11097467A	 	2005-04-01
						
	TRIVASCULAR INC.	 	US	 	Hybrid modular endovascular graft	 	US20060224232A1	 	US11097718A	 	2005-04-01
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US20060009833A1	 	US11205793A	 	2005-08-15
						
	TRIVASCULAR INC.	 	US	 	Methods, compositions and devices for embolizing body lumens	 	US20050158272A1	 	US11031311A	 	2005-01-07
						
	TRIVASCULAR INC.	 	US	 	Endoluminal prosthesis endoleak management	 	US20050090804A1	 	US10691849A	 	2003-10-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Endovascular graft joint and method for manufacture	 	US20050027347A1	 	US10640368A	 	2003-08-13
						
	TRIVASCULAR INC.	 	US	 	Layered endovascular graft	 	US20040220664A1	 	US10803153A	 	2004-03-17
						
	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US20040138734A1	 	US10686863A	 	2003-10-16
						
	TRIVASCULAR INC.	 	US	 	Endovascular graft	 	US20030216802A1	 	US10289136A	 	2002-11-05
						
	TRIVASCULAR INC.	 	US	 	Inflatable intraluminal graft	 	US20030225453A1	 	US10289137A	 	2002-11-05
						
	TRIVASCULAR INC.	 	US	 	Advanced endovascular graft	 	US20030120338A1	 	US10091641A	 	2002-03-05

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	US	 	Delivery system and method for bifurcated graft	 	US20030004560A1	 	US10122474A	 	2002-04-11
						
	TRIVASCULAR INC.	 	US	 	Layered endovascular graft	 	US20020010508A1	 	US09970576A	 	2001-10-04
						
	TRIVASCULAR, INC.	 	US	 	Stent-graft with improved flexibility	 		 	15/568834	 	10/24/17
						
	Trivascular, Inc.	 	US	 	Passive hemostatic sheath valve	 	US7901379	 	US11298285	 	12/9/05
						
	Trivascular, Inc.	 	US	 	Fluid mixing apparatus and method	 	US7178978	 	US10658074	 	9/8/03
						
	Trivascular, Inc.	 	US	 	 Delivery system and method for
 expandable
intracorporeal device
	 	US6602280	 	US09774733	 	1/31/01

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Endovascular graft	 	US6395019	 	US09133978	 	8/14/98
						
	Trivascular, Inc.	 	US	 	Layered endovascular graft	 	US6331191	 	US09200317	 	11/25/98
						
	Trivascular, Inc.	 	US	 	Endovascular graft having longitudinally displaceable sections	 	US6132457	 	US09177295	 	10/22/98
						
	Trivascular, Inc.	 	US	 	Low profile stent graft and delivery system	 		 	US15263469	 	9/13/16
						
	Trivascular, Inc.	 	US	 	Delivery catheter for endovascular device	 		 	US15298166	 	10/19/16
						
	Trivascular, Inc.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 		 	US15299542	 	10/21/16

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US15251011	 	8/30/16
						
	Trivascular, Inc.	 	US	 	Endovascular delivery system with an improved radiopaque marker scheme	 		 	US14970621	 	12/16/15
						
	Trivascular, Inc.	 	US	 	 Non-degradable, low swelling, water

soluble radiopaque hydrogel polymer
	 		 	US15068415	 	3/11/16
						
	Trivascular, Inc.	 	US	 	 Internal iliac preservation devices and

methods
	 		 	US14958085	 	12/3/15
						
	Trivascular, Inc.	 	US	 	Stent graft delivery system with access conduit	 		 	US14920828	 	10/22/15
						
	Trivascular, Inc.	 	US	 	Bifurcated endovascular prosthesis having tethered contralateral leg	 		 	US14823076	 	8/11/15

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Low profile stent and delivery system	 		 	US14923477	 	10/27/15
						
	Trivascular, Inc.	 	US	 	Endovascular delivery system with flexible and torqueable hypotube	 		 	US14717080	 	5/20/15
						
	Trivascular, Inc.	 	US	 	Inflatable occlusion wire-balloon for aortic applications	 		 	US14643217	 	3/10/15
						
	Trivascular, Inc.	 	US	 	Advanced endovascular graft and delivery system	 		 	US14631818	 	2/25/15
						
	Trivascular, Inc.	 	US	 	Durable stent graft with tapered struts and stable delivery methods and devices	 		 	US14615337	 	2/5/15
						
	Trivascular, Inc.	 	US	 	Tandem modular endograft	 		 	US14492674	 	9/22/14

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Endoleak isolation sleeves and methods of use	 		 	US14481834	 	9/9/14
						
	Trivascular, Inc.	 	US	 	Sac liner for aneurysm repair	 		 	US14151195	 	1/9/14
						
	Trivascular, Inc.	 	US	 	Gate wire for contralateral leg access	 		 	US14151373	 	1/9/14
						
	Trivascular, Inc.	 	US	 	Asymmetric stent apparatus and method	 		 	US14157350	 	1/16/14
						
	Trivascular, Inc.	 	US	 	Low profile stent graft and delivery system	 		 	US13803033	 	3/14/13
						
	Trivascular, Inc.	 	US	 	Advanced kink resistant stent graft	 		 	US13803046	 	3/14/13

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Vascular graft having limited end structure	 		 	US13650705	 	10/12/12
						
	Trivascular, Inc.	 	US	 	Inflatable intraluminal graft	 		 	US13532887	 	6/26/12
						
	Trivascular, Inc.	 	US	 	Advanced endovascular graft and delivery system	 		 	US13297219	 	11/15/01
						
	Trivascular, Inc.	 	US	 	 System and method of pivoted stent

deployment
	 		 	US13277117	 	10/19/11
						
	Trivascular, Inc.	 	US	 	 Barbed radially expandable stent with
 slotted
struts
	 		 	US13245652	 	9/26/11
						
	Trivascular, Inc.	 	US	 	Fill tube manifold and delivery methods for endovascular graft	 		 	US13024255	 	2/9/11

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Hinged endovascular device	 		 	US12747499	 	9/7/10
						
	Trivascular, Inc.	 	US	 	Inflatable implant	 		 	US12628623	 	12/1/09
						
	Trivascular, Inc.	 	US	 	 Method of delivering advanced
 endovascular
graft
	 		 	US12566808	 	9/25/09
						
	Trivascular, Inc.	 	US	 	Modular vascular graft for low profile percutaneous delivery	 		 	US12245620	 	10/3/08
						
	Trivascular, Inc.	 	US	 	System and method of securing stent barbs	 		 	US11861731	 	9/26/07
						
	Trivascular, Inc.	 	US	 	Alignment stent apparatus and method	 		 	US11861746	 	9/26/07

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Apparatus for securing stent barbs	 		 	US11861739	 	9/26/07
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US12250946	 	10/14/08
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US12250915	 	10/14/08
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US11106150	 	4/13/05
						
	Trivascular, Inc.	 	US	 	Ptfe layers and methods of manufacturing	 		 	US11106131	 	4/13/05
						
	Trivascular, Inc.	 	US	 	Hybrid modular endovascular graft	 		 	US11097718	 	4/1/05

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	 Non-degradable low swelling, water

soluble radiopaque hydrogel polymer
	 		 	US11097467	 	4/1/05
						
	Trivascular, Inc.	 	US	 	Delivery system and method for bifurcated graft	 		 	US11205793	 	8/15/05
						
	Trivascular, Inc.	 	US	 	Modular endovascular graft	 		 	US11077938	 	3/11/05
						
	Trivascular, Inc.	 	US	 	Methods, compositions and devices for embolizing body lumens	 		 	US11031311	 	1/7/05
						
	Trivascular, Inc.	 	US	 	 Endoluminal prosthesis endoleak

management
	 		 	US10691849	 	10/22/03
						
	Trivascular, Inc.	 	US	 	Endovascular graft joint and method for manufacture	 		 	US10640368	 	8/13/03

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Layered endovascular graft	 		 	US10803153	 	3/17/04
						
	Trivascular, Inc.	 	US	 	Delivery system and method for bifurcated graft	 		 	US10686863	 	10/16/03
						
	Trivascular, Inc.	 	US	 	Inflatable intraluminal graft	 		 	US10289137	 	11/5/02
						
	Trivascular, Inc.	 	US	 	Endovascular graft	 		 	US10289136	 	11/5/02
						
	Trivascular, Inc.	 	US	 	Advanced endovascular graft	 		 	US10091641	 	3/5/02
						
	Trivascular, Inc.	 	US	 	Delivery system and method for bifurcated graft	 		 	US10122474	 	4/11/02

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	Trivascular, Inc.	 	US	 	Layered endovascular graft	 		 	US09970576	 	10/3/01
						
	TRIVASCULAR INC.	 	EP	 	ADVANCED KINK-RESISTANT STENT GRAFT | HOCHENTWICKELTES KNICKBESTÄNDIGES STENTTRANSPLANTAT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE	 	EP2833827B1	 	EP2013714471A	 	2013-03-21
						
	TRIVASCULAR INC.	 	EP	 	INFLATABLE IMPLANT | AUFBLASBARES IMPLANTAT | IMPLANT GONFLABLE	 	EP1635738B1	 	EP2004776568A	 	2004-06-14
						
	TRIVASCULAR INC.	 	EP	 	 ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | ENDOVASKULÄRES

TRANSPLANTAT FÜR ANEURYSMEN MIT BETEILIGUNG VON GROSSEN VERZWEIGTEN GEFÄSSEN | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES
VAISSEAUX RAMIFIÉS PRINCIPAUX
	 	EP2906144B1	 	EP2013780282A	 	2013-10-10
						
	TRIVASCULAR INC.	 	EP	 	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT UND SYSTEM ZU SEINER VERABREICHUNG | GREFFE ENDOVASCULAIRE AVANCÉE ET SYSTÈME DE POSE ASSOCIÉ	 	EP2640319B1	 	EP2011841183A	 	2011-11-15

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	EP	 	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | EINFÜHRKATHETER FÜR EINE ENDOVASKULÄRE VORRICHTUNG | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE	 	EP2833845B1	 	EP2013771941A	 	2013-04-01
						
	TRIVASCULAR INC.	 	EP	 	Endovascular graft | Endovaskuläres Gewebe | Greffe endovasculaire	 	EP1464301B1	 	EP200475832A	 	1999-02-09
						
	TRIVASCULAR INC.	 	EP	 	PTFE LAYERS AND METHODS OF MANUFACTURING | PTFE-LAGEN UND HERSTELLUNGSVERFAHREN | COUCHES DE PTFE ET PROCEDES DE FABRICATION	 	EP1888318B1	 	EP2006740124A	 	2006-03-30
						
	TRIVASCULAR INC.	 	EP	 	ADVANCED ENDOVASCULAR GRAFT | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT | GREFFON ENDOVASCULAIRE EVOLUE	 	EP1467679B1	 	EP2002796047A	 	2002-12-20
						
	TRIVASCULAR INC.	 	EP	 	Non-degradable low swelling, water soluble radiopaque hydrogels | Nicht abbaubares, schwach anschwellendes, wasserlösliches röntgendichtes Hydrogelpolymer | Polymère absorbant
l’eau, radiopaque, soluble dans l’eau, à faible gonflement et non dégradable	 	EP2332590B1	 	EP2010194236A	 	2006-03-28

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	EP	 	Endovascular graft | Endovaskuläres Transplantat | Greffe endovasculaire	 	EP2147658B1	 	EP200913660A	 	1999-02-09
						
	TRIVASCULAR INC.	 	EP	 	Kink resistant endovascular graft | Knickbeständiges Stentimplantat | Stent à greffer resistant au pliage	 	EP2319456B1	 	EP2010183146A	 	2004-03-05
						
	TRIVASCULAR INC.	 	EP	 	Delivery system for graft | Abgabesystem für Graft | Système de mise en place pour prothèse	 	EP2145607B1	 	EP2009175398A	 	2004-10-15
						
	TRIVASCULAR INC.	 	EP	 	DELIVERY SYSTEM FOR BIFURCATED GRAFT | VORRICHTUNG ZUR PLATZIERUNG VON ZWEIGETEILTEN ENDOPROTHESEN | SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION	 	EP1377234B1	 	EP2002725639A	 	2002-04-11
						
	TRIVASCULAR INC.	 	EP	 	Advanced endovascular graft | Erweitertes endovaskuläres Transplantat | Greffe endovasculaire évoluée	 	EP2135583B1	 	EP20099090A	 	2002-12-20
						
	TRIVASCULAR INC.	 	EP	 	KINK RESISTANT ENDOVASCULAR GRAFT | KNICKFESTES ENDOVASKULÄRES IMPLANTAT | IMPLANT ENDOVASCULAIRE RÉSISTANT A LA DÉFORMATION	 	EP1601314B1	 	EP2004718097A	 	2004-03-05

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	EP	 	NON-DEGRADABLE LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGELS | NICHT-ABBAUBARE WENIG QUELLENDE WASSERLÖSLICHE RÖNTGENDICHTE HYDROGELS | HYDROGEL RADIOPAQUE, SOLUBLE DANS
L’EAU, NON DEGRADABLE ET A FAIBLE GONFLEMENT	 	EP1874370B1	 	EP2006739747A	 	2006-03-28
						
	TRIVASCULAR INC.	 	EP	 	INFLATABLE INTRALUMINAL GRAFT | AUFBLASBARER INTRALUMINALER PFROPFEN | GREFFON INTRALUMINAL GONFLABLE	 	EP1176926B1	 	EP2000907760A	 	2000-03-03
						
	TRIVASCULAR INC.	 	EP	 	ENDOVASCULAR GRAFT | ENDOVASKULÄRES IMPLANTAT | GREFFON ENDOVASCULAIRE	 	EP1054648B1	 	EP1999906812A	 	1999-02-09
						
	TRIVASCULAR INC.	 	EP	 	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | STENTGRAFTEINFÜHRUNGSSYSTEM MIT ZUGANGSKANAL | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES	 	EP3209249A1	 	EP2015852460A	 	2015-10-22
						
	TRIVASCULAR INC.	 	EP	 	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | VORRICHTUNGEN UND VERFAHREN ZUR INTERNEN BECKENKONSERVIERUNG | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE	 	EP3226814A1	 	EP2015816618A	 	2015-12-03

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	EP	 	INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | AUFBLASBARER OKKLUSIONSDRAHTBALLON FÜR ANWENDUNGEN IN DER AORTA | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES	 	EP3116439A1	 	EP2015711020A	 	2015-03-10
						
	TRIVASCULAR INC.	 	EP	 	SYSTEMS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTEME FÜR FÜHRUNGSDRAHTÜBERGANG FÜR VERZWEIGTE PROTHESEN | SYSTÈMES POUR UN CROISEMENT DE FIL-GUIDE
POUR DES PROTHÈSES BIFURQUÉES	 	EP3091944A1	 	EP2014752969A	 	2014-07-30
						
	TRIVASCULAR INC.	 	Germany	 	 SYSTEMS FOR GUIDEWIRE
 CROSSOVER FOR
BIFURCATED
 PROSTHESES
	 	3091944	 	14752969.7	 	7/18/2018
						
	TRIVASCULAR INC.	 	UK	 	 SYSTEMS FOR GUIDEWIRE
 CROSSOVER FOR
BIFURCATED
 PROSTHESES
	 	3091944	 	14752969.7	 	7/18/2018
						
	TRIVASCULAR INC.	 	IT	 	 SYSTEMS FOR GUIDEWIRE
 CROSSOVER FOR
BIFURCATED
 PROSTHESES
	 	3091944	 	14752969.7	 	7/18/2018

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	EP	 	TANDEM MODULAR ENDOGRAFT | MODULARES TANDEM-ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM	 	EP3049021A1	 	EP2014782021A	 	2014-09-23
						
	TRIVASCULAR INC.	 	EP	 	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | DAUERHAFTES STENTIMPLANTAT MIT KONISCHEN STREBEN UND STABILE FREISETZUNGSVERFAHREN SOWIE VORRICHTUNGEN | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC
ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES	 	EP2833830A4	 	EP2013772199A	 	2013-03-29
						
	TRIVASCULAR INC.	 	EP	 	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | ENDOVASKULÄRES FREISETZUNGSSYSTEM MIT VERBESSERTEM RÖNTGENMARKERSCHEMA | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR
RADIO-OPAQUE AMÉLIORÉE	 	EP2861189A1	 	EP2013733113A	 	2013-05-31
						
	TRIVASCULAR INC.	 	EP	 	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | GEGABELTE ENDOVASKULÄRE PROTHESE MIT ANGEBUNDENEM KONTRALATERALEM BEIN | PROTHÈSE ENDOVASCULAIRE	 	EP2861183A1	 	EP2013733115A	 	2013-05-31

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

		 		 	BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE	 		 		 	
						
	TRIVASCULAR INC.	 	EP	 	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | FLACHES STENTTRANSPLANTAT UND FREISETZUNGSSYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE	 	EP2833829A1	 	EP2013717893A	 	2013-03-21
						
	TRIVASCULAR INC	 	EP	 	ALIGNMENT STENT APPARATUS AND METHOD | VORRICHTUNG UND VERFAHREN ZUR STENTAUSRICHTUNG | APPAREIL D’ENDOPROTHÈSE D’ALIGNEMENT ET PROCÉDÉ	 	EP2194919A4	 	EP2008834027A	 	2008-09-25
						
	TRIVASCULAR INC	 	EP	 	MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY | MODULARER GEFÄSSERSATZ FÜR PERKUTANE FREISETZUNG MIT NIEDRIGEM PROFIL | GREFFON VASCULAIRE MODULAIRE POUR ADMINISTRATION PERCUTANÉE À PROFIL
RÉDUIT	 	EP2194921A4	 	EP2008835032A	 	2008-10-03
						
	TRIVASCULAR INC	 	EP	 	METHOD AND APPARATUS FOR MANUFACTURING AN ENDOVASCULAR GRAFT SECTION | VERFAHREN UND VORRICHTUNG ZUR HERSTELLUNG EINES ENDOVASKULÄREN TRANSPLANTATABSCHNITTS | PROCEDE ET APPAREIL DE	 	EP1465685A4	 	EP2002805657A	 	2002-12-20

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

		 		 	FABRICATION D’UNE SECTION DE GREFFON ENDOCORONAIRE	 		 		 	
						
	TRIVASCULAR INC	 	WO	 	ENDOLUMINAL PROSTHESIS DEPLOYMENT DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE	 	WO2017019913A1	 	WO2016US44583A	 	2016-07-28
						
	TRIVASCULAR INC	 	WO	 	STENT-GRAFT WITH IMPROVED FLEXIBILITY | GREFFON DE STENT À FLEXIBILITÉ AMÉLIORÉE	 	WO2016183128A1	 	WO2016US31728A	 	2016-05-11
						
	TRIVASCULAR INC	 	WO	 	BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT | DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE ASSISTÉ PAR BALLONNET	 	WO2016191602A1	 	WO2016US34427A	 	2016-05-26
						
	TRIVASCULAR INC	 	WO	 	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE	 	WO2016090112A1	 	WO2015US63686A	 	2015-12-03
						
	TRIVASCULAR INC	 	WO	 	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES	 	WO2016065208A1	 	WO2015US57016A	 	2015-10-22

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	WO	 	INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES	 	WO2015138402A1	 	WO2015US19626A	 	2015-03-10
						
	TRIVASCULAR INC	 	WO	 	SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTÈMES ET PROCÉDÉS POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES
BIFURQUÉES	 	WO2015105530A1	 	WO2014US48769A	 	2014-07-30
						
	TRIVASCULAR INC	 	WO	 	TANDEM MODULAR ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM	 	WO2015048004A1	 	WO2014US56953A	 	2014-09-23
						
	TRIVASCULAR INC	 	WO	 	ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX	 	WO2014059114A3	 	WO2013US64290A	 	2013-10-10
						
	TRIVASCULAR INC	 	WO	 	SAC LINER FOR ANEURYSM REPAIR | REVÊTEMENT SAC POUR RÉPARATION D’ANÉVRISME	 	WO2014110231A3	 	WO2014US10828A	 	2014-01-09
						
	TRIVASCULAR INC	 	WO	 	GATE WIRE FOR CONTRALATERAL LEG ACCESS | FIL GUIDE POUR PERMETTRE UN ACCÈS À UN JAMBAGE CONTROLATÉRAL	 	WO2014110254A1	 	WO2014US10870A	 	2014-01-09

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	WO	 	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | PROTHÈSE ENDOVASCULAIRE BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE	 	WO2013188134A1	 	WO2013US43630A	 	2013-05-31
						
	TRIVASCULAR INC	 	WO	 	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE	 	WO2013188132A1	 	WO2013US43615A	 	2013-05-31
						
	TRIVASCULAR INC	 	WO	 	ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE | SYSTÈME DE POSE ENDOVASCULAIRE POURVU D’UN HYPOTUBE FLEXIBLE ET POUVANT ÊTRE SOUMIS À UN COUPLE DE TORSION	 	WO2013188133A1	 	WO2013US43623A	 	2013-05-31
						
	TRIVASCULAR INC	 	WO	 	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE	 	WO2013151924A1	 	WO2013US34787A	 	2013-04-01
						
	TRIVASCULAR INC	 	WO	 	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES	 	WO2013151896A1	 	WO2013US34654A	 	2013-03-29

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	WO	 	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE	 	WO2013151793A1	 	WO2013US33250A	 	2013-03-21
						
	TRIVASCULAR INC	 	WO	 	ADVANCED KINK-RESISTANT STENT GRAFT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE	 	WO2013151794A3	 	WO2013US33252A	 	2013-03-21
						
	TRIVASCULAR INC	 	WO	 	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | GREFFE ENDOVASCULAIRE AVANCÉE ET SYSTÈME DE POSE ASSOCIÉ	 	WO2012068175A3	 	WO2011US60873A	 	2011-11-15
						
	TRIVASCULAR INC	 	WO	 	FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT | COLLECTEUR DE TUBE DE REMPLISSAGE ET PROCÉDÉS DE POSE DE GREFFON ENDOVASCULAIRE	 	WO2011100367A3	 	WO2011US24248A	 	2011-02-09
						
	TRIVASCULAR INC	 	DE	 	ENDOVASKULÄRES IMPLANTAT	 	DE69918272T2	 	DE69918272A	 	1999-02-09
						
	TRIVASCULAR INC	 	CA	 	VIRTUAL PROTOTYPING AND TESTING FOR MEDICAL DEVICE DEVELOPMENT | ESSAI ET PROTOTYPAGE VIRTUELS DE MISE AU POINT DE DISPOSITIFS MEDICAUX	 	CA2424252C	 	CA2424252A	 	2001-09-28

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	CA	 	DELIVERY SYSTEM AND METHOD FOR BIFURCATED GRAFT | METHODE ET SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION	 	CA2443104C	 	CA2443104A	 	2002-04-11
						
	TRIVASCULAR INC	 	CA	 	ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE	 	CA2501892C	 	CA2501892A	 	1999-02-09
						
	TRIVASCULAR INC	 	CA	 	INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE	 	CA2640263C	 	CA2640263A	 	2000-03-03
						
	TRIVASCULAR INC	 	CA	 	INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE	 	CA2376253C	 	CA2376253A	 	2000-03-03
						
	TRIVASCULAR INC	 	CA	 	ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE	 	CA2319052C	 	CA2319052A	 	1999-02-09
						
	TRIVASCULAR INC	 	AU	 	Modular vascular graft for low profile percutaneous delivery	 	AU2008308474B2	 	AU2008308474A	 	2008-10-03
						
	TRIVASCULAR INC	 	AU	 	Advanced endovascular graft	 	AU2009230748B2	 	AU2009230748A	 	2009-10-26
						
	TRIVASCULAR INC	 	AU	 	Advanced endovascular graft	 	AU2009201682B2	 	AU2009201682A	 	2009-04-28
						
	TRIVASCULAR INC	 	AU	 	Method and apparatus for manufacturing an endovascular graft section	 	AU2008258148B2	 	AU2008258148A	 	2008-12-17
						
	TRIVASCULAR INC	 	AU	 	Advanced endovascular graft	 	AU2002360765C1	 	AU2002360765A	 	2002-12-20

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC	 	AU	 	Method and apparatus for manufacturing an endovascular graft section	 	AU2002366805B8	 	AU2002366805A	 	2002-12-20
						
	TRIVASCULAR INC	 	AU	 	Virtual prototyping and testing for medical device development	 	AU2001293179A1	 	AU2001293179A	 	2001-09-28
						
	TRIVASCULAR INC	 	AU	 	 Delivery system and method for
 expandable
intracorporeal device
	 	AU200133250A	 	AU200133250A	 	2001-02-01
						
	TRIVASCULAR INC	 	JP	 	ADVANCED KINK-RESISTANT STENT GRAFT	 	6297023	 	2015-504610	 	3/2/2018
						
	TRIVASCULAR INC	 	UK	 	 INFLATABLE OCCLUSION WIRE-
 BALLOON FOR
AORTIC
 APPLICATIONS
	 	15711020.6	 	3116439	 	2/7/2018
						
	TRIVASCULAR INC	 	UK	 	 PASSIVE HEMOSTATIC SHEATH
 VALVE
	 	04780128.7	 	1651135	 	2/28/2018
						
	TRIVASCULAR INC	 	CN	 	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	 		 	201810370663.0	 	2015-5-5
						
	ENDOLOGIX, INC.	 	CN	 	CATHETER SYSTEM AND METHODS OF USING SAME	 	ZL201510649289.4	 	201510649289.4	 	2018-6-8
						
	ENDOLOGIX, INC.	 	JP	 	CATHETER SYSTEM AND METHODS OF USING SAME	 	6294669	 	2013-556828	 	2018-2-23
						
	TRIVASCULAR INC	 	Germany	 	 PASSIVE HEMOSTATIC SHEATH
 VALVE
	 	1651135	 	04780128.7	 	2018-2-28
						
	ENDOLOGIX, INC.	 	JP	 	BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT	 		 	2017-560952	 	5/26/2016
						
	ENDOLOGIX, Inc.	 	EP	 	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	 		 	16882476.1	 	12/23/2016

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	ENDOLOGIX, Inc.	 	JP	 	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	 		 	2018-534852	 	12/23/2016
						
	ENDOLOGIX INC.	 	US	 	 STENT GRAFT SYSTEMS WITH
 RESTRAINTS IN
CIRCUMFERENTIAL
 CHANNELS AND METHODS
 THEREOF
	 		 	62/678961	 	5/31/2018
						
	ENDOLOGIX INC.	 	US	 	 PERCUTANEOUS METHOD AND
 DEVICE TO TREAT
DISSECTIONS
	 		 	15/429090	 	2/9/2017
						
	NELLIX, INC.	 	US	 	 SYSTEM AND METHODS FOR
 ENDOVASCULAR
ANEURYSM
 TREATMENT
	 	2018-0064566	 	15/682414	 	8/21/2017
						
	TRIVASCULAR INC.	 	US	 	 ENDOVASCULAR DELIVERY
 SYSTEM WITH AN
IMPROVED
 RADIOPAQUE MARKER SCHEME
	 		 	16/049560	 	7/30/2018
						
	ENDOLOGIX INC.	 	PCT	 	SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM	 	WO2000053251	 	PCT/US2000/006070	 	3/7/2000
						
	ENDOLOGIX INC.	 	PCT	 	GRAFT DEPLOYMENT SYSTEM	 	WO2004047885	 	PCT/US2003/37685	 	11/25/2003
						
	ENDOLOGIX INC.	 	PCT	 	 DUAL CONCENTRIC GUIDEWIRE
 AND METHODS OF
BIFURCATED GRAFT DEPLOYMENT
	 	WO2008089097	 	PCT/US2008/050915	 	1/11/2008
						
	ENDOLOGIX INC.	 	PCT	 	 ENDOLUMENAL VASCULAR
 PROSTHESIS WITH
NEOINTIMA
 INHIBITING POLYMERIC SLEEVE
	 	WO2005096997	 	PCT/US2005/11522	 	4/6/2005
						
	ENDOLOGIX INC.	 	PCT	 	IMPLANTABLE VASCULAR GRAFT	 	WO2002039888	 	PCT/US2001/47028	 	11/8/2001
						
	ENDOLOGIX INC.	 	PCT	 	DUAL WIRE PLACEMENT CATHETER	 	WO2001003762	 	PCT/US2000/016352	 	6/14/2000
						
	ENDOLOGIX INC.	 	PCT	 	 MULTI-SEGMENTED GRAFT
 DEPLOYMENT
SYSTEM
	 	WO2008034106	 	PCT/US2007/78565	 	9/14/2007
						
	ENDOLOGIX INC.	 	PCT	 	METHOD AND APPARATUS FOR DECOMPRESSING ANEURYSMS	 	WO2005099807	 	PCT/US2005/12306	 	4/12/2005

											
	 Grantor
	 	 Country
	 	 Patent
	 	 Publication/

Patent No.
	 	 Application

Number
	 	 Application

Date

	TRIVASCULAR INC.	 	EP	 	 ENDOLUMINAL PROSTHESIS
 DEPLOYMENT DEVICES
AND
 METHODS
	 	3328326	 	16831382.3	 	7/28/2016
						
	TRIVASCULAR INC.	 	EP	 	BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT	 	3302356	 	16800744.1	 	5/26/2016
						
	TRIVASCULAR INC.	 	EP	 	 STENT-GRAFT WITH IMPROVED
 FLEXIBILITY
	 	3294210	 	16793394.4	 	5/11/2016
						
	TRIVASCULAR INC.	 	EP	 	PTFE LAYERS AND METHODS OF MANUFACTURING	 	3095585	 	16171681.6	 	3/30/2006

 SCHEDULE 11 

TRADEMARKS 
 See attached. 

 Trademarks 

 

													
	 Grantor
	  	 Country
	  	 Mark
	  	 Application No.
	  	 Application Date
	  	 Registration No.
	  	 Registration Date

	Endologix, Inc.	  	U.S.	  	

	  	86/854470	  	12/18/15	  		  	
							
	Endologix, Inc.	  	U.S.	  	ACTIVESEAL	  	85/518,608	  	01/17/12	  	5396605	  	02/06/18
							
	Endologix, Inc.	  	U.S.	  	AFX	  	85/069,068	  	06/22/10	  	4214460	  	09/25/12
							
	Endologix, Inc.	  	U.S.	  	ANGIOTIP	  	85/767055	  	10/30/12	  	5205176	  	05/16/17
							
	Endologix, Inc.	  	U.S.	  	DURAPLY	  	86/362822	  	08/11/14	  	5433696	  	3/27/18
							
	Endologix, Inc.	  	U.S.	  	ENDOLOGIX	  	75/323,314	  	07/11/97	  	2257799	  	06/29/99
							
	Endologix, Inc.	  	U.S.	  	EVAS FORWARD	  	86/116940	  	11/12/13	  	5306786	  	10/10/17
							
	Endologix, Inc.	  	U.S.	  	 INNOVATION

TAKING SHAPE
	  	85/369,728	  	07/12/11	  	4220343	  	10/09/12
							
	Endologix, Inc.	  	U.S.	  	 INNOVATION

THAT EMPOWERS
	  	85/514516	  	01/11/12	  	4841631	  	10/27/15
							
	Endologix, Inc.	  	U.S.	  	INTELIX	  	86/316249	  	06/20/14	  	5059968	  	10/11/16
							
	Endologix, Inc.	  	U.S.	  	INTUITRAK	  	77/494,729	  	06/09/08	  	3649757	  	07/07/09
							
	Endologix, Inc.	  	U.S.	  	 INTUITRAK

DELIVERY
 SYSTEM
	  	77/520,529	  	07/11/08	  	3649866	  	07/07/09
							
	Endologix, Inc.	  	U.S.	  	NELLIX	  	77/090544	  	01/24/07	  	3880178	  	11/23/10

													
							
	Endologix, Inc.	  	U.S.	  	POWERLINK	  	75/658,969	  	03/12/99	  	2456038	  	05/29/01
							
	Endologix, Inc.	  	U.S.	  	POWERLINK XL	  	78/718,728	  	09/22/05	  	3573999	  	02/10/09
							
	Endologix, Inc.	  	U.S.	  	SUREPASS	  	78/965,443	  	08/31/06	  	3593259	  	03/17/09
							
	Endologix, Inc.	  	U.S.	  	VELA	  	85/857988	  	02/22/13	  	5296578	  	09/26/17
							
	Endologix, Inc.	  	U.S.	  	XPAND	  	85/126,464	  	09/09/10	  	4168563	  	07/03/12
							
	Endologix, Inc.	  	Argentina	  	

	  	3514846	  	06/16/16	  	2888199	  	05/19/17
							
	Endologix, Inc.	  	Argentina	  	

	  	3514844	  	06/16/16	  	2888198	  	05/19/17
							
	Endologix, Inc.	  	Argentina	  	

	  	3514844	  	06/16/16	  		  	
							
	Endologix, Inc.	  	Argentina	  	

	  	3514842	  	06/16/16	  	2888196	  	05/19/17
							
	Endologix, Inc.	  	Argentina	  	AFX	  	3064304	  	01/27/11	  	2496722	  	04/04/12
							
	Endologix, Inc.	  	Argentina	  	DURAPLY	  	3386456	  	02/11/15	  	2773735	  	12/09/15
							
	Endologix, Inc.	  	Argentina	  	INTELIX	  	3375648	  	12/19/14	  	2766285	  	12/04/15
							
	Endologix, Inc.	  	Argentina	  	INTELIX	  	3375649	  	12/19/14	  	2766286	  	11/04/15

													
							
	Endologix, Inc.	  	Argentina	  	INTELIX	  	3375650	  	12/19/14	  	2766287	  	11/04/15
							
	Endologix, Inc.	  	Argentina	  	NELLIX	  	3243024	  	05/02/13	  	2658594	  	06/26/14
							
	Endologix, Inc.	  	Argentina	  	VELA	  	3271551	  	08/22/13	  	2808433	  	06/03/16
							
	Endologix, Inc.	  	Argentina	  	XPAND	  	3072929	  	03/16/11	  	2506706	  	06/01/12
							
	Endologix, Inc.	  	Australia	  	

	  	1326557	  	06/14/16	  	1326557	  	04/24/17
							
	Endologix, Inc.	  	Australia	  	DURAPLY	  	1710503	  	02/10/15	  	1710503	  	11/04/15
							
	Endologix, Inc.	  	Australia	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	11/25/16
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.521	  	06/17/16	  		  	
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.572	  	06/17/16	  		  	
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.599	  	06/17/16	  		  	
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.602	  	06/17/16	  		  	
							
	Endologix, Inc.	  	Brazil	  	ACTIVESEAL	  	909861684	  	08/20/15	  		  	

													
							
	Endologix, Inc.	  	Brazil	  	AFX	  	830891226	  	12/21/10	  		  	
							
	Endologix, Inc.	  	Brazil	  	AFX	  	912186283	  	01/19/17	  		  	
							
	Endologix, Inc.	  	Brazil	  	DURAPLY	  	909861722	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	INTELIX	  	909861749	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	INTELIX	  	909861765	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	INTELIX	  	909861773	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	NELLIX	  	840506538	  	05/06/13	  	840506538	  	02/16/16
							
	Endologix, Inc.	  	Brazil	  	VELA	  	840618530	  	08/22/13	  		  	
							
	Endologix, Inc.	  	Canada	  	DURAPLY	  	1714718	  	02/10/15	  		  	
							
	Endologix, Inc.	  	Canada	  	INTELIX	  	1707569	  	12/17/14	  		  	
							
	Endologix, Inc.	  	Canada	  	VELA	  	1640416	  	08/21/13	  		  	
							
	Endologix, Inc.	  	Chile	  	XPAND	  	1137099	  	12/30/14	  	1187135	  	11/27/15
							
	Endologix, Inc.	  	China	  	

	  	1326551	  	06/14/16	  		  	
							
	Endologix, Inc.	  	China	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	02/10/15
							
	Endologix, Inc.	  	China	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	12/19/14
							
	Endologix, Inc.	  	Colombia	  	AFX	  	16-133051	  	05/11/26	  	582446	  	11/17/17
							
	Endologix, Inc.	  	Colombia	  	ENDOLOGIX	  	16-121402	  	05/11/16	  	582446	  	11/17/17
							
	Endologix, Inc.	  	Colombia	  	XPAND	  	1246435	  	12/26/14	  	1246435	  	12/26/14

													
							
	Endologix, Inc.	  	 European

Community
	  	AFX	  	009609884	  	12/20/10	  	009609884	  	12/01/11
							
	Endologix, Inc.	  	 European

Community
	  	ANGIOTIP	  	011780129	  	04/30/13	  	011780129	  	09/24/13
							
	Endologix, Inc.	  	 European

Community
	  	 CLASSICAL

REMODELING
	  	4598728	  	08/19/05	  	4598728	  	08/02/06
							
	Endologix, Inc.	  	 European

Community
	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	02/10/15
							
	Endologix, Inc.	  	 European

Community
	  	ENDOLOGIX, INC.	  	720649	  	01/12/98	  	720649	  	01/12/98
							
	Endologix, Inc.	  	 European

Community
	  	INTELIX	  	13361399	  	10/15/14	  		  	
							
	Endologix, Inc.	  	 European

Community
	  	INTUITRAK	  	7453401	  	11/28/08	  	7453401	  	09/21/09
							
	Endologix, Inc.	  	 European

Community
	  	 INTUITRAK

DELIVERY
 SYSTEM
	  	7513302	  	12/23/08	  	7513302	  	07/21/09
							
	Endologix, Inc.	  	 European

Community
	  	NELLIX	  	011771011	  	04/26/13	  	011771011	  	09/18/13
							
	Endologix, Inc.	  	 European

Community
	  	POWERLINK XL	  	5002977	  	03/22/06	  	5002977	  	04/11/07
							
	Endologix, Inc.	  	 European

Community
	  	 VISIFLEX

DELIVERY
 SYSTEM
	  	5075528	  	04/24/06	  	5075528	  	04/16/07
							
	Endologix, Inc.	  	 European

Community
	  	 VISIFLEX SURE

PASS
	  	5749338	  	02/28/07	  	5749338	  	01/31/08

													
							
	Endologix, Inc.	  	European Union	  	

	  	1326551	  	06/14/16	  	1326551	  	06/12/17
							
	Endologix, Inc.	  	France	  	POWERLINK	  	043299490	  	09/13/99	  	043299490	  	12/31/04
							
	Endologix, Inc.	  	Hong Kong	  	DURAPLY	  	303301280	  	02/15/15	  	303301280	  	10/05/15
							
	Endologix, Inc.	  	Hong Kong	  	INTELIX	  	303240954	  	12/18/14	  	303240954	  	09/07/16
							
	Endologix, Inc.	  	Italy	  	POWERLINK	  	001724	  	09/13/99	  	0001376420	  	02/27/08
							
	Endologix, Inc.	  	Japan	  	

	  	1326551	  	06/14/16	  	1326551	  	05/02/17
							
	Endologix, Inc.	  	Japan	  	ACTIVESEAL	  	2015-078597	  	08/17/15	  	5857166	  	06/10/16
							
	Endologix, Inc.	  	Japan	  	AFX	  	2015-078596	  	08/17/15	  	5824704	  	02/05/16
							
	Endologix, Inc.	  	Japan	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	01/19/16
							
	Endologix, Inc.	  	Japan	  	ENDOLOGIX, INC.	  	1155/1998	  	01/12/98	  	4352035	  	01/14/00
							
	Endologix, Inc.	  	Japan	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	10/27/15
							
	Endologix, Inc.	  	Japan	  	NELLIX	  	2013-031634	  	04/25/13	  	5613989	  	09/06/13
							
	Endologix, Inc.	  	Japan	  	VELA	  	2013-6/4901	  	08/21/13	  		  	
							
	Endologix, Inc.	  	Japan	  	 VISIFLEX

DELIVERY
 SYSTEM
	  	2006-035170	  	04/17/06	  	4974084	  	07/28/06
							
	Endologix, Inc.	  	Japan	  	 VISIFLEX

SUREPASS
	  	2007-017236	  	02/28/07	  	5066349	  	07/27/07

													
							
	Endologix, Inc.	  	Korea	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	02/10/15
							
	Endologix, Inc.	  	Korea	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	06/13/16
							
	Endologix, Inc.	  	Malaysia	  	DURAPLY	  	2015052019	  	02/11/15	  	2015052019	  	12/29/16
							
	Endologix, Inc.	  	Malaysia	  	INTELIX	  	2014069128	  	12/18/14	  	2014069128	  	04/22/16
							
	Endologix, Inc.	  	Malaysia	  	INTELIX	  	2014069135	  	12/18/14	  	2014069135	  	05/10/16
							
	Endologix, Inc.	  	Mexico	  	XPAND	  	1246435	  	12/26/14	  	1246435	  	07/26/16
							
	Endologix, Inc.	  	New Zealand	  	DURAPLY	  	1024501	  	02/10/15	  	1024501	  	12/02/15
							
	Endologix, Inc.	  	New Zealand	  	INTELIX	  	1247823	  	12/19/14	  	1019974	  	09/27/16
							
	Endologix, Inc.	  	Peru	  	XPAND	  	601318	  	12/29/14	  	00223114	  	04/22/15
							
	Endologix, Inc.	  	Singapore	  	DURAPLY	  	40201513229	  	02/10/15	  	40201513229	  	01/06/16
							
	Endologix, Inc.	  	Singapore	  	INTELIX	  	40201508694	  	12/19/14	  	40201508694	  	11/11/15
							
	Endologix, Inc.	  	Taiwan	  	DURAPLY	  	104008448	  	02/11/15	  	1764288	  	04/16/16
							
	Endologix, Inc.	  	Taiwan	  	INTELIX	  	103072703	  	12/18/14	  	1740066	  	11/16/15
							
	Endologix, Inc.	  	Thailand	  	DURAPLY	  	973443	  	02/11/15	  	171110590	  	09/28/17
							
	Endologix, Inc.	  	Thailand	  	INTELIX	  	966979	  	12/19/14	  		  	
							
	Endologix, Inc.	  	Thailand	  	INTELIX	  	966980	  	12/19/14	  		  	
							
	Endologix, Inc.	  	United Kingdom	  	POWERLINK	  	2369587	  	09/13/99	  	2369587	  	12/09/05
							
	Endologix, Inc.	  	Venezuela	  	XPAND	  	20754-14	  	12/30/14	  	P352404	  	06/07/16
							
	Endologix, Inc.	  	Vietnam	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	11/03/16

													
							
	Endologix, Inc.	  	Vietnam	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	05/21/15
							
	Endologix, Inc.	  	U.S.	  	ALTO	  	87/906,099	  	5/3/2018	  		  	
							
	Endologix, Inc.	  	U.S.	  	VERTA	  	87/116,482	  	7/26/2016	  		  	
							
	TriVascular, Inc.	  	U.S.	  	ALLEGRO	  	86/758,465	  	9/16/2015	  		  	
							
	TriVascular, Inc.	  	U.S.	  	CUSTOMSEAL	  	86/047,875	  	8/26/2013	  	4,732,342	  	5/5/2015
							
	TriVascular, Inc.	  	U.S.	  	OVATION	  	77/941,535	  	2/22/2010	  	4,440,468	  	11/26/2013
							
	TriVascular, Inc.	  	U.S.	  	OVATION ALTO	  	86/047,894	  	8/26/2013	  	5,195,890	  	5/2/2017
							
	TriVascular, Inc.	  	U.S.	  	OVATION PRIME	  	85/900,037	  	4/10/2013	  	4,452,625	  	12/17/2013
							
	TriVascular, Inc.	  	U.S.	  	

	  	85/832,445	  	1/25/2013	  	4,449,077	  	12/10/2013
							
	TriVascular, Inc.	  	U.S.	  	TRIVASCULAR	  	75/879,907	  	12/21/1999	  	2,867,015	  	7/27/2004
							
	TriVascular, Inc.	  	U.S.	  	

	  	85/831,355	  	1/24/2013	  	4,395,789	  	9/3/2013
							
	TriVascular, Inc.	  	Australia	  	CUSTOMSEAL	  	1608471	  	2/27/2014	  	1608471	  	1/21/2015
							
	TriVascular, Inc.	  	Australia	  	OVATION	  	1379343	  	8/20/2010	  	1379343	  	1/10/2011
							
	TriVascular, Inc.	  	Australia	  	OVATION ALTO	  	1608211	  	2/26/2014	  	1608211	  	5/28/2014
							
	TriVascular, Inc.	  	Australia	  	OVATION PRIME	  	1583683	  	10/2/2013	  	1583683	  	1/7/2014
							
	TriVascular, Inc.	  	Australia	  	

	  	1537921	  	1/29/2013	  	1537921	  	7/31/2013
							
	TriVascular, Inc.	  	Australia	  	TRIVASCULAR	  	888603	  	9/7/2001	  	888603	  	9/7/2001
							
	TriVascular, Inc.	  	Australia	  	

	  	983475	  	12/30/2003	  	983475	  	8/16/2004

													
							
	TriVascular, Inc.	  	Brazil	  	CUSTOMSEAL	  	840.803.346	  	2/26/2014	  	840803346	  	10/18/2016
							
	TriVascular, Inc.	  	Brazil	  	OVATION	  	830727035	  	8/20/2010	  	830727035	  	1/6/2015
							
	TriVascular, Inc.	  	Brazil	  	OVATION ALTO	  	840.803.419	  	2/26/2014	  		  	
							
	TriVascular, Inc.	  	Brazil	  	OVATION PRIME	  	840.666.152	  	10/4/2013	  	840666152	  	8/23/2016
							
	TriVascular, Inc.	  	Brazil	  	

	  	830854487	  	11/24/2010	  	830854487	  	6/3/2014
							
	TriVascular, Inc.	  	Canada	  	CUSTOMSEAL	  	1,665,277	  	2/25/2014	  		  	
							
	TriVascular, Inc.	  	Canada	  	OVATION	  	1493184	  	8/20/2010	  	TMA858,759	  	8/28/2013
							
	TriVascular, Inc.	  	Canada	  	OVATION ALTO	  	1,665,276	  	2/25/2014	  		  	
							
	TriVascular, Inc.	  	Canada	  	OVATION PRIME	  	1,645,991	  	10/2/2013	  		  	
							
	TriVascular, Inc.	  	Canada	  	

	  	1,611,335	  	1/25/2013	  	TMA934,553	  	4/12/2016
							
	TriVascular, Inc.	  	Canada	  	TRIVASCULAR	  	1,612,136	  	1/31/2013	  	TMA882,992	  	7/29/2014
							
	TriVascular, Inc.	  	Canada	  	

	  	1200748	  	12/30/2003	  	TMA825955	  	6/8/2012
							
	TriVascular, Inc.	  	China	  	CUSTOMSEAL	  	14075157	  	2/26/2014	  	14075157	  	4/28/2015
							
	TriVascular, Inc.	  	China	  	OVATION	  	8598413	  	8/23/2010	  	8598413	  	11/7/2011
							
	TriVascular, Inc.	  	China	  	OVATION ALTO	  	14075158	  	2/26/2014	  	14075158	  	4/28/2015
							
	TriVascular, Inc.	  	China	  	OVATION PRIME	  	13321289	  	10/8/2013	  	13321289	  	6/21/2015
							
	 TriVascular, Inc.
	  	China	  	

	  	8898103	  	11/30/2010	  	8898103	  	12/14/2011

													
							
	TriVascular, Inc.	  	EUTM	  	OVATION	  	009325234	  	8/20/2010	  	009325234	  	2/3/2011
							
	TriVascular, Inc.	  	EUTM	  	OVATION ALTO	  	012636908	  	2/25/2014	  	012636908	  	7/16/2014
							
	TriVascular, Inc.	  	EUTM	  	OVATION PRIME	  	012189148	  	10/2/2013	  	012189148	  	2/26/2014
							
	TriVascular, Inc.	  	EUTM	  	

	  	011523305	  	1/28/2013	  	011523305	  	6/24/2013
							
	TriVascular, Inc.	  	EUTM	  	TRIVASCULAR	  	002374593	  	9/13/2001	  	002374593	  	3/12/2003
							
	TriVascular, Inc.	  	EUTM	  	

	  	003598836	  	12/31/2003	  	003598836	  	4/29/2005
							
	TriVascular, Inc.	  	EUTM	  	 TRIVASCULAR2 &

Design
	  	007457344	  	11/27/2008	  	007457344	  	6/16/2009
							
	TriVascular, Inc.	  	India	  	OVATION	  	2012141	  	8/20/2010	  	2012141	  	8/23/2016
							
	TriVascular, Inc.	  	India	  	

	  	2060383	  	11/29/2010	  	2060383	  	11/29/2010
							
	TriVascular, Inc.	  	Japan	  	CUSTOMSEAL	  	2014-14237	  	2/26/2014	  	5672406	  	5/23/2014
							
	TriVascular, Inc.	  	Japan	  	OVATION	  	2010-065871	  	8/20/2010	  	5614976	  	9/13/2013
							
	TriVascular, Inc.	  	Japan	  	OVATION ALTO	  	2014-14238	  	2/26/2014	  	5672407	  	5/23/2014
							
	TriVascular, Inc.	  	Japan	  	OVATION PRIME	  	2013-024875	  	4/4/2013	  	5613251	  	9/6/2013
							
	TriVascular, Inc.	  	Japan	  	

	  	2013-5504	  	1/30/2013	  	5643434	  	1/17/2014
							
	TriVascular, Inc.	  	Japan	  	TRIVASCULAR	  	2001-115594	  	12/27/2001	  	4731627	  	12/5/2003
							
	TriVascular, Inc.	  	Japan	  	

	  	2004-030615	  	3/18/2004	  	4778040	  	6/11/2004
							
	TriVascular, Inc.	  	Mexico	  	OVATION	  	1113689	  	8/20/2010	  	1235645	  	8/20/2010
							
	TriVascular, Inc.	  	Mexico	  	

	  	1139285	  	12/2/2010	  	1213946	  	4/27/2011EX-10.6

 Exhibit 10.6 

INTERCOMPANY SUBORDINATION AGREEMENT 

THIS INTERCOMPANY SUBORDINATION AGREEMENT (this “Subordination Agreement”), dated as of August 9,
2018 is made among the companies from time to time party hereto (the “Companies”), and Deerfield Private Design Fund IV, L.P., a Delaware limited partnership (“Deerfield PDF”), as agent (in such
capacity, together with its successors and assigns in such capacity, the “Agent”) for the Secured Parties (as defined in the below-defined Facility Agreement). 

WHEREAS, Endologix, Inc., a Delaware corporation (the “Borrower”), the other Companies from time to time party
thereto, the lenders from time to time party thereto (the “Lenders”) and Agent are parties to that certain Amended and Restated Facility Agreement, dated as of even date herewith (as amended, restated, supplemented or
otherwise modified from time to time, the “Facility Agreement”), pursuant to which the Lenders have made loans and other financial accommodations to the Borrower and the other Companies and have agreed to make certain
amendments and restatements to the Prior Facility Agreement (as defined in the Facility Agreement); 
 WHEREAS, the Companies have entered
into that certain Amended and Restated Guaranty and Security Agreement, dated as of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “Amended and Restated Guaranty and Security
Agreement”), in favor of Agent, pursuant to which such Companies (together with any other Person (as defined in the below-defined Facility Agreement) who is a “Guarantor,” as defined in the Facility Agreement, the
“Guarantors;” and together with the Borrower, the “Obligors”) have guaranteed the obligations (including any Non-Callable Make Whole Amount, any CoC Fee, the
Exit Payment and all other Obligations) of the Borrower and the other Companies under the Facility Agreement and the other Loan Documents; 

WHEREAS, each Company has made or may make certain loans or advances from time to time to one or more Obligors; and 

WHEREAS, in order to induce the Agent and the Lenders to (a) continue to allow the Loans and other financial accommodations under the
Loan Documents to remain outstanding, (b) provide for the amendment and restatement of the Prior Facility Agreement and (c) permit the ABL Credit Facility pursuant to the terms of the Facility Agreement and the other Loan Documents, each
Company has agreed to the subordination of such indebtedness of each Obligor to such Company, upon the terms and subject to the conditions set forth in this Subordination Agreement. 

NOW, THEREFORE, in consideration of the mutual promises, covenants, conditions, representations, and warranties set forth herein and for other
good and valuable consideration, the parties hereto agree as follows: 

 SECTION 1. Definitions; Interpretation. 

(a) Terms Defined in Facility Agreement. All capitalized terms used in this Subordination Agreement and not otherwise defined herein
shall have the meanings assigned to them in the Facility Agreement. 
 (b) Certain Defined Terms. As used in this Subordination
Agreement, the following terms shall have the following meanings: 
 “Discharge of Senior Indebtedness” means the
Final Payment. 
 “Insolvency Events” has the meaning set forth in Section 3. 

“Intercompany Subordinated Debt” means, with respect to each Company, all indebtedness, liabilities, and other
obligations of each Obligor owing to such Company, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined, including all fees and all other amounts
payable by any Obligor to such Company under or in connection with any documents or instruments related thereto. 
 “Intercompany
Subordinated Debt Payment” means any payment or distribution by or on behalf of the Obligors, directly or indirectly, of assets of the Obligors of any kind or character, whether in cash, property, or securities for or on account of the
Intercompany Subordinated Debt, including on account of the purchase, redemption, or other acquisition of Intercompany Subordinated Debt, as a result of a collection, sale, or other disposition of collateral, or by setoff, exchange, or in any other
manner. 
 “Senior Indebtedness” means the Obligations (as defined in the Facility Agreement) and other indebtedness
and liabilities of the Obligors to the Secured Parties under or in connection with the Facility Agreement, the Amended and Restated Guaranty and Security Agreement and/or the other Loan Documents, including any
Non-Callable Make Whole Amount, any CoC Fee, the Exit Payment, all unpaid principal of the outstanding Loans, all interest accrued thereon (including all interest that, but for the provisions of the Bankruptcy
Code, would have accrued), all fees due under the Facility Agreement and the other Loan Documents (including all fees that, but for the provisions of the Bankruptcy Code, would have accrued), and all other amounts payable by the Obligors to the
Agent and the other Secured Parties thereunder or in connection therewith, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined. 

(c) Interpretation. Unless the context of this Subordination Agreement clearly requires otherwise, references to the plural include the
singular, references to the singular include the plural, the term “including” is not limiting, and the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.” The words
“hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this Subordination Agreement refer to this Subordination Agreement as a whole and not to any particular provision of this Subordination
Agreement. Section, subsection, clause, schedule, and exhibit references are to this Subordination Agreement unless otherwise specified. References to agreements and other 

  
 -2- 

 
contractual instruments shall be deemed to include all subsequent amendments and other modifications thereto. References to statutes or regulations are to be construed as including all statutory
and regulatory provisions consolidating, amending, or replacing the statute or regulation referred to. The captions and headings are for convenience of reference only and shall not affect the construction of this Subordination Agreement. 

SECTION 2. Subordination to Payment of Senior Indebtedness. As to each Company, all payments on account of the Intercompany
Subordinated Debt shall be subject, subordinate, and junior, in right of payment and exercise of remedies, to the extent and in the manner set forth herein, to the prior Discharge of Senior Indebtedness. 

SECTION 3. Subordination Upon Any Distribution of Assets of the Obligors. As to each Company, in the event of any payment
or distribution of assets of any Obligor (the “Affected Obligor”) of any kind or character, whether in cash, property, or securities, upon the dissolution, winding up, or total or partial liquidation or reorganization,
readjustment, arrangement, or similar proceeding relating to such Obligor or its property, whether voluntary or involuntary, or in bankruptcy, insolvency, receivership, arrangement, or similar proceedings or upon an assignment for the benefit of
creditors, or upon any other marshaling or composition of the assets and liabilities of such Obligor, or otherwise (such events, other than any such events permitted by the Loan Documents, collectively, the “Insolvency
Events”): (i) the Discharge of Senior Indebtedness must have occurred before any Intercompany Subordinated Debt Payment is made by or on behalf of the Affected Obligor; and (ii) to the extent permitted by Applicable Law, any
Intercompany Subordinated Debt Payment to which such Company would be entitled except for the provisions hereof, shall be paid or delivered by the trustee in bankruptcy, receiver, assignee for the benefit of creditors, or other liquidating agent
making such payment or distribution directly to Agent, for the benefit of itself and the other Secured Parties, for application to the payment of the Senior Indebtedness in accordance with clause (i) and Section 2.3(d) of the Facility
Agreement, after giving effect to any concurrent payment or distribution or provision therefor to Agent or any other Secured Party in respect of such Senior Indebtedness. 

SECTION 4. Payments on Intercompany Subordinated Debt. 

(a) Permitted Payments. So long as no Event of Default would result therefrom or has occurred and is continuing, each Obligor may make,
and each Company shall be entitled to accept and receive, payments on account of the Intercompany Subordinated Debt in the ordinary course of business and any other payment permitted by the Loan Documents, in each case, in accordance with the terms
of the Loan Documents. 
 (b) No Payment Upon Senior Indebtedness Defaults. Upon the occurrence of any Event of Default, and until
such Event of Default is cured or waived in accordance with the terms of the Facility Agreement, each Obligor shall not make, and each Company shall not accept or receive, any Intercompany Subordinated Debt Payment; provided, however,
notwithstanding the foregoing, (i) any Obligor may pay to the Borrower, and the Borrower may accept and receive payments on account of any Intercompany Subordinated Debt owed to the Borrower so long as such payments are immediately remitted to
a deposit account or securities account that is subject to a Control Agreement and (ii) any Obligor that is not the Borrower may 

  
 -3- 

 
pay to a Guarantor, and a Guarantor may accept and receive payments on account of any Intercompany Subordinated Debt owed to such Guarantor so long as such payments are immediately remitted to a
deposit account or securities account that is subject to a Control Agreement; provided, further, that each Obligor shall be permitted to make any such payments missed due to the application of this sentence upon the written waiver of
any such Event of Default in accordance with the terms of the Facility Agreement. 
 SECTION 5. Subordination of Remedies. Until the
Discharge of Senior Indebtedness, following the occurrence of any Event of Default and until such Event of Default is cured or waived in accordance with the terms of the Facility Agreement, each Company shall not, without the prior written consent
of Agent: 
 (a) accelerate, make demand, or otherwise make due and payable prior to the original due date thereof any Intercompany
Subordinated Debt or bring suit or institute any other actions or proceedings to enforce its rights or interests in respect of the obligations of any Obligor owing to such Company; 

(b) exercise any rights under or with respect to guaranties of the Intercompany Subordinated Debt, if any; 

(c) exercise any rights to set-offs and counterclaims in respect of any indebtedness, liabilities, or
obligations of such Company to any Obligor against any of the Intercompany Subordinated Debt; or 
 (d) commence, or cause to be commenced,
or join with any creditor other than Agent and the other Secured Parties in commencing, any bankruptcy, insolvency, or receivership proceeding against any Obligor. 

SECTION 6. Payment Over to Agent. In the event that, notwithstanding the provisions of Section 3,
Section 4, and Section 5, any Intercompany Subordinated Debt Payments shall be received in contravention of Section 3, Section 4, or
Section 5 by any Company before the Discharge of Senior Indebtedness has occurred, such Intercompany Subordinated Debt Payments shall be held in trust for the benefit of Agent, for the benefit of itself and the other
Secured Parties, and shall be paid over or delivered to Agent, for the benefit of the itself and the other Secured Parties, for application to the payment, in full, in cash or Cash Equivalents of all Senior Indebtedness remaining unpaid to the
extent necessary to give effect to Section 3, Section 4, and Section 5 and to the extent necessary to cause a Discharge of Senior Indebtedness to occur, after giving
effect to any concurrent payments or distributions to Agent or any other Secured Party in respect of the Senior Indebtedness. 
 SECTION 7.
Insolvency. 
 (a) Authorization to Agent. If, while any Intercompany Subordinated Debt is outstanding, any Insolvency Event
shall occur and be continuing with respect to any Obligor or its property: (i) Agent hereby is irrevocably authorized and empowered (in the name of each Company or otherwise), but shall have no obligation, to demand, sue for, collect, and
receive every payment or distribution in respect of the Intercompany Subordinated Debt owing by the 

  
 -4- 

 
Affected Obligor and give acquittance therefor and to file claims and proofs of claim (as set forth below in Section 7(b)) and take such other action (including voting such Intercompany
Subordinated Debt) as it may deem necessary or advisable for the exercise or enforcement of any of the rights or interests of Agent or any other Secured Party; and (ii) each Company shall promptly take such action as Agent reasonably may
request (A) to collect the Intercompany Subordinated Debt owing by the Affected Obligor for the account of Agent and the other Secured Parties and to file appropriate claims or proofs of claim in respect of the Intercompany Subordinated Debt,
(B) to execute and deliver to Agent such powers of attorney, assignments, and other instruments as it may request to enable it to enforce any and all claims with respect to such Intercompany Subordinated Debt, and (C) to collect and
receive any and all Intercompany Subordinated Debt Payments owing by the Affected Obligor. 
 (b) Rights in Insolvency Events. 

(i) Each of the Companies hereby authorizes and empowers the Agent, for the benefit of itself and the other Secured Parties, in any Insolvency
Event to file a proof of claim on behalf of such Company with respect to the Intercompany Subordinated Debt owing by the Affected Obligor (A) if such Company fails to file such proof of claim prior to thirty (30) days before the expiration
of the time period during which such claims must be submitted, or (B) if the Agent, exercising reasonable discretion, believes that any statements or assertions in a proof of claim filed by such Company are not consistent with the terms and
conditions hereof; provided, however, that any failure of the Agent to file such proof of claim shall not be deemed to be a waiver by the Agent of any of the rights and benefits granted herein by such Company. Each Company shall
provide the Agent with a copy of any proof of claim filed by such Company in any Insolvency Event. 
 (ii) Each Company hereby irrevocably
grants the Agent the sole and exclusive authority and power in any Insolvency Event, unless and until this Subordination Agreement is terminated in accordance with its terms: (A) to accept and receive any payment or distribution which may be
payable or deliverable at any time upon or in respect of the Intercompany Subordinated Debt owing by the Affected Obligor; and (B) to take such other action as may be necessary or advisable to effectuate the foregoing. Each Company shall
provide to the Agent all information and documents necessary to present claims or seek enforcement as described in the immediately preceding sentence. 

(iii) Each of the Companies hereby agrees that, while it shall retain the right to vote its claims and, except as otherwise provided in this
Subordination Agreement, otherwise act in any Insolvency Event relative to any Obligor (including, without limitation, the right to vote to accept or reject any plan of partial or complete liquidation, reorganization, arrangement, composition, or
extension), such Company shall not: (A) take any action or vote in any way so as to directly or indirectly challenge or contest (1) the validity or the enforceability of the Facility Agreement, the Amended and Restated Guaranty and
Security Agreement, the other Loan Documents, or the Liens and security interests granted to Agent with respect to the Senior Indebtedness, (2) the rights and duties of Agent or the other Secured Parties established in the Facility Agreement,
the Amended and Restated Guaranty and Security Agreement or any other Loan Document, or (3) the validity or enforceability of this Subordination Agreement; (B) seek, 

  
 -5- 

 
or acquiesce in any request, to dismiss any Insolvency Event or to convert an Insolvency Event under chapter 11 of the Bankruptcy Code to a case under chapter 7 of the Bankruptcy Code;
(C) seek, or acquiesce in any request for, the appointment of a trustee or examiner with expanded powers for any Obligor; (D) propose, vote in favor of or otherwise approve a plan of reorganization, arrangement or liquidation, or file any
motion or pleading in support of any plan of reorganization, arrangement or liquidation, unless it provides for the Discharge of Senior Indebtedness or unless Agent has approved of the treatment of its claims with respect to the Senior Indebtedness
under such plan; (E) object to the treatment under a plan of reorganization or arrangement of Agent’s claims with respect to the Senior Indebtedness; (F) seek relief from the automatic stay of Section 362 of the Bankruptcy Code
or any other stay in any Insolvency Event in respect of any portion of the Collateral; or (G) directly or indirectly oppose any relief requested or supported by Agent, on behalf of the itself and the other Secured Parties, including any sale or
other disposition of property free and clear of the Liens and security interests of any Company under Section 363(f) of Title 11 of the United States Code or any other similar provision of Applicable Law. 

SECTION 8. Certain Agreements of Each Company. 

(a) No Benefits. Each Company understands that there may be various agreements between Agent, the other Secured Parties and the Obligors
evidencing and governing the Senior Indebtedness, and each Company acknowledges and agrees that (except to the extent provided in any such agreement) such agreements are not intended to confer any benefits on such Company and that neither Agent nor
any other Secured Party shall have any obligation to such Company (except to the extent expressly provided in any such agreement) or any other Person to exercise any rights, enforce any remedies, or take any actions which may be available to them
under such agreements. 
 (b) No Interference. Each Company acknowledges that each Obligor has granted to Agent, for the benefit of
the Secured Parties, security interests in all of such Obligor’s assets, and agrees not to interfere with or in any manner oppose a disposition of any Collateral by Agent in accordance with Applicable Law. 

(c) Reliance by Agent and the Other Secured Parties. Each Company acknowledges and agrees that Agent and the other Secured Parties will
have relied upon and will continue to rely upon the subordination provisions provided for herein and the other provisions hereof in entering into the Loan Documents (including in amending and restating certain of the Prior Loan Documents) and making
or issuing the Loan. 
 (d) Waivers. Each Company hereby waives any and all notice of the incurrence of the Senior Indebtedness or any
part thereof and any right to require marshaling of assets. 
 (e) Rights of Agent and the Other Secured Parties Not Affected. Each
Company hereby agrees that at any time and from time to time, without notice to or the consent of such Company, without incurring responsibility to such Company, and without impairing or releasing the subordination provided for herein or otherwise
impairing the rights of Agent or any 

  
 -6- 

 
other Secured Party hereunder, (i) the time for any Obligor’s performance of or compliance with any of its agreements contained in the Loan Documents may be extended or such performance
or compliance may be waived by Agent and/or the Lenders (in accordance with the Loan Documents); (ii) the agreements of any Obligor with respect to the Loan Documents may from time to time be modified by such Obligor, Agent and the Lenders (in
accordance with the Loan Documents) for the purpose of adding any requirements thereto or changing in any manner the rights and obligations of such Obligor, Agent or the Lenders thereunder; (iii) the manner, place, or terms for payment of
Senior Indebtedness or any portion thereof may be altered or the terms for payment extended, or the Senior Indebtedness may be renewed in whole or in part; (iv) the maturity of the Senior Indebtedness may be accelerated in accordance with the
terms of any present or future agreement by any Obligor, Agent and the Lenders (in accordance with the Loan Documents); (v) any Collateral may be sold, exchanged, released, or substituted in accordance with the Loan Documents and any Lien in
favor of Agent or any other Secured Party may be terminated, subordinated, or fail to be perfected or become unperfected; (vi) any Person liable in any manner for Senior Indebtedness may be discharged, released, or substituted; and
(vii) all other rights against the Obligors, any other Person, or with respect to any Collateral may be exercised (or Agent or any other Secured Party may waive or refrain from exercising such rights in accordance with the Loan Documents). 

(f) Rights of Agent and the Other Secured Parties Not to Be Impaired. No right of Agent or any other Secured Party to enforce the
subordination provided for herein or to exercise its other rights hereunder shall at any time in any way be prejudiced or impaired by any act or failure to act by any Company, Agent or any other Secured Party hereunder or under or in connection with
the other Loan Documents or by any noncompliance by any Company with the term and provisions and covenants herein or in any other Loan Document, regardless of any knowledge thereof Agent or any other Secured Party may have or otherwise be charged
with. 
 (g) Financial Condition of the Obligors. Except as provided under the Facility Agreement, no Company shall have any right to
require Agent or any other Secured Party to obtain or disclose any information with respect to: (i) the financial condition or character of any Obligor or the ability of the Obligors to pay and perform Senior Indebtedness; (ii) the Senior
Indebtedness; (iii) the Collateral or other security for any or all of the Senior Indebtedness; (iv) the existence or nonexistence of any guarantees of, or any other subordination agreements with respect to, all or any part of the Senior
Indebtedness; (v) any action or inaction on the part of Agent, any other Secured Party or any other Person; or (vi) any other matter, fact, or occurrence whatsoever. 

(h) Acquisition of Liens or Guaranties. No Company shall, without the prior written consent of Agent, acquire any right or interest in
or to any Collateral not owned by such Company or accept any guaranties for the Intercompany Subordinated Debt, except as expressly permitted by the Loan Documents. 

(i) Release of Liens. In the event of any private or public sale or other disposition of all or any portion of the Collateral by or with
the consent of the Agent in accordance with the Loan Documents, or as otherwise permitted by the Facility Agreement, at any time prior to the date upon which the Discharge of Senior Indebtedness shall have occurred,

  
 -7- 

 
each Company agrees that such sale or disposition will be free and clear of the Liens and security interests securing the Intercompany Subordinated Debt (if any) of such Company and, if the sale
or other disposition includes Stock in any Obligor, such Company agrees to release the Persons whose Stock is sold or disposed of from all Intercompany Subordinated Debt so long as the Agent also releases the Persons whose Stock is sold or disposed
of from all Senior Indebtedness. In furtherance thereof, each Company agrees that (i) the Agent is authorized to file any and all UCC Lien releases and/or terminations of the Liens and security interests held by such Company in connection with
such a sale or other disposition, and (ii) it will execute any and all Lien and security interest releases or other documents reasonably requested by the Agent in connection therewith. 

SECTION 9. Subrogation, etc. 

(a) Subrogation. Until Discharge of the Senior Indebtedness and the full payment and satisfaction of all Obligations under the Warrant,
any Stock and the Registration Rights Agreement, subject to Section 10(b), each Company hereby waives any and all rights that it may acquire by way of subrogation under this Subordination Agreement, by reason of any payment
or distribution to Agent or any other Secured Party hereunder or otherwise. 
 (b) Payments Over to the Companies. If any payment or
distribution to which any Company would otherwise have been entitled but for the provisions of Section 3, Section 4, or Section 5 shall have been applied pursuant to the
provisions of Section 3, Section 4, or Section 5 to the payment of all amounts payable under the Senior Indebtedness, subject to Section 10(b),
such Company shall be entitled to receive from Agent or any other Secured Party, as the case may be, any payments or distributions received by such Person in excess of the amount sufficient to cause the Discharge of Senior Indebtedness and the full
payment and satisfaction of all Obligations under the Warrant, any Stock and the Registration Rights Agreement. If any such excess payment is made to Agent or any Lender, such Person shall promptly remit such excess to such Company and until so
remitted shall hold such excess payment for the benefit of such Company. 
 SECTION 10. Continuing Agreement; Reinstatement. 

(a) Continuing Agreement. This Subordination Agreement is a continuing agreement of subordination and shall continue in effect and be
binding upon each Company until the Discharge of Senior Indebtedness has occurred. The subordinations, agreements, and priorities set forth herein shall remain in full force and effect regardless of whether any party hereto in the future seeks to
rescind, amend, terminate, or reform, by litigation or otherwise, its respective agreements with any other Company. 
 (b)
Reinstatement. If any Secured Party receives payment or property on account of the Senior Indebtedness, and the payment is subsequently invalidated, avoided, declared to be fraudulent or preferential, set aside, or otherwise required to be
transferred to a trustee, receiver, an Obligor, an estate of an Obligor or any other Person (a “Recovery”), then, to the extent of the Recovery, the Senior Indebtedness intended to have been satisfied by such payment or property
will be reinstated as Senior Indebtedness on the date of the Recovery, and 

  
 -8- 

 
no Discharge of Senior Indebtedness will be deemed to have occurred for all purposes hereunder. If this Subordination Agreement is terminated prior to a Recovery, this Subordination Agreement
will be automatically reinstated in full force and effect, and such prior termination will not diminish, release, discharge, impair, or otherwise affect the obligations of the parties hereto from (or prior to) the date of reinstatement. Upon any
such reinstatement of Senior Indebtedness, the Companies will deliver to Agent any payments, other amounts or property (or proceeds thereof) received between the date of Discharge of Senior Indebtedness and the Recovery. The Companies may not
benefit from a Recovery, and any distribution, payment or transfer made to any Company as a result of a Recovery will be paid or transferred over to Agent immediately upon the occurrence of such Recovery for application to (and/or the benefit of)
Senior Indebtedness. 
 SECTION 11. Transfer of Intercompany Subordinated Debt. No Company may assign or transfer its rights and
obligations in respect of the Intercompany Subordinated Debt, except as expressly permitted by the Loan Documents, without the prior written consent of Agent, and any such transferee or assignee, as a condition to acquiring an interest in the
Intercompany Subordinated Debt shall agree to be bound hereby, in form satisfactory to Agent. Any prohibited assignment or transfer by any Company shall be void ab initio. 

SECTION 12. Obligations of the Obligors Not Affected. The provisions of this Subordination Agreement are intended solely for the
purpose of defining the relative rights of each Company against the Obligors, on the one hand, and of Agent and the other Secured Parties against the Obligors, on the other hand. Nothing contained in this Subordination Agreement shall
(i) impair, as between each Company and each Obligor, the obligation of such Obligor to pay its respective obligations with respect to the Intercompany Subordinated Debt as and when the same shall become due and payable, or (ii) otherwise
affect the relative rights of each Company against each Obligor, on the one hand, and of the creditors (other than Agent and the other Secured Parties) of the Obligors against the Companies, on the other hand. 

SECTION 13. Endorsement of Documents; Further Assurances and Additional Acts. 

(a) Endorsement of Documents. At the request of Agent, all documents, agreements and instruments evidencing any of the Intercompany
Subordinated Debt, if any, shall be endorsed with a legend noting that such documents and instruments are subject to this Subordination Agreement, and each Company shall promptly deliver to Agent evidence of the same. 

(b) Further Assurances and Additional Acts. Each Company shall execute, acknowledge, deliver, file, notarize, and register at its own
expense all such further agreements, instruments, certificates, financing statements, documents, and assurances, and perform such acts as Agent reasonably shall deem necessary or appropriate to effectuate the purposes of this Subordination
Agreement, and promptly provide Agent with evidence of the foregoing reasonably satisfactory in form and substance to Agent. 

  
 -9- 

 SECTION 14. Notices. All notices and other communications provided for hereunder
shall, unless otherwise stated herein, be in writing (including by facsimile or other electronic method of transmission) and shall be mailed, sent, or delivered in accordance with the notice provisions contained in the Facility Agreement. 

SECTION 15. No Waiver; Cumulative Remedies. No failure on the part of Agent or any other Secured Party to exercise, and no delay in
exercising, any right, remedy, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power, or privilege preclude any other or further exercise thereof or the exercise of
any other right, remedy, power, or privilege. The rights and remedies under this Subordination Agreement are cumulative and not exclusive of any rights, remedies, powers, and privileges that may otherwise be available to Agent or any other Secured
Party. 
 SECTION 16. Survival. All covenants, agreements, representations and warranties made in this Subordination Agreement shall,
except to the extent otherwise provided herein, survive the execution and delivery of this Subordination Agreement, and shall continue in full force and effect until the Discharge of Senior Indebtedness has occurred. 

SECTION 17. Benefits of Agreement. This Subordination Agreement is entered into for the sole protection and benefit of the parties
hereto (and the benefit of the Secured Parties that are not party hereto) and their permitted successors and assigns, and no other Person shall be a direct or indirect beneficiary of, or shall have any direct or indirect cause of action or claim in
connection with, this Subordination Agreement. 
 SECTION 18. Binding Effect. This Subordination Agreement shall be binding upon,
inure to the benefit of and be enforceable by each Company, Agent, each other Secured Party and their respective permitted successors and permitted assigns. 

SECTION 19. GOVERNING LAW. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS SUBORDINATION
AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN SUCH STATE. . 

SECTION 20. SUBMISSION TO JURISDICTION. Each party hereto agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Subordination Agreement (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state
and federal courts sitting in the City of New York, Borough of Manhattan. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives personal service of process and

  
 -10- 

 
consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party
at the address in effect for notices to it under this Subordination Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any
right to serve process in any other manner permitted by law. THE PARTIES HERETO, TO THE EXTENT PERMITTED BY APPLICABLE LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION WITH OR RELATING TO, THIS
SUBORDINATION AGREEMENT AND ANY TRANSACTION CONTEMPLATED HEREBY. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE. EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO AGENT,
REPRESENTATIVE OR OTHER PERSON AFFILIATED WITH OR RELATED TO ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT
IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS SUBORDINATION AGREEMENT BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 20. 

SECTION 21. Entire Agreement; Amendments and Waivers. 

(a) Entire Agreement. This Subordination Agreement constitutes the entire agreement of each of the Companies, Agent and each of the
other Secured Parties with respect to the matters set forth herein and supersedes any prior agreements, commitments, draft, communications, discussions and understandings, oral or written, with respect thereto. 

(b) Amendments and Waivers. No amendment, restatement or other modification to any provision of this Subordination Agreement shall in
any event be effective unless the same shall be in writing and signed by each of the Companies and Agent; and no waiver of any provision of this Subordination Agreement, or consent to any departure by any Company therefrom, shall in any event be
effective unless the same shall be in writing and signed by Agent. Any such amendment, restatement, other modification waiver, or consent shall be effective only in the specific instance and for the specific purpose for which given. 

SECTION 22. Conflicts. In case of any conflict or inconsistency between any terms of this Subordination Agreement, on the one hand, and
any documents, agreement or instruments in respect of the Intercompany Subordinated Debt, on the other hand, then the terms of this Subordination Agreement shall control. 

SECTION 23. Severability. Whenever possible, each provision of this Subordination Agreement shall be interpreted in such manner as to
be effective and valid under all Applicable Laws and regulations. If, however, any provision of this Subordination Agreement shall be prohibited by or invalid under any such Applicable Law or regulation in any jurisdiction, it shall, as to such
jurisdiction, be deemed modified to conform to the minimum requirements of such Applicable Law or regulation, or, if for any reason it is not deemed so 

  
 -11- 

 
modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Subordination Agreement or the validity or
effectiveness of such provision in any other jurisdiction. 
 SECTION 24. Interpretation. This Subordination Agreement is the result
of negotiations between, and has been reviewed by the respective counsel to, the Companies, Agent and each other Secured Party and is the product of all parties hereto. Accordingly, this Subordination Agreement shall not be construed against Agent
or any other Secured Party merely because of their involvement in the preparation hereof. 
 SECTION 25. Counterparts. This
Subordination Agreement may be executed in several counterparts, and by each party hereto on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original,
but all of which together shall constitute one and the same agreement.. 
 SECTION 26. Termination of Agreement. Subject to
Section 10(b), upon the Discharge of Senior Indebtedness, this Subordination Agreement shall terminate and Agent shall promptly, upon the request of the Borrower and at the sole expense of the Borrower, execute and deliver to
the Borrower such documents and instruments as shall be reasonably necessary to evidence such termination. 
 [Signature page follows.] 

  
 -12- 

 IN WITNESS WHEREOF, the undersigned have executed and delivered this Subordination Agreement
as of the date first written above. 
  

			
	ENDOLOGIX, INC., a Delaware corporation, as a Company and an Obligor
		
	By:	 	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer
	
	CVD/RMS ACQUISITION CORP., a Delaware corporation, as a Company and an Obligor
		
	By:	 	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary
	
	NELLIX, INC., a Delaware corporation, as a Company and an Obligor
		
	By:	 	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary
	
	TRIVASCULAR TECHNOLOGIES, INC., a Delaware corporation, as a Company and an Obligor
		
	By:	 	 /s/ Vaseem Mahboob

		 	 Name: Vaseem Mahboob

		 	 Title: Chief Financial Officer and Secretary

 [Signature Page to Intercompany Subordination Agreement] 

 
			
	TRIVASCULAR, INC., a California corporation, as a Company and an Obligor
		
	By:	 	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary
	
	ENDOLOGIX CANADA, LLC, a Delaware limited liability company, as a Company and an Obligor
		
	By:	 	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary

  

			
	 TRIVASCULAR SALES LLC,
 a
Texas limited liability company, as a Company and an Obligor

		
	By:	 	 /s/ Vaseem Mahboob

	Name: Vaseem Mahboob
	Title: Chief Financial Officer and Secretary
	
	RMS/ENDOLOGIX SIDEWAYS MERGER CORP., a Delaware corporation, as a Company and an Obligor
		
	By:	 	 /s/ Vaseem Mahboob

	Name: Vaseem Mahboob
	Title: Chief Financial Officer and Secretary

 [Signature Page to Intercompany Subordination Agreement] 

 
			
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.,
	as Agent
	
	By: Deerfield Mgmt IV, L.P., General Partner
	
	By: J.E. Flynn Capital IV, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

 [Signature Page to Intercompany Subordination Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]